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RÉSUMÉ LARGE PUBLIC 
 
Les lymphocytes T CD8+ sont des cellules du système immunitaire qui reconnaissent et 
tuent les cellules infectées ou transformées. Cette reconnaissance se produit par 
l'interaction entre le récepteur des lymphocytes T (TCR) exprimé par la cellule T CD8+ 
et un peptide d’origine virale ou tumorale chargé sur les molécules de classe I du 
complexe majeur d'histocompatibilité (pMHC) sur la cellule cible. Malgré la présence de 
cellules T CD8+ spécifiques contre la tumeur, chez de nombreux patients cancéreux, les 
cellules cancéreuses parviennent tout de même à échapper à leur attaque menant à la 
progression du cancer. Ceci est dû à deux raisons principales: 1) la force de l’interaction 
généralement faible entre les TCR spécifiques aux tumeurs et les molécules pMHC 
tumoraux et 2) le microenvironnement tumoral immunosuppresseur. L'interaction entre 
le récepteur inhibiteur PD-1 sur les cellules T CD8+ et son ligand PD-L1 sur les cellules 
cancéreuses et les cellules myéloïdes est l'un des nombreux facteurs qui suppriment les 
réponses des cellules T CD8+ dans la tumeur. 
Dans le cadre de ma thèse de doctorat, j'ai étudié l'impact de la force d'interaction TCR-
pMHC sur: 1) la différenciation des cellules T CD8+ et la réponse anti-tumorale, 2) la 
réponse au blocage PD-1 médié par des anticorps et 3) l’expression du microRNA-155 
(miR-155), qui régule l'expression de différentes protéines et s'est avéré précédemment 
important pour les réponses des lymphocytes T CD8+. 
En utilisant des tumeurs de mélanome de souris B16 exprimant un antigène tumoral 
d'affinité élevée ou faible, nous avons montré que, en effet, la force d'interaction TCR-
pMHC influence fortement le résultat de la réponse anti-tumorale des lymphocytes T 
CD8+. La vaccination avec un peptide qui interagit fortement avec le TCR spécifique de 
la tumeur est nécessaire pour permettre une activation et une prolifération efficaces des 
lymphocytes T CD8+ dans la périphérie et contrôler la croissance des tumeurs exprimant 
un peptide faiblement reconnu par le TCR spécifique de la tumeur. Fait important, le 
contrôle de ces tumeurs de faible affinité peut être encore amélioré avec le traitement par 
l'anticorps anti-PD-1. 
Nous avons également remarqué que la force d'interaction TCR-pMHC et la quantité de 
molécules pMHC reconnue déterminent les niveaux d'expression de miR-155 dans les 
lymphocytes T CD8+ humains et de souris. Fait intéressant, nous avons observé une 
corrélation négative entre les niveaux d'expression de miR-155 dans les cellules T CD8+ 
infiltrant la tumeur et le volume des tumeurs exprimant un peptide de faible affinité. Dans 
la même lignée, nous avons mis en évidence une corrélation positive entre les niveaux 
d'expression de miR-155 dans les cellules T CD8+ effectrices des ganglions lymphatiques 
infiltrés par cellules tumorales (TILNs) et les fréquences de ces cellules T CD8+ 
effectrices dans les TILN, ce qui est positivement corrélé avec la survie globale des 
patients. Ainsi, nous proposons que les niveaux d'expression de miR-155 reflètent la 
réactivité et l'affinité pour le peptide tumoral et peuvent être utilisés comme marqueur de 
la qualité fonctionnelle des cellules T CD8+ des tumeurs.  
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RÉSUMÉ 
Malgré la capacité des cellules T CD8+ à reconnaître et tuer les cellules cancéreuses, les 
tumeurs parviennent à échapper au contrôle immunitaire par des mécanismes multiples. Les 
stratégies immunothérapeutiques ont montré des avantages cliniques chez certains types de 
cancer, mais pas chez tous les patients. Par conséquent, une meilleure compréhension des 
paramètres clés régissant la relation complexe entre les cellules T CD8+ et les tumeurs est 
nécessaire pour assurer le succès de l'immunothérapie chez la plupart des patients du cancer. 
 
La réponse des cellules T anti-tumorales implique principalement les lymphocytes T CD8+ 
avec une haute affinité pour les antigènes du soi mutés et une faible affinité pour les antigènes 
associés aux tumeurs. Par conséquent, la première partie de mon projet de thèse a porté sur 
l'impact de la force de reconnaissance entre le TCR et son antigène dans les réponses anti-
tumorales induites par les lymphocytes T CD8+. Nous avons remarqué que l’activation 
périphérique des lymphocytes T CD8+ avec un vaccin peptidique de haute affinité était 
nécessaire pour contrôler la croissance des tumeurs de mélanome B16 exprimant un antigène 
de faible affinité. En outre, malgré une activation périphérique de haute affinité, l'affinité que 
les lymphocytes T CD8+ ont pour l’antigène qu’ils rencontrent dans la tumeur influe sur la 
qualité de leur réponse : la reconnaissance d’un antigène de faible affinité conduit à une faible 
expansion des lymphocytes T CD8+ et à un contrôle réduit de la croissance tumorale, mais 
induit une expression plus faible de récepteurs inhibiteurs et une meilleure production de 
cytokines lors d’une restimulation ex vivo. De manière intéressante, les cellules T CD8+ 
infiltrant la tumeur répondaient également au traitement par l'anti-PD-1 indépendamment de 
leur affinité pour l'antigène tumoral. De plus, lorsque les lymphocytes T CD8+ infiltrés dans 
les tumeurs ont été retransférés dans des hôtes sans tumeur, ils ont démontré une capacité de 
ré-expansion in vivo similaire à celle des lymphocytes T CD8+ isolés des organes lymphoïdes 
secondaires, ce qui suggère que la fonction des lymphocytes T CD8+ peut être restaurée 
lorsque l’immunosuppression induite de la tumeur est absente. 
 
Notre groupe avait précédemment démontré l'importance du micro-ARN-155 (miR-155) lors 
des réponses anti-tumorales des cellules T CD8+, car sa surexpression augmentait leur 
capacité à contrôler des tumeurs murines. Cependant, les aspects quantitatifs de la régulation 
des niveaux d’expression de miR-155 étaient peu caractérisés. Ainsi, la deuxième partie de 
ma thèse a porté sur la régulation de l'expression de miR-155 dans les cellules T CD8+ 
humaines et murines provenant de tissus sains et de tumeurs de mélanome. J'ai démontré que 
l'affinité des cellules T et la dose d'antigène déterminent le niveau d'expression de miR-155 
dans les cellules T CD8+. De plus, un taux d'expression élevé de miR-155 était corrélé avec 
un contrôle tumoral accru dans les tumeurs B16 exprimant l'antigène de faible affinité et un 
traitement par anti-PD-1 augmentait l'expression de miR-155 des cellules T CD8+. De plus, 
les cellules T CD8+ surexprimant miR-155 présentaient une persistance accrue dans un 
contexte d’infection chronique. En accord avec ces observations dans les modèles murins, le 
taux d'expression de miR-155 dans les cellules T CD8+ effectrices de mémoire (EM) 
humaines est corrélé avec leurs fréquences dans les ganglions lymphatiques infiltrés par la 
tumeur. Ainsi, nous suggérons que le niveau d'expression de miR-155 reflète la réactivité et 
l'affinité des lymphocytes T CD8+ pour leurs antigènes et peut être utilisé comme un 
marqueur de leur qualité fonctionnelle.  
 
Finalement, nous démontrons que la combinaison de vaccination avec ligands peptidiques 
altérés en combinaison avec un traitement anti-PD-1 peut permettre le contrôle de tumeurs 
exprimant un antigène de faible affinité, ce qui peut être révélé par une surexpression du miR-
155 dans les cellules T CD8+ infiltrant la tumeur. 
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SUMMARY 
Despite the ability of CD8+ T-cells to recognize and kill cancer cells, tumors manage to 
evade immune control through multiple mechanisms. Immunotherapeutic strategies have 
shown clinical benefit in some but not all cancer types or patients.  Hence, a better 
understanding of the key parameters governing the complex relationship between CD8+ 
T-cells and tumors is necessary to ensure the success of immunotherapy in most cancer 
patients.   
 
Anti-tumor T-cell responses mostly involve CD8+ T-cells with high affinity for mutated 
self-antigens and of low affinity for tumor-associated antigens. Therefore, the first part 
of my thesis project addressed the impact of the recognition strength between the TCR 
and its antigen in CD8+ T-cell mediated anti-tumor responses. We found that CD8+ T-
cell peripheral priming with a high affinity peptide vaccine was necessary to control low 
affinity antigen expressing B16 melanoma tumors. In addition, despite a high affinity 
peripheral priming, the affinity for the antigen that CD8+ T-cells encountered later in the 
tumor influenced on the CD8+ T-cell response: low affinity antigen recognition led to 
decreased CD8+ T-cell expansion and tumor control while induced lower expression 
levels of inhibitory receptors and increased cytokine production upon ex vivo 
restimulation. Interestingly, tumor infiltrating CD8+ T-cells regardless of their affinity for 
the tumor antigen, responded equally to PD-1 blocking monoclonal antibodies. Moreover, 
when tumor infiltrating CD8+ T-cells were re-transferred to tumor-free hosts, they 
showed similar in vivo re-expansion capacity irrespectively of the affinity for the tumor 
antigen. Interestingly, the re-expansion capacity of these T-cells was similar to that of 
their counterparts isolated from secondary lymphoid organs, suggesting that CD8+ T-cells 
in tumors may be rekindled upon relief of tumor immunosuppression.  
 
Our group had previously shown the importance of micro-RNA-155 (miR-155) for CD8+ 
T cells anti-tumor responses, as its overexpression enhanced tumor control by CD8+ T 
cells. However, the quantitative aspects of the regulation of miR-155 expression levels 
were poorly characterized. Thus, the second part of my thesis addressed miR-155 
expression regulation in mouse and human CD8+ T cells from healthy tissues and 
melanoma tumors. I demonstrated that T cell affinity and antigen dose are two important 
factors determining miR-155 expression levels in CD8+ T cells. Interestingly, high miR-
155 expression levels correlated with increased tumor control in low affinity antigen 
expressing B16 tumors and anti-PD-1 treatment increased CD8+ T cells miR-155 
expression levels.  Moreover, CD8+ T cells overexpressing miR-155 showed enhanced 
persistence in chronic infections. In line with these observations in mouse model systems, 
miR-155 expression levels in human effector memory CD8+ T cells positively correlated 
with their frequencies in tumor infiltrated lymph nodes. Thus, we propose that miR-155 
expression levels reflect responsiveness and affinity for the antigen and may be used as 
an overall marker of tumor infiltrating CD8+ T cells fitness.  
 
Altogether, we suggest that combination of high affinity peripheral priming by altered 
peptide ligands and checkpoint blockade may enable tumor control of even low affinity 
antigen expressing tumors, which can be revealed by miR-155 upregulation in tumor 
infiltrating CD8+ T cells. 
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ABBREVIATIONS
Ab: Antibody 
ACT: Adoptive cell therapy 
APC: Antigen-presenting cell 
B6: C57BL/6 mouse 
BCR: B-cell receptor 
BrdU: 5-Bromo-2’-deoxyuridine 
CAR: Chimeric antigen receptor 
CFU: Colony forming units 
CM: Central memory 
cTEC: Cortical thymic epithelial cell 
DC: Dendritic cell 
dLN: Draining lymph nodes 
DN: Double negative 
DP: Double positive 
EAE: Experimental autoimmune 
encephalomyelitis 
EM: Effector-memory 
EMA: European medicines agency 
EMRA: CD45RA+ effector memory  
FCS: Fetal calf serum 
FDA: Food and drug administration 
GM-CSF: Granulocyte-macrophage 
colony-stimulating factor 
HD: Healthy donor 
HLA: Human leukocyte antigen 
ICB: Immune checkpoint blockade 
ILC: Innate-lymphoid cell 
i.p: Intraperitoneal 
ISO: Isotype control 
ITAM: Immunoreceptor tyrosine-based 
activation motif 
i.v: Intravenous 
KD: Dissociation constant 
LCMV: Lymphocytic choriomeningitis 
virus 
Lm: Listeria monocytogenes 
MDSC: Myeloid-derived suppressor 
cell 
MFI: Mean fluorescence intensity 
MHC: Major histocompatibility 
complex 
MiR: Micro-RNA 
MPEC: Memory precursor effector cell 
mTEC: Medullary thymic epithelial 
cell 
N4: SIINFEKL 
NK: Natural killer 
NLN: Non-tumor-infiltrated lymph 
node 
NTAmer: Ni (2+)-nitrilotriacetic acid 
histidine tag-containing multimers 
OVA: Ovalbumin  
PB: Peripheral blood 
Pfu: Plaque forming unit 
PMA: Phorbol 12-myristate 13-acetate 
pMHC: Peptide-loaded major 
histocompatibility complexPRR: 
Pattern-recognition receptor 
RM: Repeated measurement 
RT: Room temperature 
s.c: Subcutaneous 
SCM: Memory stem cell 
SD: Standard deviation 
SLEC: Short-lived effector cell 
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SP: Single positive 
SPR: Surface plasmon resonance 
SSC: Saline-sodium citrate buffer 
T4: SIITFEKL 
TAA: Tumor-associated antigen 
TCR: T-cell receptor 
TE: Terminal effector 
TF: Transcription factor 
Th: T helper 
TILN: Tumor-infiltrated lymph node 
TIL: Tumor-infiltrating lymphocyte  
Treg: Regulatory T cell 
TRM: Tissue resident memory 
WT: Wild-type 
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GENERAL INTRODUCTION 
1. The immune system 
1.1. Innate and adaptive immune system 
The immune system protects the host from infection by pathogens and development of 
tumors. It is composed by various cell types which develop from pluripotent 
hematopoietic stem cells in the bone marrow and then patrol through the blood and 
lymphatic system to guard the peripheral tissues (Janeway, 2001). Upon an infection, 
cells from the innate system are the first ones to respond by sensing danger signals. Four 
cell types belong to the innate immune system: granulocytes (neutrophils, eosinophils and 
basophils), macrophages, innate-lymphoid cells (ILCs) (Spits & Di Santo, 2011) and 
dendritic cells (DCs). Macrophages phagocyte and destroy pathogens through the 
recognition of pattern-recognition receptors (PRRs). Once activated they secrete 
inflammatory cytokines and chemokines that initiate the so-called inflammation process. 
Local inflammation will activate the complement system and recruit other cells of the 
innate immune system such as neutrophils, who are also able to engulf and destroy 
pathogens. The innate immune response might clear the infection, but not always. In those 
cases, the adaptive immune response will be activated thanks to tissue resident DCs. 
Phagocytosis of invading microorganisms via PRRs recognition induces activation and 
maturation of DCs that will migrate to a nearby secondary lymphoid organ. There, mature 
DCs present pathogen-derived antigens on major histocompatibility complex (MHC) 
molecules to T and B cells as well as secrete cytokines that will tune the innate and 
adaptive immune response.  T and B cells are lymphocytes which express antigen-specific 
receptors (TCRs and BCRs respectively) and form the adaptive immune system. Upon 
specific antigen recognition in secondary lymphoid organs, they expand and differentiate. 
More specifically, T cells mainly differentiate into antigen-specific effector cells that 
migrate to the site of infection to eradicate the infection by killing infected cells or 
secreting cytokines that activate other immune cells, while B cells differentiate into 
antibody-secreting cells. Antibodies recognize specific epitopes of the pathogen allowing 
its neutralization. In addition, antibody bound pathogens can be recognized by other 
immune cells and induce antibody-dependent cell-mediated cytotoxicity (ADCC) as well 
as by the complement system and trigger complement-dependent cytotoxicity (CDC) 
(Janeway, 2001). 
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1.2. T cell development 
All cells of the blood including 
immune cells derive from 
hematopoietic stem cells in the 
bone marrow. During 
hematopoiesis, these 
pluripotent cells divide and 
produce more specialized stem 
cells: common lymphoid 
progenitors, common myeloid 
progenitors, erythrocytes and 
megakaryocytes.  T and B cells 
both derive from a common 
lymphoid progenitor. However, 
whereas B cell maturation 
occurs in the bone marrow, 
naïve T cells develop in the thymus.  Common lymphoid progenitors migrate from the 
bone marrow to the thymus where they lose the capacity to become B cells (Pui et al., 
1999; Radtke et al., 1999) and natural-killer (NK) cells (Michie et al., 2000). These early 
committed T cells still lack the expression of the T cell receptor (TCR) as well as CD4 or 
CD8 co-receptors and are referred as double negative (DN) thymocytes. DN thymocytes 
can give rise to T cells expressing ab or gd TCR chain pairs. For ab T cell development, 
DN thymocytes rearrange the TCR b and a-chain by recombination-activating gene 1 
(RAG1) (Mombaerts et al., 1992)  and RAG2 (Shinkai et al., 1993) dependent somatic 
DNA recombination. They also initiate the expression of CD4 and CD8 co-receptors 
becoming double-positive (DP) thymocytes. DP thymocytes interact with cortical thymic 
epithelia cells (cTECs) that express high levels of self-peptide loaded MHC I and MHC 
II molecules. DP thymocytes that recognize self-peptide MHC molecules (pMHC) bellow 
a minimal affinity do not get enough TCR signalling to survive and die by apoptosis 
(death by neglect). Those with enough affinity for the MHC molecules go to the medulla 
and further interact with medullary thymic epithelial cells (mTECs) that express MHC 
molecules loaded with a range of self-antigens thanks to the expression of the 
Autoimmune Regulator (AIRE) transcription factor. Neighbouring thymic dendritic cells 
may also capture self-antigens from mTECs and interact with DP thymocytes (Anderson 
Figure 1. T cell development in the thymus. Lymphoid progenitors 
undergo a positive and negative selection process during their maturation 
into naïve CD4+ or CD8+ single positive (SP) lymphocytes. Such 
selection process enables the elimination of cells that recognize too 
weakly or too strongly self-peptide loaded MHC molecules. DP: Double 
positive (Germain, 2002).  
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& Takahama, 2012). Strong interaction between TCRs of DP thymocytes and these self-
pMHC molecules invokes thymocyte death (negative selection). Only intermediate TCR 
signalling allows complete maturation of DP thymocytes (positive selection), which  
become conventional single positive (SP) CD4+ or CD8+ T-cells depending on the 
recognition of MHC II or MHC I molecules respectively (Germain, 2002; von Boehmer, 
Teh, & Kisielow, 1989) (Figure 1). This selection process generates a TCR repertoire that 
recognizes self MHC I and MHC II molecules but only with low affinity when loaded 
with self-peptides,  with the exception of TCRs of regulatory T cells (Josefowicz, Lu, & 
Rudensky, 2012). This highly sophisticated thymic selection system prevents possible 
activation of self-antigen specific T cells in the periphery and consequent autoimmunity. 
This mechanism  contributes to the central tolerance initially described by Joshua 
Lederberg for B cells (Lederberg, 1959). Finally, naïve mature CD4+ and CD8+ T-cells 
exit the thymus and circulate through the blood and lymphatic system ready to get 
activated and mount an immune response against their specific antigen.  
 
1.3. T cell activation  
Naïve (CD44lowCD62LhighCCR7high) T cell activation is a complex process in which many 
molecules in addition to the TCR and pMHC enable the signal transduction of the 
extracellular antigen recognition stimuli into an intracellular signalling cascade and cell 
reprogramming.  The TCR is associated to CD3ε, γ, δ, and ζ polypeptides which contain 
immunoreceptor tyrosine-based activation motifs (ITAMs) on their cytoplasmic tails. 
Upon TCR-pMHC interaction, the TCR-CD3 complex undergoes a conformational 
change and the cytoplasmic tails of CD3ε and CD3ζ become accessible to the LCK 
tyrosine kinase (Gil, Schamel, Montoya, Sanchez-Madrid, & Alarcon, 2002; Joshi et al., 
2011; Mingueneau et al., 2008; H. Zhang, Cordoba, Dushek, & van der Merwe, 2011). 
LCK is associated to CD4 and CD8 co-receptors, which also participate in the recognition 
of pMHC molecules.  CD3 ITAM phosphorylation by LCK (Straus & Weiss, 1992) leads 
to the recruitment, phosphorylation and consequent activation  of ZAP-70 tyrosine kinase 
(Chan et al., 1995; Iwashima, Irving, van Oers, Chan, & Weiss, 1994) that will then 
phosphorylate LAT and SLP-76 adaptor proteins (Malissen & Bongrand, 2015). 
Phosphorylated LAT will then recruit phospholipase C γ (PLCγ) that will be activated by 
interleukin-2-inducible-T-cell kinase (ITK), a kinase that is activated by LCK and binds 
phosphorylated SLP-76 (Smith-Garvin, Koretzky, & Jordan, 2009). Active PLCγ 
generates diacyl glycerol (DAG) and inositol 1,4,5-triphosphate (IP3) secondary 
PhD Thesis   Amaia Martínez Usatorre 
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messengers that ultimately lead to the activation of NFAT and NFkB transcription factors.   
Although T cells can be activated in vitro by TCR stimulation alone, physiological T cell 
activation requires two additional signals:  costimulation via surface molecules such as 
CD28 (Lenschow, Walunas, & Bluestone, 1996) and/or 4-1BB (Tan, Whitmire, Ahmed, 
Pearson, & Larsen, 1999) and inflammatory signals: IL-12 (Trinchieri, 2003) and type I 
IFNs (Curtsinger, Valenzuela, Agarwal, Lins, & Mescher, 2005). Combination of the 
three signals induces T cell proliferation and transcriptional, epigenetic and metabolic 
reprogramming that ultimately give rise to effector and memory cells (Kaech & Cui, 
2012; Lanzavecchia & Sallusto, 2002).  
1.4. CD4+ T cell differentiation 
Naïve CD4+ T cells get activated by antigen presenting cells in secondary lymphoid 
organs upon recognition of their specific peptide antigen presented on MHC-II molecules 
and interaction with costimulatory molecules. Once activated, CD4+ T cells clonally 
expand and differentiate into different T helper (Th) subsets. CD4+ T cell polarization is 
controlled by specific transcription factors, whose expression depends on several signals 
including soluble factors.  Figure 2 
summarizes the main Th subsets 
described up to now, and 
characterized by the expression of 
defined transcription factors. Th1, 
Th2 and Th17 boost other 
lymphocytes’ responses thanks to 
the secretion of IFN-g and TNF 
(Th1), IL-4, IL-5 and IL-13 (Th2), 
and IL-17 and IL-22 (Th17) 
respectively. In addition, 
follicular helper T cells (TFH) are 
necessary for optimal B cell responses through their secretion of IL-6, and regulatory T 
cells (Tregs) dampen T cell responses by different mechanisms such as IL-10 secretion. 
Finally, more recently discovered, cytolytic CD4+ T cells are able to kill infected cells 
similarly to CD8+ T cells (Swain et al., 2012). 
 
 
Figure 2. CD4+ T cell subsets. Depending on the cytokines present 
in the milieu, CD4+ T cells polarize into distinct cell subsets. Each 
subset is characterized by the expression of a master TF and secretion 
of determined cytokines (Swain, McKinstry, & Strutt, 2012). 
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1.5. CD8+ T cell differentiation  
Among the cells of the adaptive immune system, CD8+ T cells play a critical role in the 
immune response against intracellular pathogens and cancer cells. Upon pMHC I antigen 
recognition in secondary lymphoid organs, the majority of activated CD8+ T cells 
differentiate into cytotoxic effector cells, which migrate to the site of infection or 
proliferation of malignant transformed cells to exert their effector functions (N. Zhang & 
Bevan, 2011). They can induce apoptosis of target cells via three different mechanisms: 
1) exocytosis of granules containing lytic molecules such as perforin, granzymes and 
granulysin (Faroudi et al., 2003; Wiedemann, Depoil, Faroudi, & Valitutti, 2006) 2) Fas-
FasL cell-cell contact and 3) cross-linking of TNF and TNFR type I (Chavez-Galan, 
Arenas-Del Angel, Zenteno, Chavez, & Lascurain, 2009). As the antigen is cleared and 
the inflammation resolves, most effector CD8+ T cells undergo apoptosis. Only some of 
the expanded cells will differentiate into memory CD8+ T cells that self-renew in an 
antigen independent manner and may persist for a lifetime ready to initiate a rapid and 
potent specific recall response against a second encounter with the antigen.   
In acute viral and bacterial infections, at least two effector CD8+ T cell subsets can be 
distinguished. CD127highKLRG1low memory-precursor effector cells (MPECs) and 
CD127lowKLRG1high short-lived or terminal effector cells (SLECs or TEs). Distinction of 
these two cell subsets is particularly relevant as it has been shown in acute infections that 
MPECs have increased potential to form memory cells compared to TEs (Joshi et al., 
2007; Kaech et al., 2003).  
The formation of effector and memory CD8+ T cells is tightly regulated by transcription 
factors (TF). In particular, T-bet and Eomesodermin (Eomes) T-box TFs are key for CD8+ 
T cell effector and memory formation. Both TFs contribute to the induction of IFNγ, 
Granzyme B and perforin in early effector cells (Banerjee et al., 2010; Joshi et al., 2007; 
Pipkin et al., 2010) and IL2-Rβ (CD122) in memory cells that enables IL-15 dependent 
homeostatic proliferation (Banerjee et al., 2010; Intlekofer et al., 2005; Yajima et al., 
2006). T-bet expression is directly induced by TCR signaling and amplified by IL-12 and 
mammalian target of rapamycin (mTOR) activity (Joshi et al., 2011; Rao, Li, Odunsi, & 
Shrikant, 2010; Takemoto, Intlekofer, Northrup, Wherry, & Reiner, 2006). Its deficiency 
leads to impaired CD8+ TE cell formation (Joshi et al., 2007). In contrast, Eomes 
expression is induced after T-bet in early effector cells, is amplified by IL-2 (Pipkin et 
al., 2010) but repressed by IL-12 and mTOR activity (Rao et al., 2010; Takemoto et al., 
2006). Lack of Eomes leads to efficient primary expansion and MPEC formation but 
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fewer central memory cells with impaired long-term persistence (Banerjee et al., 2010). 
Despite some redundant functions, the expression pattern of these two TFs differ. While 
highest T-bet expression levels are reached in effector cells and decline in memory cells 
(Joshi et al., 2011), Eomes expression increases from effector to memory cells, probably 
in response to TCF-1 TF (Banerjee et al., 2010; Zhou et al., 2010). Thus, the ratio of T-
bet versus Eomes expression level may define effector CD8+ T cells fate (Banerjee et al., 
2010; Joshi et al., 2007; Joshi et al., 2011). Although the exact mechanism regulating this 
ratio remains to be elucidated, it is known that pro-inflammatory cytokines (IL-12, type 
I IFNs, IL-2) and other immunomodulatory factors (IL-4, IL-10, and IL-21) are involved 
(Pipkin et al., 2010; Takemoto et al., 2006; Wiesel et al., 2012).  
B lymphocyte-induced maturation protein (BLIMP1) and BCL-6 TFs also participate in 
CD8+ T cell effector and memory formation. BLIMP1 is a transcriptional repressor that, 
like T-bet, is highly expressed in effector cells and downregulated in memory CD8+ T 
cells (Kallies, Xin, Belz, & Nutt, 2009; Rutishauser et al., 2009). On the contrary, BCL-
6 expression increases in memory cells and is particularly crucial for central memory 
CD8+ T cell formation and maintenance (Cui, Liu, Weinstein, Craft, & Kaech, 2011; Ichii 
et al., 2007; Ichii et al., 2002). Additional TFs such as ID2, ID3 and members of the STAT 
family (reviewed by Kaech and Cui (Kaech & Cui, 2012)) also participate in CD8+ T cell 
fate decision. Thus, CD8+ T cell effector and memory formation is a complex process 
finely regulated by multiple transcription factors that respond to cell intrinsic and 
environmental cues.  
 
1.6. Memory CD8+ T cells  
Memory formation is a hallmark of the adaptive immunity. Acute infection and 
vaccination models have broadly been used to describe CD8+ differentiation and memory 
formation. Single cell transfer and barcoding experiments revealed that a single naïve T 
cell can give rise to both effector and memory cells (Gerlach et al., 2010; Stemberger et 
al., 2007). However, several mechanisms have been proposed to explain T cell fate 
decision: the asymmetric cell division during APC and T cell interaction (Chang et al., 
2007), the signal strength during T cell priming (Joshi et al., 2007; Masopust, Kaech, 
Wherry, & Ahmed, 2004; Sallusto, Geginat, & Lanzavecchia, 2004; Wiesel et al., 2012) 
and the overall accumulation of signals over the T cell response (Badovinac, Porter, & 
Harty, 2004; Joshi et al., 2007; Sarkar et al., 2008). 
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Based on their function, anatomical location and phenotypic markers, three different 
memory T cell subsets can be distinguished: effector-memory (EM) 
(CD44highCD62LlowCCR7low), central-memory (CM) (CD44highCD62LhighCCR7high) and 
tissue-resident-memory (TRM) (CD44high CD62Llow CD103high CD69high CD27low) T 
cells. While EM and CM T cells circulate through the blood vessels as well as lymphoid 
and non-lymphoid tissues, TRM T cells show very limited recirculation and reside in the 
brain and mucosal tissues. TRM and EM T cells confer immediate effector functions at 
the pathogen entry site, whereas CM T cells tend to mount a more robust recall response 
by generating many secondary effector cells (Kaech & Cui, 2012). More recently, a forth 
memory T cell subset has been described from the original naïve T cell pool defined as 
CCR7highCD62LhighSCA1+IL-2Rb+CXCR3+ in mice and CD95+IL-
2Rb+CXCR3+CD58+CD11a+ in humans. They are referred as T memory stem cells 
(SCM) and are characterized by long persistence, high proliferative potential and ability 
to generate a diverse range of T cell subsets (Gattinoni, Speiser, Lichterfeld, & Bonini, 
2017). In humans, an additional CCR7low CD45RA+ CD8+ T cell subset has been 
identified, characterized by larger amounts of perforin than EM CD8+ T cells. It is highly 
differentiated and defined as CD45RA+ effector memory (EMRA) T cells (Appay, van 
Lier, Sallusto, & Roederer, 2008). 
 
1.7. T cell affinity 
TCR pMHC recognition is essential for the activation and differentiation of T cells. In 
fact, the strength of the interaction between the TCR and pMHC directly correlates with 
the amplitude of T cell expansion (Vigano et al., 2012; Zehn, Lee, & Bevan, 2009). Three 
terms can be defined to describe the strength of the T cell interaction with an APC or 
target cell: T cell affinity, avidity and functional avidity (Figure 3). To assess each of 
these parameters, different techniques have been developed as described below. 
 
T cell receptor affinity 
It defines the physical binding strength between a single TCR and pMHC molecule 
(Figure 3, left panel). The dissociation constant (KD) between soluble TCRs and pMHCs 
is measured by surface plasmon resonance (SPR) and has mainly been used to define T 
cell affinity. KD measures the dissociation rate of two molecules. Therefore, the higher 
the KD, the lower the T cell affinity. More recently, NTA-His tag-containing multimers 
(NTAmers) have been developed. These multimers, as conventional multimers, bind to 
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TCRs, but upon imidazole addition they rapidly dissociate into pMHC monomers 
allowing the measurement of monomeric TCR –pMHC dissociation rates (Koff and t1/2). 
Unlike SPR experiments which involve recombinant soluble TCR and pMHC complexes, 
NTAmers measure TCR – pMHC interactions on the cell surface, and so far, only MHC 
I NTAmers are available (Schmidt, Dojcinovic, Guillaume, & Luescher, 2013). 
Therefore, NTAmers but not SPR, include the contribution of the CD8 co-receptor, 
known to stabilize TCR –pMHC complexes. Nonetheless, NTAmer based dissociation 
kinetics generally correlate well with SPR measured affinities (Hebeisen et al., 2015).  
 
T cell avidity 
It defines the interaction strength between several TCRs and pMHC molecules (Figure 3, 
middle panel). It can be measured by pMHC multimer staining on the cell surface of T 
cells. The binding of multimeric pMHC to T cells correlates with monomeric TCR –
pMHC affinity (Crawford, Kozono, White, Marrack, & Kappler, 1998). Therefore, the 
fluorescence intensity of pMHC multimer staining can be used to have an idea of the 
affinity of a T cell for its ligand, avoiding the laborious and expensive production of 
Figure 2. Illustration of T cell affinity, T cell avidity and functional avidity of T cells. The three parameters measure 
the interaction strength between the TCR and pMHC. However, while the TCR affinity defines the strength between 
single pMHC-TCR molecules, the T cell avidity measures the strength of the multimeric TCR-pMHC interaction and 
the contribution of the CD8/CD4 co-receptor. The functional avidity determines the amount of antigen needed for a T 
cell response and therefore depends on the TCR avidity but also the presence of co-stimulatory and co-inhibitory 
receptors as well as the differentiation state of the cell (Jandus, Martínez-Usatorre, Vigano, Zhang, & Romero, 2017). 
TCR affinity T cell avidity Functional avidity
APC/target cell
pMHC
CD4/CD8
Co-stimulatory 
molecules
Perforin
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soluble TCRs for SPR measurements. Of note, pMHC multimer staining also reflects the 
contribution of the CD8 or CD4 co-receptor (Crawford et al., 1998). 
 
Functional avidity 
It defines the sensitivity of a T cell to the antigen as translated in effector functions (Figure 
3, right panel). It inversely correlates with the antigen dose needed for the triggering of a 
T-cell response. The antigen concentration needed to reach half of a maximum response 
(EC50) is the parameter used to define the functional avidity of a T cell. The main 
functional readouts are the EC50 for proliferation, cytokine production, and target cell 
lysis. As the functional avidity is a cellular measurement, it is influenced by many 
parameters. T cell affinity normally correlates with functional avidity, yet not always. 
Expression levels of the TCR, co-receptors and adhesion molecules also influence the 
binding strength between a T cell and an antigen presenting cell/target cell. Moreover, 
expression of inhibitory and co-stimulatory molecules modulates the T cell response and 
sensitivity to the antigen. 
High functional avidity T cell responses mediate efficient virus clearance (Berger et al., 
2011). In addition, since many tumors are characterized by low antigen presentation and 
absence of co-stimulatory signals, higher-avidity CD8+ T cells promote more efficient 
tumor rejection (Dutoit et al., 2001). However, low avidity antigen recognition may be 
useful to better discriminate self-antigens overexpressing tumors from healthy tissues (D. 
J. Morgan et al., 1998), thus preventing autoimmunity. Moreover, when T cells are 
chronically exposed to the antigen as in chronic infections, low functional avidity T cells 
may be less sensitive to activation induced cell death, exhaustion, and senescence 
(Anderton, Radu, Lowrey, Ward, & Wraith, 2001; Utzschneider, Alfei, et al., 2016). 
Thus, in the first part of this thesis we study the impact of T cell avidity on CD8+ T cells 
anti-tumor responses.  
 
1.8. T cell exhaustion 
Upon acute infections, CD8+ T cells massively expand. However, when the antigen is 
cleared and inflammation is resolved most of them die and only memory CD8+ T cells 
remain. In contrast, in chronic infections and cancer, there is a persistent inflammation 
and antigen exposure which alters the conventional CD8+ T differentiation and memory 
formation described in acute responses (Wherry, 2011). For instance, studies on HIV 
infected patients and on mice chronically infected with the LCMV cl13, revealed that 
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CD8+ T cells progressively and hierarchically loose effector functions, first the ability to 
kill target cells and produce IL-2, followed by TNFa secretion and finally IFNg 
production (Wherry, Blattman, Murali-Krishna, van der Most, & Ahmed, 2003). In 
addition, they up-regulate multiple inhibitory receptors (PD-1, CTLA-4, LAG-3, 2B4, 
CD160 and TIM-3) (Blackburn et al., 2009), show poor proliferative capacity and are 
unable to persist in the absence of antigen (Altfeld et al., 2002; Wherry, Barber, Kaech, 
Blattman, & Ahmed, 2004). This differentiation state is commonly known as T cell 
exhaustion and characterized by a transcriptional state that differs from the one of effector 
and memory cells during acute infections. Transcriptional changes are observed in cell 
metabolism pathways, cell cycle regulation and transcription factor expression (Doering 
et al., 2012; Wherry et al., 2007).  
Chronic antigen stimulation has been identified as the major driver leading to this 
differentiation state (Utzschneider, Alfei, et al., 2016; Wherry et al., 2003). Nonetheless,  
lack of CD4+ T cell help (Matloubian, Concepcion, & Ahmed, 1994), signaling through 
inhibitory receptors (Quigley et al., 2010) and immunosuppressive cytokines (Brooks et 
al., 2006; Teijaro et al., 2013) also contribute to this status. As chronic infections and 
tumors are commonly characterized by chronic antigen stimulation and inflammation, 
tumor infiltrating CD8+ T lymphocytes (CD8+ TILs) also show exhausted T cell 
characteristics such as increased expression of inhibitory receptors (Baitsch et al., 2011) 
and decreased capacity to produce IFNg, perforin and Granzyme B upon ex vivo 
restimulation (Zippelius et al., 2004). However, less is known about the exact 
mechanisms leading to this impairment. Chronic antigen stimulation may be one of the 
reasons as tumor specific CD8+ T cells from blood of patients show robust inflammatory 
and cytotoxic functions and have low expression levels of inhibitory receptors (Baitsch 
et al., 2011; Zippelius et al., 2004). In addition, CD4+ T cells are important for CD8+ T 
cell mediated anti-tumor responses as they enhance recruitment and cytolytic activity of 
tumor specific CD8+ T cells (Bos & Sherman, 2010) and prevent CD8+ T cells peripheral 
tolerance (Kirberg, Bruno, & von Boehmer, 1993). In fact, central tolerance of the 
majority of tumor-associated antigens results on the maturation of only low affinity 
self/tumor-specific CD8+ T cells that are poorly primed by antigen presenting cells 
(APCs) due to the lack of innate stimulators needed for APC maturation in the 
immunosuppressive tumor microenvironment (Gabrilovich, 2004). Therefore, CD8+ TILs 
are found in a mixed anergic and exhausted hyporesponsive state.  
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Despite the inability of exhausted CD8+ T cells to clear the tumor or infection, they are 
not inert but retain some functionality that limits pathogen replication and tumor 
progression. It is now accepted that this exhausted state is a way of minimizing tissue 
damage while still mediating some pathogen/tumor control (Speiser et al., 2014).  In fact, 
a memory-like TCF-1-expressing CD8+ T cell population has recently been described as 
able to sustain the CD8+ T cell response in chronic viral infections (Utzschneider, 
Charmoy, et al., 2016). In addition, T cell exhaustion seems to be reversible, at least at 
the bulk population level, as seen by the success of immunotherapies blocking inhibitory 
receptors and targeting co-stimulatory molecules expressed by exhausted T cells, which 
rescue T cell functionality (Sharma & Allison, 2015). This suggests that high inhibitory 
signals in combination with lack of costimulation is the major constraint of tumor 
infiltrating CD8+ T cell functionality.   
 
2. Micro-RNAs 
2.1. Biogenesis and roles of microRNAs 
MicroRNAs (miRs) are endogenous noncoding ~22nt long RNAs found in multicellular 
organisms which regulate the expression of proteins at post-transcriptional level. They 
target mRNAs, mostly for their degradation or translational repression (Bartel, 2004). 
Each miR can target numerous mRNAs, and each single mRNA is commonly targeted by 
multiple miRs (Bartel, 2009). Thus, miRs have an enormous combinatorial complexity 
and regulatory potential. The majority of miRs are processed from longer primary 
transcripts (pri-miRs), which are either encoded in independent miR genes or are matured 
from introns or exons of protein-coding mRNAs (V. N. Kim, Han, & Siomi, 2009). 
Pri-miRs are divided into two major classes, canonical and non-canonical, depending on 
their maturation process. The canonical pri-miRs (Figure 4) are transcribed by RNA 
polymerase II and recognized by the Microprocessor complex. This complex is mainly 
composed by the RNase type III endonuclease Drosha and the double-stranded RNA-
binding protein DiGeorge critical region 8 (DGCR8). DGCR8 recognizes the RNA 
substrate that Drosha will cleave in a processed known as cropping, producing ~70 
nucleotide hairpin structured precursor miRs (pre-miRs) (Denli, Tops, Plasterk, Ketting, 
& Hannon, 2004). Pre-miRs exit the nucleus by exportin5 via a Ran-GTP dependent 
mechanism. Once in the cytoplasm, pre-miRs are processed by the RNase type III enzyme 
Dicer (Yi, Qin, Macara, & Cullen, 2003). An argonaute (AGO) protein and a glycine–
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tryptophan repeat-containing protein of 182 kDa (GW182) bind the resulting ~22 
basepair miR, forming the core of a multi-subunit complex called miR-induced silencing 
complex (miRISC) (Fabian & Sonenberg, 2012). While one of the miR strands is 
discarded from the complex, the remaining one determines which mRNAs will be 
targeted. Partial complementarity of the miR seed region (nucleotides 2-8 from the 5’ 
end) to the target mRNA typically induces translational repression followed by de-
adenylation and mRNA decay (Bethune, Artus-Revel, & Filipowicz, 2012; Djuranovic, 
Nahvi, & Green, 2012; Fabian & Sonenberg, 2012), whereas perfect base pairing leads 
to endonucleolytic cleavage of the target mRNA by AGO2 in vertebrates (J. Liu et al., 
2004). Nonetheless, in specific cellular conditions such as cell cycle arrest, miR-mediated 
mRNA upregulation has also been observed (Vasudevan, Tong, & Steitz, 2007).    
The non-canonical pri-miRs differ from the canonical pri-miRs on their maturation 
process. They do not require all the protein factors required by the canonical pri-miRs to 
become mature miRs. For example, some pre-miRs are produced by splicing, not by 
Drosha cleavage (Okamura, Hagen, Duan, Tyler, & Lai, 2007). However, most of the ~22 
nt long mammalian RNAs are canonical miRs (Graves & Zeng, 2012).  
Over 2500 miRs have been identified 
in humans (http://www.mirbase.org, 
miRBase 21 release,(Kozomara & 
Griffiths-Jones, 2014)) which play an 
important role in several biological 
processes by targeting multiple 
components of regulatory networks 
(Lewis, Shih, Jones-Rhoades, Bartel, 
& Burge, 2003). Combinations of 
bioinformatic, biochemical and 
genetic approaches have revealed the 
role of miRs as regulatory elements in 
the control of cellular development, 
homeostasis and response of the 
immune system (Xiao & Rajewsky, 
2009). For instance, Dicerflox/flox 
CD4cre mice, whose T cells lose the 
expression of Dicer in the double 
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Figure 4. Biogenesis of canonical miRs. RNA polymerase 
transcribed pri-miRNAs are processed in the nucleus by the 
DROSHA and DGCR8 containing Microprocessor complex 
generating pre-miRNAs. These pre-miRNAs exit the nucleus, 
where they are further processed by DICER, producing mature 
miRNAs. One of the miRNA strands is discarded while the other 
binds an Argonaute protein generating the miRNA-induced 
silencing complex (miRISC) that cleaves or represses the 
translation of target mRNAs.  
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positive stage during thymic development, show reduced numbers of peripheral T cells, 
suggesting the requirement of Dicer for maturation and homeostasis of peripheral T 
lymphocytes. Moreover, Dicer deficient T cells show decreased proliferation and 
increased apoptosis in response to activation (Muljo et al., 2005). Nonetheless, the roles 
of individual miRs in T cell biology are just beginning to emerge.  
 
2.2. miR-155 
The human and mouse miR-155 resides in the exon 3 of B-cell integration cluster (BIC) 
transcript, originally identified as a gene transcriptionally activated by promoter insertion 
at a common retroviral integration site in B cell lymphomas  (Tam, Ben-Yehuda, & 
Hayward, 1997). In fact, overexpression of miR-155 is found not only in human B cell 
lymphomas (Eis et al., 2005) but also in non-hematopoietic cancers such as breast (Iorio 
et al., 2005), pancreatic (Lee et al., 2007) and lung cancer (Yanaihara et al., 2006). In 
addition, transgenic mice overexpressing miR-155 develop B cell malignancies 
(Costinean et al., 2006). Thus, miR-155 is considered as an oncomiR. However, the 
recently assembled list of miR-155 targets by Neilsen et al. comprise 140 genes including 
regulatory proteins for myelopoiesis and leukemogenesis (AICDA, ETS1, JARID2 etc.), 
inflammation (BACH1, FADD, IKBKE, INPP5D, MYD88, SPI1, SOCS1 etc.) and tumor 
suppressor genes (C/EBPβ, IL17RB, PCCD4, TCF12 etc) (Neilsen et al., 2013), 
indicating that miR-155 plays an important role in many biological processes. It has been 
suggested that miR-155 plays a role in TNF-a dependent adipogenesis inhibition (S. Liu, 
Yang, & Wu, 2011), and since the human miR-155 resides on chromosome 21 
(http://www.mirbase.org), it has been hypothesized that certain characteristics of  
individuals  with trisomy 21 are due to reduced expression of miR-155 target proteins. 
For instance, reduced blood pressure and risk for cardiovascular diseases in individuals 
with trisomy 21 may be due to increased miR-155 expression levels and consequent 
reduced angiotensin II receptor type 1 (AT1R) expression in fibroblasts (Draheim, 
McCubbin, & Williams, 2002; Sethupathy et al., 2007). Moreover, the defective DC 
mediated antigen presentation and impaired T and B cell responses observed in BIC 
deficient mice indicates that miR-155 is essential for immune responses (Rodriguez et 
al., 2007).  
Altogether, through the transcriptional repression of different mRNAs, miR-155 plays an 
important role in many biological functions including the immune system (Figure 5). 
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2.3.  Role of miR-155 in the immune system 
miR-155 is upregulated upon antigen receptor stimulation in mouse and human B and T 
cells (Haasch et al., 2002; Rodriguez et al., 2007; Stahl et al., 2009), as well as upon 
stimulation of Toll-like receptors in macrophages and dendritic cells (Taganov, Boldin, 
Chang, & Baltimore, 2006) via NF-κB and AP-1 transcription factors (Kluiver et al., 
2007; O'Connell, Taganov, Boldin, Cheng, & Baltimore, 2007; Tili et al., 2007; Yin et 
al., 2008).  
However, soluble factors also modulate miR-155 expression. While IL-2 and IL-15 
induce miR-155 expression in T cells in a STAT5 dependent manner (Kopp et al., 2013), 
IL-10 has been shown to suppress miR-155 expression in bone marrow derived 
macrophages. This suppression depends on STAT3 and Ets1 transcription factor binding 
site, located in the miR-155 promoter (McCoy et al., 2010).  
MiR-155 expression is also controlled by FoxP3, the essential transcription factor for 
Tregs (Cobb et al., 2006). In fact, miR-155 deficiency results in diminished Treg 
numbers, suggesting that it is an important miR for Treg development (Kohlhaas et al., 
2009). In addition, miR-155 deficient Tregs show reduced proliferation in the presence 
of limiting amounts of IL-2 due to increased expression of suppressors of cytokine 
signaling 1 (SOCS1), a miR-155 target that negatively regulates IL-2 signaling  (L. F. Lu 
et al., 2009). Not only Tregs, other CD4+ T cell subsets also require miR-155. Th1 and 
Th17 CD4+ T cell differentiation is controlled by miR-155 as miR-155 deficient CD4+ T 
cells show skewed differentiation towards Th2. Such imbalanced differentiation is 
probably due to increased expression of the c-Maf miR-155 target TF (Rodriguez et al., 
2007). In addition, CD4-cre MiR155fl/fl mice have increased resistance to Th17-
dependent experimental autoimmune encephalomyelitis (EAE) (O'Connell et al., 2010), 
suggesting that miR-155 could be a therapeutic target for the treatment of autoimmune 
diseases.  
MiR-155 also plays a role in T cell dependent B cell responses as it is important for Tfh 
CD4+ T cell differentiation (Hu et al., 2014) and B cells. MiR-155 deficiency in B cells 
leads to reduced generation of germinal centers (GC) and diminished production of high 
affinity isotype switched Abs (Thai et al., 2007; Vigorito et al., 2007). MiR-155 GC 
regulation is, at least impart, through PU.1 targeting, which at the same time regulates 
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proteins involved in T-B cell interactions and down-regulates Pax5, a negative regulator 
of B cell terminal differentiation (D. Lu et al., 2014). 
Not only the adaptive immune system, miR-155 is also important for cells of the innate 
immune system such as macrophages (Squadrito, Etzrodt, De Palma, & Pittet, 2013). It 
is involved in the macrophage-fate commitment from progenitors, as its upregulation 
drives differentiation of RAW264.7 into macrophages by inhibition of osteoclast 
transcriptional machinery (Mann, Barad, Agami, Geiger, & Hornstein, 2010). In addition, 
miR-155 enhances TNFa production by stabilizing TNFa mRNA (Bala et al., 2011) and 
promotes classical inflammatory M1 macrophage differentiation (Jablonski, Gaudet, 
Amici, Popovich, & Guerau-de-Arellano, 2016) by downregulating SOCS1 (Wang et al., 
2010), BCL-6 (Nazari-Jahantigh et al., 2012) and IL13 receptor, which promotes 
alternative/M2 macrophage differentiation (Martinez-Nunez, Louafi, & Sanchez-Elsner, 
2011). In fact, miR-155 delivery in alternatively activated macrophages was shown to be 
sufficient to repolarize the cells into proinflammatory macrophages (Cai et al., 2012). 
Moreover, miR-155 deficiency in myeloid cells led to a skewed differentiation into a 
M2/Th2 phenotype and accelerated spontaneous breast cancer development  (Zonari et 
DC		
CD8+	T	cells
TregsMacrophages
CD4+ T	cells
miR-155
B	cells
Figure 5. Role of miR-155 in immune cells. miR-155 plays important and specific roles in cells of the innate 
(macrophages and DCs) and adaptive immune system (T cells and B cells). Therefore, it is essential to mount effective 
immune responses.  
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al., 2013). Finally, the key players in the cross-talk between the innate and adaptive 
immune system, DCs, also require miR-155 for the efficient activation of T cells 
(Rodriguez et al., 2007).  
 
2.4. miR-155 and CD8+ T cell function 
The differential expression of miR-155 observed in healthy individuals’ peripheral blood 
CD8+ T cell subsets (Salaun et al., 2011) indicate that miR-155 plays a role in CD8+ T 
cell function. In fact, studies in our lab using miR-155-deficient murine T cells have 
shown that miR-155 is required for effector CD8+ T cell responses against viruses and 
tumors. MiR-155 deficiency leads to curtailed proliferation and CD8+ T cell expansion 
upon acute LCMV and WSN acute viral infections (Dudda et al., 2013; Gracias et al., 
2013). Gracias et al. observed that miR-155 deficiency led to enhanced susceptibility to 
type I interferon’s antiproliferative signaling (Gracias et al., 2013). However, Dudda et 
al. showed that reduced proliferation and increased apoptosis of miR-155 deficient CD8+ 
T cells was due to increased expression of the miR-155 target SOCS-1 (Dudda et al., 
2013), a negative regulator of gc cytokine signalling (Cornish et al., 2003). In fact, the 
increased anti-tumor efficacy of miR-155 overexpressing CD8+ T cells also depended on 
homeostatic gc cytokine signalling. Not only SOCS-1 but another negative regulator of 
STAT5, PTPN2, was downregulated in miR-155 overexpressing CD8+ T cells and 
contributed to their enhanced survival (Ji et al., 2015). Of note, CD8+ T cells effector 
functions, such as IFNg and TNF-a production, are also increased upon miR-155 
overexpression (Gracias et al., 2013; Ji et al., 2015).  
Altogether, extensive studies on murine CD8+ T cells have demonstrated that miR-155 is 
important for CD8+ T cell responses but less is known about how this is translated into 
human CD8+ T cell responses, in particular, in cancer patients. Therefore, one of the aims 
of this thesis, addressed in part 2, is to study the role and regulation of miR-155 in cancer 
patients’ CD8+ T cells. 
 
3. Cancer immunity 
3.1. Cancer 
Cancer is a major public health problem with an increasing global burden due to the aging 
and growth of the world population, as well as to cancer-causing behaviors (Jemal et al., 
2011).  Tumor cell transformation is driven by the accumulation of somatic mutations 
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that ultimately lead to the acquisition of the hallmarks of cancer: genomic instability, 
sustained cell proliferation, resistance to cell death, evasion of growth suppressors, 
replicative immortality, metabolic deregulation, promotion of inflammation, 
angiogenesis induction, evasion of immune regulation, invasion and metastasis (Hanahan 
& Weinberg, 2011). Conventional surgery, radiotherapy and chemotherapy efficiently 
induce remission of certain cancer types. However, cancer is still one of the most difficult 
humankind affecting disease to cure as it is a highly dynamic disease that constantly 
adapts and eventually progresses most of the time. One of the reasons is that many 
different genes are implicated in the development of cancer, which differ between types 
of cancers, tumor sites, cancer cells within the same tumor and over time in response to 
selective pressure induced by treatments. Moreover, cancer cells recruit stromal cells that 
also contribute to tumorigenesis. Hence, tumors are heterogeneous tissues composed by 
distinct types of cells that interact with one another creating a complex tumor 
microenvironment that evolves during the course of the disease (Hanahan & Weinberg, 
2011). Such dynamic complexity makes it difficult to treat. Thus, efforts are being made 
to understand cancer biology and develop new therapies against cancers like melanoma, 
which is generally considered resistant to irradiation and conventional chemotherapy 
(Trinh, 2008).  
 
3.2. Cancer immunosurveillance 
Opposing roles of the immune system in cancer have been described: support of tumor 
growth and anti-tumor immune response. Certain types of immune cells can induce 
proliferation, survival and invasion of cancer cells as well as angiogenesis (Hanahan & 
Weinberg, 2011). However, already 50 years ago, the idea that the adaptive immune 
system recognizes and destroys tumor cells was conceived (Burnet, 1957). In the last 
decade, several laboratories have demonstrated that the immune system can protect mice 
from outgrowth of many different types of primary and transplantable tumors (Shankaran 
et al., 2001; Swann & Smyth, 2007). Moreover, Shankaran et al. observed that tumors 
from immunocompetent mice were less immunogenic than tumors from immunodeficient 
mice when transplanted into secondary immunocompetent hosts, demonstrating that the 
immune system not only prevents tumor formation but also edits tumor immunogenicity 
(Shankaran et al., 2001). Nonetheless, tumors arise in immunocompetent hosts.  Thus, 
the interaction between the immune system and tumors is a complex and evolving 
process, nowadays conceived as tumor immunoediting. This process can be divided into 
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three phases: elimination, equilibrium and escape, in which cells of the innate and 
adaptive immune system participate. In the first phase, immune cells prevent tumor 
formation by recognizing and destroying arising cancer cells. The equilibrium or tumor 
dormancy phase is a dynamic balance between the immune system and the tumor. The 
immune system can still recognize and destroy cancer cells but some of them already 
acquire immune evasion properties preventing the complete eradication of cancer cells. 
Finally, in the escape phase the immune system is no longer able to control the tumor 
growth and may even select more aggressive tumor cell variants and promote tumor cell 
proliferation (Vesely, Kershaw, Schreiber, & Smyth, 2011). 
 
3.3. Tumor antigens  
Based on the observation that T cells can recognize and specifically kill tumor cells, 
genetic and biochemical approaches have been used to identify tumor associated antigens 
that trigger anti-tumor immune response (Cox et al., 1994; Sahin et al., 1995; van der 
Bruggen et al., 1991). As a result, a relatively long list of MHC I and MHC II restricted 
tumor antigens is now available under http://cancerimmunity.org/peptide/.  Two major 
groups of tumor antigens can be distinguished: non-mutated shared antigens and unique 
neoantigens originated from non-synonymous somatic mutations. Shared antigens are 
present on many independent tumors and can be further divided into three groups: 1) 
cancer-germline antigens such as NY-ESO-1 whose expression are restricted to germ 
cells and trophoblast tissues but frequently overexpressed in cancer cells due to epigenetic 
dysregulation (Akers, Odunsi, & Karpf, 2010), 2) differentiation antigens like Melan-A 
in melanoma, which are expressed in the tumor and the normal tissue of origin and 3) 
overexpressed antigens such as telomerase or HER2, which are antigens expressed in a 
wide variety of normal tissues and overexpressed in tumors. This classification is useful 
to determine the potential usefulness of a given tumor antigen for cancer immunotherapy 
such as vaccine based immunotherapy (Speiser et al., 2008; Valmori et al., 2007; J. Weber 
et al., 2008; Weide et al., 2008; Yamada, Sasada, Noguchi, & Itoh, 2013) or adoptive 
transfer of engineered T cells (Kalos & June, 2013). In melanoma, NY-ESO-1 and Melan-
A have been for a long-time priority targets for immunotherapy (Balasse, Gatouillat, 
Patigny, Andry, & Madoulet, 2009; Caballero & Chen, 2009).  
MHCI and MHCII restricted neoantigens have more recently been identified thanks to 
advances in deep sequencing of nucleic acids. They result from point mutations in genes 
that are expressed ubiquitously and are unique to the tumor of an individual patient or 
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restricted to some patients. Two studies using mouse tumor models demonstrated for the 
first time the possibility to identify neoantigens that are recognized by T cells. The 
technological pipeline used to identify such neoantigens involved deep exome sequencing 
of tumor material, followed by in silico prediction of major histocompatibility complex-
binding capacity of the identified mutated peptides and final query of T cell reactivity 
(Castle et al., 2012; Matsushita et al., 2012). Following these studies, cancer exome based 
neoantigen identification has also been reported in human malignancies (Robbins et al., 
2013; van Rooij et al., 2013). However, most non-synonymous mutations identified by 
cancer exome sequencing are not recognized by autologous T cells. Thus, additional 
filtering of neoantigen candidates is crucial. In preclinical models, cancer exome 
sequencing data has been used to guide neoantigen discovery by mass spectrometry 
(Gubin et al., 2014; Yadav et al., 2014). However, implementation of this approach as 
standard care in clinical settings is nowadays technically and economically unfeasible. 
Nonetheless, mass spectrometry data of MHC-bound peptides, immunoproteasome 
processing predictive algorithms (Gubin et al., 2014), MHCI binding algorithms and 
information about gene expression levels (Fortier et al., 2008) could be combined to 
optimize MHC presentation algorithms and facilitate the identification of immunogenic 
neoantigens.   
As neoantigens arise from somatic mutations it is reasonable to expect that tumors with 
high mutational load (Alexandrov et al., 2013) are more likely to present neoantigens.  In 
fact, neoantigens are frequent in tumors with mutational loads above 10 somatic 
mutations per Mbp such as melanoma, lung carcinoma and colorectal cancer  
(Alexandrov et al., 2013; Schumacher & Schreiber, 2015). Somatic mutations are 
consequence of exogenous factors such carcinogens (Pfeifer et al., 2002), ultraviolet 
exposure and anticancer drugs (Hunter et al., 2006) as well as defects in cell intrinsic 
mechanisms: altered activity of the error-prone polymerase Pol e (Cancer Genome Atlas, 
2012), over activity of APOBEC family of cytidine deaminases (Alexandrov et al., 2013), 
inactivation of DNA mismatch repair machinery (Boland & Goel, 2010) and defects in 
DNA-double-strand break repair machinery. However, the presence of somatic mutation 
derived neoantigens does not guarantee the existence of reactive T cells (Schumacher & 
Schreiber, 2015). 
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3.4. Immunotherapy 
Although tumor-specific CD8+ T cells can be detected in cancer patients, they display an 
exhausted phenotype in the tumor (Baitsch et al., 2011). Several factors contribute to this 
dysfunctional state such as impaired antigen-presentation, lack of costimulation, low 
affinity antigen recognition, T cell inhibition and the presence of immunosuppressive 
soluble factors. Therefore, different immunotherapies are being developed to overcome 
such hurdles and boost the immune system to eliminate the tumor and cure patients that 
are refractory to conventional chemotherapy and radiotherapy.  
 
Therapeutic cancer vaccines 
One of the strategies to improve antigen presentation and CD8+ T cell priming is 
vaccination. The field of therapeutic cancer vaccines has greatly evolved in the past years, 
whereby vaccines with different antigenic composition, delivery system, adjuvants and 
administration modalities have been designed. Administration of native tumor antigen 
peptides in combination with adjuvants (Incomplete Freund’s adjuvant and CpG) elicited 
some specific T cell responses in melanoma patients but failed to confer clinical benefit 
(Parkhurst et al., 2004; Speiser et al., 2008). Vaccination with an analog tumor peptide 
(gp100209-217) in combination with IL-2, however, showed clinical benefit in melanoma 
patients (Schwartzentruber et al., 2009), indicating that antigens that are not subject to 
central tolerance may be better candidates for therapeutic cancer vaccines. In fact, 
vaccination with idiotypes, epitopes found in the hypervariable regions of the Ig variable 
domain of B cells, elicited humoral and cellular responses and increased disease-free 
survival in follicular lymphoma patients (Inoges et al., 2006). Moreover, vaccination with 
neoantigen peptides in combination with poly-ICLC (Caskey et al., 2011) and 
percutaneous injection of neoantigen coding RNA into lymph nodes induced 
polyfunctional CD4+ and CD8+ specific T cell responses and  prolonged progression-free 
survival in melanoma patients (Ott et al., 2017; Sahin et al., 2017).  
In an attempt to enhance tumor-antigen presentation, vaccines containing peptides, 
proteins, whole tumor lysates or mRNA loaded DCs have also been used in clinical trials 
and induced specific T cell responses (Chiang et al., 2013; Linette et al., 2005). For 
instance, vaccination with autologous APCs loaded with GM-CSF-prostatic acid 
phosphatase (PAP) fusion protein (Sipuleucel-T, Provenge) has prolonged overall 
survival of castrate-resistant metastatic prostate cancer patients and was approved by the 
FDA in 2010 (Kantoff et al., 2010). Neoantigens have also been combined with DCs in 
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vaccine formulations and elicited neoantigen-specific T cell responses in three malignant 
melanoma patients (Carreno et al., 2015). Tumor antigen delivery with viral vectors or 
by intramuscular injection of coding DNA have also been applied, yet with poor clinical 
benefit (Jager et al., 2006; Lienard et al., 2004; van Baren et al., 2005; Yuan et al., 2009). 
Thus, cancer vaccines have shown capacity to induce specific CD8+ T cell responses but 
still need to be improved to increase their so far modest clinical efficacy. International 
consortiums to converge efforts may be necessary to fully understand the human 
antitumor immune responses and develop clinically effective therapeutic cancer vaccines 
(Romero et al., 2016).  
 
Adoptive cell therapy 
Despite the detection of naturally occurring tumor specific CD8+ T cells in cancer 
patients, they are outnumbered in tumors. That led to the development of adoptive cell 
therapy (ACT), which consists on isolating lymphocytes from fresh tumors, expanding 
them in vitro and transferring them back to the patients. Already in 1988, metastatic 
melanoma patients were treated with in vitro expanded autologous tumor infiltrating 
lymphocytes and objective regression was achieved in 60% of the patients (Rosenberg et 
al., 1988). Selection and expansion of tumor-reactive TILs was later applied and induced 
clinical remission in 46% of metastatic melanoma patients (Dudley et al., 2002). This 
selection process however is limited as it requires between 21 and 36 days of in vitro 
culture, not always available autologous melanoma cell lines and IFNg-secreting TILs, 
that are only found in half of the patients (Besser et al., 2009). Therefore, a short-term 
(10-18 days), tumor reactivity independent, TIL culture was later stablished that enabled 
generation of young-TILs with longer telomeres and higher levels of costimulatory 
molecules CD27 and CD28, which led to longer in vivo persistence (Donia et al., 2012; 
Powell, Dudley, Robbins, & Rosenberg, 2005; Tran et al., 2008). Administration of these 
ex vivo young-TILs induced tumor regression in 50% of previously lympho-depleted 
metastatic melanoma patients (Besser et al., 2010; Besser et al., 2009). Among young-
TIL products, specificities for shared-tumor antigens, mainly melanoma differentiation 
antigens followed by cancer/testis antigens and ultimately overexpressed antigens could 
be identified, but also neoantigen specificities (Kvistborg et al., 2012). 
An alternative to the T cell isolation from fresh tumors is the selection of tumor specific 
lymphocytes from patients’ peripheral blood. To do that, peripheral blood lymphocytes 
are cocultured with tumor antigens expressing antigen-presenting cells and after several 
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cycles of stimulations tumor-specific T cell clones can be generated. Infusion of tumor-
specific T cell clones in combination with low dose of IL-2 led to regression of metastases 
and stable responses in 8/10 metastatic melanoma patients (Yee et al., 2002). 
Genetic engineering has also been used to introduce tumor specific TCRs into T cells of 
any specificity and thus bypass tumor-specific T cell selection process. Natural occurring 
tumor specific TCRs but also TCRs with enhanced affinity for the tumor antigen have 
been applied reaching 80% of clinical response with the latest strategy in multiple 
myeloma patients (Rapoport et al., 2015). Another strategy to confer tumor antigen 
recognition is the transduction of chimeric antigen receptors (CARs) which couple 
antibody-mediated tumor recognition to TCR signaling domains (Gross, Waks, & Eshhar, 
1989). CARs carry a B cell receptor derived single chain variable fragment on the 
extracellular domain and CD3ζ alone (first generation CAR) or in combination with one 
(second generation) or more (third generation) intracellular costimulatory domains. In 
addition of having around 105 increased affinity for the ligand (KD=10-9M) (Arcangeli et 
al., 2017)  compared to self-tumor antigen specific TCRs (KD=10-4-10-5 M) (Cole et al., 
2007), CARs bypass the weak MHC dependent antigen presentation in tumors. Thus, 
enabling HLA haplotype independent treatment of patients. CAR therapy has shown 
impressive results in hematopoietic malignancies, reaching up to 80-90% complete 
responses. Therefore, the FDA approved anti-CD19 CARs Tisagenlecleucel (Kymriah, 
Novartis) for pediatric and young adult patients with relapsed and/or refractory B-cell 
precursor acute lymphoblastic leukaemia (B-ALL) and Axicabtagene ciloleucel 
(Yescarta, Kite Pharma) for patients with refractory large B-cell lymphoma in 2017. Both 
CARs are second generation CARs containing 4-1BB and CD28 costimulatory molecules 
respectively (Maude et al., 2014; Neelapu et al., 2017). However, despite the high clinical 
efficacy of anti-CD19 CARs, toxicity is still an issue to overcome (Shank et al., 2017).  
Unlike hematological malignancies, solid tumors often remain refractory to CAR therapy 
(Gauthier & Yakoub-Agha, 2017). Poor T cell trafficking and immunosuppressive tumor 
microenvironment are the main factors that contribute to the low efficacy of CAR therapy, 
and ACT in general, in solid tumors. Impaired T cell trafficking is linked to the lack of 
homing chemokine receptors expression in T cells (Chen et al., 2016) and abnormal tumor 
vasculature (Peske, Woods, & Engelhard, 2015; Sapoznik et al., 2012). Thus, engineered 
T cells expressing homing chemokine receptors such as CXCR1 and normalization of the 
tumor vasculature with antiangiogenic agents have shown improvement of ACT 
effectiveness (Sapoznik et al., 2012; Shrimali et al., 2010). Nonetheless, even if T cells 
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reach the tumor, they encounter a highly immunosuppressive environment that impairs 
their functionality. Immune cells such as CD4+ Tregs, myeloid-derived suppressor cells 
(MDSCs) and immunosuppressive macrophages contribute to the suppression by 
producing TGF-β and IL-10 immunosuppressive cytokines, releasing oxygen and 
nitrogen radicals and/or several enzymatic activities, e.g indoleamine 2,3-dioxygenase 
(IDO) and arginase that deplete tryptophan and L-arginine supplies respectively (Chen et 
al., 2016; T. Lu et al., 2011; Mantovani, Sozzani, Locati, Allavena, & Sica, 2002).   
Moreover, the tumor cells can directly inhibit T cells by secreting immunosuppressive 
cytokines (Coffey, Shipley, & Moses, 1986; J. Kim et al., 1995; Salomon, Ciardiello, 
Valverius, Saeki, & Kim, 1989) or expressing PD-L1 which binds to the TCR signaling 
negative regulator PD-1 receptor expressed in T cells  (Blank, Gajewski, & Mackensen, 
2005). Together with PD-1, many other negative regulators expressed by tumor 
infiltrating T cells that contribute to their reduced functionality have been described in 
the past years, leading to the onset of the immune checkpoint blockade (ICB) therapy 
field.  
 
Immune checkpoint blockade therapy 
ICB therapy aims to block negative regulators or activate stimulatory pathways to unleash 
full functionality of tumor-infiltrating T cells. Ipilimumab, an antibody against the 
CTLA-4 negative regulator of T cell responses that binds to B7 molecules (Krummel & 
Allison, 1995; Leach, Krummel, & Allison, 1996; Walunas et al., 1994), was the first ICB 
therapy brought to the clinics after successful preclinical testing (Leach et al., 1996). 
Phase I/II trials showed clinical response in patients with melanoma (J. S. Weber et al., 
2008), renal cell carcinoma (Yang et al., 2007), prostate cancer (van den Eertwegh et al., 
2012), urothelial carcinoma (Carthon et al., 2010) and ovarian cancer (Hodi et al., 2008). 
Moreover, two ipilimumab phase III trials showed improved overall survival in metastatic 
melanoma patients (Hodi et al., 2010; Robert et al., 2011).  
The discovery of the PD-1/PD-L1 inhibitory pathway (Freeman et al., 2000; Ishida, 
Agata, Shibahara, & Honjo, 1992) led to the generation of PD-L1 and PD-1 blocking 
antibodies. PD-L1 phase I clinical trials induced tumor regression in melanoma, renal cell 
carcinoma, non-small cell lung cancer and bladder cancer patients (Brahmer et al., 2012; 
Powles et al., 2014). Moreover, phase III clinical trials of PD-1 blocking monoclonal 
antibodies showed impressive clinical response in metastatic melanoma (Robert et al., 
2015) and non-small cell lung cancer patients (Borghaei et al., 2015). Thus, FDA 
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approved Nivolumab (OPDIVO, Bristol-Myers Squibb Company), PD-1 blocking 
antibody, in 2014 for the treatment of unresectable or metastatic melanoma, in 2015 for 
non-small cell lung cancer and advanced renal carcinoma, in 2016 for classical Hodgkin 
lymphoma and in 2017 for advanced or metastatic urothelial carcinoma, metastatic 
colorectal cancer and hepatocellular carcinoma. Pembrolizumab (KEYTRUDA, Merck 
& Co.), another PD-1 blocking antibody, was also approved in 2016 for recurrent or 
metastatic head and neck squamous cell carcinoma and in 2017 for the treatment of 
pediatric patients with refractory classical Hodgkin lymphoma and locally advanced or 
metastatic, gastric or gastroesophageal junction adenocarcinoma 
(https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs) . However, not all 
cancer patients respond to ICB therapy. Many studies are ongoing to identify predictive 
biomarkers. In the second part of this thesis we address the predictive value of CD8+ T 
cells miR-155 expression levels. However, the complexity of the tumor and immune 
response makes it arduous. Presence of CD8+ T cells and PD-L1 expression in tumor 
biopsies correlates with anti-PD-1 response rates (Daud et al., 2016; Eroglu et al., 2018; 
Tumeh et al., 2014), suggesting the need of a pre-existing adaptive immune response 
(“hot tumors”) to profit from ICB therapy. Moreover, high mutational load is associated 
with increased clinical benefit  (Daud et al., 2016; Eroglu et al., 2018; Hugo et al., 2016; 
Le et al., 2015; Rizvi et al., 2015; Tumeh et al., 2014), suggesting that anti-PD-1 treatment 
enhances reactivity of potentially high affinity neoantigen-specific T cells. However, 
some tumors with high mutational are still refractory to anti-PD-1 treatment, indicating 
the presence of additional intrinsic resistance mechanism (Eroglu et al., 2018). Mutations 
in beta-2-microglobulin (B2M) and JAK1/2 leading to the loss of MHCI expression and 
inability to respond to IFNg respectively have been associated to intrinsic (Sade-Feldman 
et al., 2017; Shin et al., 2017) but also acquired resistance to anti-PD-1 treatment due to 
the selection of resistant cancer clones (Zaretsky et al., 2016). Therefore, combination of 
blocking antibodies against PD-1, CTLA-4 and other inhibitory receptors (TIM-3, LAG-
3, VISTA and BTLA-4) as well as administration of stimulatory pathways agonists 
(ICOS, OX40 and 41BB) are currently been developed to bypass monotherapies 
limitations (Sharma & Allison, 2015). Combination of PD-1 and CTLA-4 blocking 
antibodies is particularly interesting due to their nonoverlapping mechanisms of action: 
while CTLA-4 blockade enhances T cell costimulation during T cell priming in secondary 
lymphoid organs, anti-PD-1 unleashes full functionality of T cells during their effector 
phase (Pardoll, 2012). Indeed, combination therapy showed increased clinical efficacy 
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compared to single treatments in patients with advance melanoma (Wolchok et al., 2013) 
and was approved by the FDA for the treatment of unresectable or metastatic melanoma 
in 2015. Nonetheless, adverse events are still an issue to overcome that scaled up in some 
combination therapy trials (Hassel et al., 2017). 
 
3.5. Malignant melanoma 
Human malignant melanoma is a type of skin cancer, which generates upon malignant 
transformation of skin melanocytes, a cell type that comprises 1-2% of epidermal skin 
cells and resides in the basal layer of the skin. Malignant melanoma is not the most 
frequent among skin cancers; however, it represents by far the most aggressive one and 
its incidence has raised up to 5-fold in Caucasian populations in the past three decades 
due to the increased exposure to ultraviolet upon sunlight exposure. In Switzerland, 30 
new cases per 100,000 inhabitants were detected per year between 2008-2012 
(https://www.bfs.admin.ch) and despite prevention campaigns, 40-50/100,000 
inhabitants/year are expected to declare a malignant melanoma in the following decades 
in Europe (Leiter, Eigentler, & Garbe, 2014). Surgical resection is only applicable in 
melanoma when diagnosed early. Once the lesions are larger and have started to spread 
to distant metastatic sites, therapeutic options such as chemotherapy have only shown low 
efficacy. Intratumoral administration of the oncolytic virus Talimogene Laherparepvec 
(IMLYGIC, Amgen), a genetically modified herpes simplex virus type 1 designed to 
locally produce GM-CSF and selectively replicate and lyse tumor cells, elicited durable 
responses in unresectable melanoma patients and was approved by the FDA and EMA in 
2015. Unfortunately, however, it did not prolonged overall survival of patients 
(Andtbacka et al., 2015). In 2011, Vemurafenib, a small-tyrosine kinase inhibitor against 
the mutated B-Raf protein, was FDA approved for the treatment of unresectable or 
metastatic melanoma patients carrying the V600E B-raf mutation, which occurs in about 
50% of cutaneous melanoma 
(https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs). Despite early 
achievement of high objective response rates and improvement of overall and 
progression-free survival, most of the patients unfortunately developed resistance 
mechanisms to B-raf inhibitors and tumor progression resumed rapidly after a median of 
5,3 months (Chapman et al., 2011). A number of different acquired resistance 
mechanisms have been described leading to reactivation of the MAPK pathway and/or 
upregulation of the PI3K pathway (Sullivan & Flaherty, 2013). Combination treatments 
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of B-raf inhibitors with other agents have been used to circumvent or delay resistance. 
For instance, combination of vemurafenib with the MEK inhibitor cobimetinib, approved 
in 2015 by the FDA, prolonged progression free survival (PFS) and overall survival 
compared to vemurafenib alone, yet induced increased toxicity (Larkin et al., 2014). 
Moreover, not all melanoma patients carry mutated B-raf and therefore are not eligible 
for such inhibitor treatments. Luckily, immunotherapy appeared as an alternative. 
Already in 1988 the first metastatic melanoma patients were treated with ex vivo 
expanded autologous TILs that could mediate objective regression of cancer (Rosenberg 
et al., 1988). Since then, many clinical trials of ex vivo expanded autologous TILs transfer 
after lymphodepletion have been conducted and showed objective response (OR) rates of 
40-55% (Rosenberg & Restifo, 2015). In addition, circulating lymphocytes transduced 
with MART-1 melanoma-melanocyte antigen specific TCR have also been used and 
mediated tumor regression. However, the OR rate (40%) was not higher than in those 
trials using bulk ex vivo expanded TILs (R. A. Morgan et al., 2006) and toxicities from 
healthy melanocyte targeting were observed (Johnson et al., 2009). Among the target 
antigens identified in autologous TILs, tumor associated antigens have been found but 
also nonsynonymous mutations containing antigens (Y. C. Lu et al., 2014; Robbins et al., 
2013). The concept that cancer regression after immunotherapy is due to targeting of 
mutated antigens could explain tumor regression without developing autoimmunity. In 
fact, recent therapeutic cancer vaccines using RNA or peptide neoantigens have also 
shown development of specific T cell responses and prolonged progression-free survival 
in melanoma patients (Ott et al., 2017; Sahin et al., 2017).  
ICB therapy was also introduced for the treatment of metastatic melanoma shortly after 
targeted therapy and has shown impressive clinical results. CTLA-4 blocking antibody, 
ipilimumab (YERVOY, Bristol Myers Squibb Company), was the first to be approved by 
the FDA, in 2011, after achieving an overall response rate (ORR) of 11% and prolonged 
by 4 months the overall survival of metastatic melanoma patients in a randomized, 
double-blind clinical trial (Hodi et al., 2010). Later in 2014, PD-1 blocking antibodies 
were approved, which demonstrated even higher ORR in previously untreated metastatic 
melanoma patients (ORR, 40%) (Robert et al., 2015) as well as in patients who progressed 
after ipilimumab or BRAF inhibitor treatment (ORR, 30%) (Weber et al., 2015), leading 
to prolonged overall survival (Larkin et al., 2017). In addition, combination of PD-1 and 
CTLA-4 blocking antibodies for the treatment of previously untreated metastatic 
melanoma patients led to an even greater ORR (60%) and a 58% survival rate after 3-
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years compared to the 52% and 34% survival rate in the nivolumab and ipilimumab single 
therapies respectively (Wolchok et al., 2017).  However, ICB related toxicities are still 
an issue to overcome and a fraction of patients remain refractory. Thus, a better 
understanding of the anti-tumor immunity of melanoma tumors is necessary to improve 
the treatments against this aggressive type of human cancer. Preclinical studies are 
essential for that purpose. The B16F10 cell line (Fidler, 1973) is one of the most 
frequently used syngeneic mouse melanoma tumor model which was recently shown to 
contain immunogenic nonsynonymous somatic mutations, as described in melanoma 
patients (Castle et al., 2012). It is the melanoma tumor model that was used in this thesis. 
However, other models such as genetically engineered mouse melanoma tumor models 
have also been employed and are particularly interesting to unravel the role of specific 
molecular pathways (Perez-Guijarro, Day, Merlino, & Zaidi, 2017).    
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AIM OF MY THESIS 
Immunotherapies have shown clinical benefit in some but not all cancer patients. Thus, 
my thesis project aimed at a better understanding of the key parameters governing the 
complex relationship between CD8+ T-cells and tumors in order to improve patients’ 
responsiveness to immunotherapies. 
My thesis project has addressed the role of two CD8+ T cell intrinsic parameters. In the 
first part, the strength of the interaction between the TCR and its tumor antigen was 
studied with regard to CD8+ T cell differentiation and response to cancer vaccines and 
PD-1 checkpoint blockade.   In the second part, the role of miR-155 levels on the CD8+ 
T cell antitumor response was studied, on one hand in mouse tumor models and, on the 
other hand, in CD8+ T cell samples from malignant melanoma patients, with an emphasis 
on the potential use of miR-155 levels as a positive prognostic factor.  
The results described in this thesis were translated into two research articles. The first one 
is under review in The Journal of Immunology and the second is ready to be submitted.  
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PART 1: ROLE OF T CELL AFFINITY ON CD8+ T CELL 
ANTI-TUMOR RESPONSES  
Introduction 
TCR-pMHC recognition is essential for T-cell activation and differentiation. In fact, TCR 
affinity affects T-cell-APC interaction (Moreau et al., 2012; Ozga et al., 2016) and 
survival (Wensveen et al., 2010) and directly correlates with the amplitude of T-cell 
expansion in bacterial infections without impacting phenotypic differentiation (Zehn et 
al., 2009). Interestingly however, low-affinity stimulation, in the LCMV clone-13 chronic 
viral infection model, led to decreased PD-1 expression and increased frequencies of 
IFNγ and TNFα-producing CD8+ T-cells  (Utzschneider, Alfei, et al., 2016), suggesting 
that in case of antigen-persistence phenotype and functionality of CD8+ T-cells are 
impacted by the TCR-pMHC interaction strength.  
 
Previous work has shown that tumor-specific CD8+ T-cells with increased affinity for the 
ligand exhibit enhanced intracellular signaling, proliferation and target cell lysis in vitro 
(Dutoit et al., 2001; Schmid et al., 2010). However, unlike viral and bacterial antigens, 
most tumor-associated antigens (TAAs) are self-antigens. As a consequence, high affinity 
tumor reactive CD8+ T-cells are eliminated during thymic selection and the remaining 
tumor-reactive T-cells found in cancer patients recognize the antigen with low avidity 
(McMahan & Slansky, 2007).  
 
Cancer vaccines using TAAs have been shown to induce TAA-specific T-cell responses 
in cancer patients in combination or not with other therapies (Jandus, Speiser, & Romero, 
2009; Murahashi et al., 2016; Reed, Cresce, Mauldin, Slingluff, & Olson, 2015). 
However, not all TAAs can elicit specific T-cell responses (Brinckerhoff, Thompson, & 
Slingluff, 2000; Legat et al., 2016), and even in cases of specific immune responses, 
clinical trials conferred modest clinical benefit (Lienard et al., 2004; Romero et al., 2016).   
 
Recently, it is becoming increasingly clear that non-synonymous somatic mutations are 
a source of neo-antigens in cancer patients’ tumors. T-cell recognition of these tumor neo-
antigens is presumably of high affinity due to the absence of central tolerance. While 
vaccination with neo-antigens may induce tumor-protective CD8+ T-cell responses (Ott 
et al., 2017; Sahin et al., 2017), the need to identify and formulate neo-antigen-based 
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vaccines in a personalized manner imposes a major hurdle and prohibitive costs. 
Therefore, it remains imperative to understand how T-cells differentiate and respond to 
vaccination with non-mutated tumor antigens and to engagement in the tumor 
microenvironment. 
 
Here, we studied the role of TCR-pMHC interaction strength during peripheral priming 
with a peptide vaccine and in the effector phase within the tumor. To that end, we first 
compared the anti-tumor responses of CD8+ T-cells carrying TCRs with high or low 
avidity for the ligand expressed by the tumor after peripheral peptide vaccination with the 
tumor antigen. Additionally, we also assessed the response of CD8+ T-cells bearing the 
same TCR when encountering tumors expressing a high or low affinity antigen after high 
or low affinity peptide vaccination. We observed that the affinity for the antigen in the 
vaccine formulation and the affinity for the ligand expressed by the tumor determined the 
expansion and differentiation of CD8+ T-cells, whereby low-affinity stimulation led to 
decreased tumor control. Of note, however, low affinity stimulation in the tumor led to 
decreased PD-1 expression and increased IFNγ and TNFα producing CD8+ T-cell 
frequencies. Moreover, both high and low affinity stimulated CD8+ TILs showed the 
same re-expansion capacity when rechallenged with a high affinity bacterial infection in 
a tumor-free host. Importantly, anti-PD-1 treatment enhanced tumor control of either high 
or low affinity ligand expressing tumors. Thus, TAA-specific low affinity CD8+ T-cells 
found in cancer patients may also benefit from anti-PD-1 treatment.   
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Material and methods 
Mice 
C57BL/6 mice were obtained from Envigo, OT-1 transgenic mice from The Jackson 
Laboratory and OT-3 transgenic mice from Prof. Zehn (Enouz, Carrie, Merkler, Bevan, 
& Zehn, 2012). Mice were at least 7 weeks old at the beginning of the experiment and 
were maintained in conventional facilities of the University of Lausanne. This study was 
approved by the Veterinary Authority of the Swiss Canton Vaud and performed in 
accordance with Swiss ethical guidelines.  
 
Generation of B16.N4 and B16.T4 cell lines 
B16-F10 cell line was transduced with MigR1-N4-GFP or MigR1-T4-GFP retroviral 
vectors provided by Prof. Zehn. Transduced cells were cloned and cell lines with similar 
GFP expression were selected.  
 
Melanoma tumor models 
105 B16.OVA or 2·105 B16.N4 and 2·105 B16.T4 cells were subcutaneously (s.c.) 
engrafted on each flank of C57BL/6 mice.  After six days, CD45.1 105 OT-1 or 106 OT-
3 T-cells were intravenously (i.v) transferred. One day later mice were s.c. vaccinated 
with 10µg SIINFEKL (N4) (OVA257-264 peptide) or SIITFEKL (T4) peptide (Protein and 
Peptide Chemistry Facility, UNIL) and 50µg CpG (CpG-ODN 1826, U133-L01A) 
(Trilink Biotechnologies). Tumors were measured manually with a caliper every two days 
from day 6 or 8 post-tumor engraftment. Spleens and tumors were harvested 14 and 21 
days post-tumor engraftment. Spleens were mashed through a 100µm diameter filter 
(Falcon) and red blood cells were lysed with RBC lysis buffer (Qiagen). Tumors were 
dissociated with Tumor Dissociation Kit (Milenyi Biotec) following manufacturer’s 
instructions.  
 
Immune checkpoint blockade 
B16.N4 and B16.T4 tumor bearing mice received 200µg of PD-1 blocking monoclonal 
antibodies (clone RMP-1-14, Rat IgG2a, BioXCell), or 2A3 isotype control (Rat IgG2a, 
BioXCell) on day 10, 13 and 16 post-tumor engraftment.  
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Listeria-monocytogenes-N4 infection 
5000 flow cytometry sorted naïve OT-1 cells or OT-1 cells sorted from spleen, B16.N4 
and B16.T4 tumors 14 and 21 days post-tumor engraftment were intravenously 
transferred into naïve C57BL/6 mice. Secondary recipients were infected the same day 
with N4 expressing Listeria-monocytogenes (Lm-N4) provided by Prof. Zehn. Eight 
days-post infection, spleens from infected mice were collected and processed for flow 
cytometry analysis of OT-1 cells.  
 
T cell proliferation assay by BrdU incorporation 
Seven days post-tumor engraftment mice received 1,8mg 5-Bromo-2’-deoxyuridine 
(BrdU) (B5002, Sigma) intraperitoneally (i.p), and thereafter 0.8mg/mL BrdU in drinking 
water until the end of the experiment. Intracellular BrdU staining was performed with 
APC BrdU Flow kit (BD Pharmigen) following manufacturer’s instructions. 
 
Ex vivo stimulation of OT-1 cells 
Mouse splenocytes or processed tumor samples were stimulated with 10ug/mL 
SIINFEKL peptide or 10ng/mL Phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich) 
+ 500ng/mL Ionomycin (Sigma-Aldrich) for 30min at 37°C in 10% fetal calf serum 
(FCS), 5mg/mL Penicillin (Invitrogen), 5mg/mL Streptomycin (Invitrogen), 10mg/mL 
Neomycin (Invitrogen), 0.05mM 2ß-mercaptoethanol (Invitrogen), 10mM HEPES 
(Amimed) in DMEM (cDMEM). BD GolgiPlug and GolgiStop (BD Bioscience) was 
added to the cells and incubated for another 4h at 37°C.   
 
Surface and intracellular antibody staining for flow cytometry 
Surface antibody staining was performed for 20min at 4°C with different combinations of 
CD3-A700 (cl.17A2, eBioscience), CD8-PE-TexasRed or CD8-A700 (cl.MCD0817, 
Life technologies and cl.536.7, FACS facility UNIL respectively), CD45.1 FITC 
(cl.A20.1, FACS facility UNIL), CD45.2 APCeF780 (cl.104, eBioscience), KLRG1-PE-
Cy7 (cl.2F1/KLRG1, Biolegend), CD127-PE (cl.A7R34, eBioscience), PD-1-APC 
(cl29F.1A12, eBioscience), LAG-3-PE (clC9B7W, BD Bioscience) CD44-PacificBlue 
(cl.IM781, FACS facility UNIL), CD62L-PE-Cy5 (cl.MEL-14, eBioscience), CD39-PE-
Cy7 (cl.24DMS1, eBioscience), CD122-PacificBlue (cl.TM-1b, eBioscience), CD25-
PerCp-Cy5.5 (cl.PC61.5, eBioscience) and CD4-BV605 (cl.RM4-5, Biolegend) in 2mM 
EDTA, 2% FBS in PBS (FACS buffer). After surface staining cells were washed with 
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PBS and stained with LIVE/DEAD Fixable Aqua Dead (L34957, ThermoFisher) for 20 
min at 4°C. Then, cells were washed again with FACS buffer. For intracellular staining 
of cytokines, cells were fixed and permeabilized with Intracellular Staining 
Permeabilization Wash Buffer (421002, Biolegend) according to manufacturer’s 
instructions and stained for 20 min at 4°C with IFNγ-PerCp-Cy5.5 (cl.XM61.2, 
eBioscience), TNFα-Pacific Blue (cl. MP6-XT22, Biolegend), IL-2-PE-Cy7 (cl. JES6-
SH4, eBioscience), CTLA-PE (cl. UC19-4F10-11, BD Bioscience) and GranzymeB-PE-
TexasRed (GRB17, Molecular probe). Cells were finally washed and resuspended in 
FACS buffer for flow cytometry analysis with LSRI-II flow cytometer (BD).   
For flow cytometry cell sorting, cells were sorted with FACSAria (BD) and collected in 
cDMEM.    
 
Data analysis and statistics 
Flow cytometry data was analysed with FlowJo (TreeStar). Graphs and statistical analysis 
were made with Prism (GraphPad Software). Specific statistical analyses are described in 
figure’s captions. Overall, normality of data distribution was analysed by Shapiro-Wilk 
normality test. Comparison between two unpaired groups was performed by parametric 
Student’s t-test or non-parametric Mann-Whitney test. When the two groups were paired, 
parametric paired t-test or non-parametric Wilcoxon test was used. For multiple 
comparison, a parametric 1-way ANOVA or non-parametric Krustal-Wallis test was 
performed followed by Tukey’s multiple comparison test or Dunn’s multiple comparison 
test, respectively. Finally, simultaneous analysis of two variables among multiple groups 
was performed by 2-way ANOVA or 2-way repeated measurements (RM) ANOVA 
followed by Tukey’s multiple comparison test. P-values are coded as *:p<0,05; 
**:p<0,01; ***:p<0,001 and ****:p<0,0001 in figures. All results are representative of 
at least two independent experiments. 
  
PhD Thesis   Amaia Martínez Usatorre 
 46 
Results 
Reduced T-cell expansion of low avidity OT-3 cells leads to weak tumor control.  
To assess the role of TCR avidity in CD8+ T-cell mediated anti-tumor responses, we 
compared naive OT-1 and OT-3 cells. TCR-transgenic OT-3 cells are ovalbumin 
(OVA257-264) specific CD8+ T-cells expressing a TCR which responds to OVA with lower 
functional avidity than OT-1 cells (Enouz et al., 2012).  As we expected that OT-3 cells 
would expand less than OT-1 cells, we transferred 106 OT-3 cells or 105 OT-1 cells six 
days after B16.OVA tumor engraftment in C57BL/6 mice followed by subcutaneous 
vaccination with SIINFEKL OVA (N4) peptide and CpG-ODN one day later (Perret et 
al., 2013) (Figure 6A).  
 
While mice receiving OT-1 cells could control B16.OVA tumor growth, those receiving 
OT-3 cells showed similar tumor growth to those receiving vaccination alone (Figure 
6B). Despite transferring 10 times more naïve OT-3 than OT-1 cells, ~10 times lower 
OT-3 cell numbers were detected in spleens, tumor draining lymph nodes (dLN) and 
tumors 14 days post-tumor engraftment. One week later, OT-1 numbers decreased in 
spleen and dLNs while they remained in higher numbers in the tumor as compared to OT-
3 cells (Figure 6C and 6D). Thus, curtailed peripheral expansion of low avidity OT-3 
cells may largely explain the reduced tumor-specific T-cell numbers in the tumor 
associated with impaired tumor control.  
  
At the peak of the response to the peptide vaccine, 14 days post-tumor engraftment, 
increased naïve (CD44low CD62L+) and decreased effector (CD44high CD62L-) T-cell 
frequencies were found in OT-3 compared to OT-1 cells in dLNs (Figure 6E). In addition, 
OT-3 cells displayed reduced PD-1 expression in dLNs (Figure 6F). In contrast, most T-
cells in the tumor were CD62L- differentiated T-cells with no differences in CM 
(CD44high CD62L+) and effector T-cell frequencies (Figure 6E), as well as PD-1 
expression levels between OT-1 and OT-3 cells (Figure 6F). Thus, while differentiation 
status differs between high and low avidity T-cells in the periphery 7 days post-
vaccination, no differences are found in the tumor, where mainly differentiated PD-1high 
T-cells are present.   
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In addition, CD127low KLRG1high TE frequencies were higher among intratumoral OT-3 
compared to OT-1 cells in contrast with the lower MPECs/TEs ratio in low compared to 
high avidity T-cells at this time point in lymphoid organs and tumor (Figure 6G).  
 
 
 
Figure 6. Low avidity OT-3 cells show reduced expansion and tumor control after peptide-CpG vaccination. A. 
Scheme of the experimental design. 105 B16.OVA cells were subcutaneously (s.c.) engrafted on the flank of C57BL/6J 
mice. After six days, 105 naive OT-1 or 106 naive OT-3 cells were transferred and mice were s.c. vaccinated with N4-
CpG one day later. B. Tumor growth curve. Dots represent the mean tumor volume in mm3 ± SD (N=10/group). C. 
Total OT-1 or OT-3 cell numbers in spleen and dLNs 14 and 21 days post-tumor engraftment. D. Numbers of OT-1 or 
OT-3 cells per mm3 of tumor. E. Percentage of naive (CD44low CD62L+), CM (CD44high CD62L+) and effector 
(CD44high CD62L-) cells in OT-1 or OT-3 cells in spleen, dLN and tumor at day 14. F. Representative histograms and 
PD-1 mean fluorescence intensity (MFI) of endogenous naive CD8+ cells (grey, filled), OT-1 (red continuous) and OT-
3 (blue, dotted) cells from spleen, dLNs and tumors at day 14. G. Percentage of MPECs (CD127high KLRG1low) and 
TEs (CD127low KLRG1high) in CD44high OT-1 or OT-3 cells in spleen, dLNs and tumor at day 14. Dots represent 
individual mice and the bar the mean. OT-1 cells are represented in red and OT-3 cells in blue. A 2-way ANOVA 
followed by Tukey’s multiple comparison test were performed in panel B, a 2-way ANOVA followed by Sidak’s 
multiple comparison test in panels C and D, a 2-way RM ANOVA followed by Sidak’s multiple comparison test in 
panel E and G and an unpaired t-test in panel F.  
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T-cell affinity during peripheral priming is critical for successful CD8+ T-cell response 
and tumor control 
To exclude the influence of cell intrinsic differences between OT-1 and OT-3 T-cells on 
the results, we compared OT-1 responses to high or low affinity peptide vaccines. In 
addition, to discriminate the impact of T-cell avidity on the CD8+ T-cell response 
occurring in the periphery versus in the tumor, mice were engrafted with high and low 
affinity antigen-expressing tumors. To address the latter, we generated B16 melanoma 
cell lines expressing SIINFEKL (N4) wild-type OT-1 ligand or its 10 times lower affinity 
SIITFEKL (T4) variant (Krummey et al., 2016; Zehn et al., 2009) by transduction of B16 
cells with N4-GFP and T4-GFP constructs expressing retrovirus. It was previously 
published that the functional avidity of OT-1 cells in response to the T4 altered peptide 
ligand is similar to that of OT-3 T-cells responding to the N4 peptide (Enouz et al., 2012). 
To normalize antigen expression levels of our newly generated B16.N4 and B16.T4 cell 
lines, stable clones with similar GFP expression levels were selected (Figure 7A). We 
also confirmed that the functional avidity of OT-1 cells to B16.T4 was lower than to 
B16.N4 cell line by analysing IFNγ secretion after in vitro restimulation of OT-1 cells 
with the cell lines and by an in vitro killing assay (Figure 7B-D). 
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Figure 7. OT-1 cells respond to B16.T4 with 
lower avidity than to B16.N4 cells. A. 
Analysis of GFP expression by flow cytometry 
of B16.N4 and B16.T4 cell lines.  B. 
Percentage of IFNγ+ OT-1 cells and IFNγ MFI 
of OT-1 cells after in vitro stimulation of OT-
1 cells with B16.N4 or B16.T4 cell lines. Bars 
represent the mean ± SD (n=2). C. Analysis of 
OT-1-mediated B16.N4 and B16.T4 target cell 
lysis by chromium release assay. Dots 
represent the mean ± SD of the percentage of 
maximum Cr51 release (n=2). D. Analysis of 
OT-1-mediated B16.N4 and B16.T4 target cell 
lysis by live imaging of co-cultures in the 
presence of Incucyte annexin V Red reagent. A 
3:1 effector:target ratio was used. Dots 
represent the number of dead target cells (red 
counts) per well ± SD (n=2). E. Tumor size in 
mm3 (left panel) and relative tumor size to 
tumor volume on day 6 post-tumor 
engraftment (right panel) of mice with B16.N4 
or B16.T4 tumors on either flank. Dots 
represent the mean ± SD (n=4). A 1-way 
ANOVA followed by Tukey’s multiple 
comparison test was performed in panel B, a 2-
way ANOVA followed by Tukey’s multiple 
comparison test in panel C and D and a 2-way 
ANOVA followed by Sidak’s multiple 
comparison test in panel E. 
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To assess tumor control of low and high affinity ligand expressing tumors after high or 
low affinity peripheral priming, mice were engrafted with B16.N4 and B16.T4 tumors on 
either flank, and vaccinated with N4-CpG or T4-CpG seven days post-tumor engraftment 
and one day after 105 OT-1 T-cell transfer (Figure 8A). Since B16.N4 and B16.T4 cell 
lines showed different in vivo engraftment capacity in C57BL/6 mice (Figure 7E), values 
were expressed as relative tumor size to the volume at day 6, before OT-1 cell transfer.  
Figure 8. Low affinity peripheral priming leads to decreased OT-1 cell activation, effector differentiation, 
expansion and tumor control. A. Scheme of the experimental design. 2·105 B16.N4 and B16.T4 cells were s.c. 
engrafted on each flank of C57BL/6J mice. After six days 105 naive OT-1 cells were transferred and mice were s.c. 
vaccinated with N4 or T4 peptide in combination with CpG one day later. B. Tumor growth curves represented as 
tumor size relative to tumor volume at day 6. Dots represent the mean ± SD. n=9 in N4 vacc, n=10 in T4 vacc and n=5 
in PBS group. C. Number of OT-1 cells in spleen of N4 or T4 vaccinated mice 14 and 21 days post-tumor engraftment. 
D. Number of OT-1 cells per mm3 of tumor in OT-1 + N4 or OT-1 + T4 vaccinated mice in N4 (red) or T4 (blue) 
tumors. E. Representative histogram and PD-1 MFI in OT-1 cells at day 14 in spleen of mice vaccinated with N4 or 
T4 peptide. F. Percentage of naive, CM and effector cells in OT-1 cells in spleen at day 14. Dots represent individual 
mice and the bar the mean. A 2-way ANOVA followed by Tukey’s multiple comparison test was performed in panel 
B, an unpaired t-test or Mann-Whitney test after Shapiro-Wilk normality test in panels C and E, a 2-way ANOVA 
followed by Sidak’s multiple comparison test in panel D and a 2-way RM ANOVA test followed by Sidak’s multiple 
comparison test in panel F.  
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Mice receiving T4 vaccination could control neither N4 nor T4 expressing B16 tumors 
(Figure 8B). This was associated with reduced peripheral expansion and OT-1 cell 
numbers infiltrating the tumor (Figure 8C and 8D). As for the vaccine primed low affinity 
OT-3 cells, reduced PD-1 expression and effector cell frequencies were observed in OT-
1 cells after T4 vaccination compared to N4 vaccination in the spleen 7 days post-
vaccination, 14 days post-tumor engraftment (Figure 8E and 8F). To exclude the 
possibility that the observed phenotypic differences between high compared to low 
affinity stimulated OT-1 cells were due to differences in the response kinetics as observed 
in a Listeria monocytogenes (Lm) infection model (Zehn et al., 2009), we followed the 
response of OT-1 cells after N4 or T4 peptide vaccination in peripheral blood for 21 days 
(Figure 9A). We observed an earlier peak of expansion upon low compared to high 
affinity vaccination, yet the expansion magnitude was around 10 times smaller, like in 
the Lm infection model (Figure 9B) as previously described (Zehn et al., 2009). 
Nonetheless, while complete CD8+ T-cell effector differentiation had been reported upon 
Lm-T4 infection, we observed sustained reduced effector cell frequencies after low 
affinity vaccination (Figure 9C). In addition, low affinity stimulation in both vaccination 
and infection settings abrogated PD-1 upregulation (Figure 9D). Altogether, the affinity 
for the peptide vaccine impacted on CD8+ T-cell activation, effector differentiation and 
expansion and consequently on the magnitude of tumor control.   
 
CD8+ T-cell accumulation in the tumor is T-cell affinity dependent.  
Reduced numbers of CD8+ T-cells in the tumor may explain the lack of tumor control 
during low affinity TCR/pMHC interaction, such as for OT-3 after N4 vaccination or OT-
1 after T4 vaccination. Therefore, we compared OT-1 responses to B16.N4 or B16.T4 
tumors after high affinity N4 vaccination (Figure 10A). Importantly, in contrast to low 
affinity vaccination, N4-primed OT-1 cells could partially control B16.T4 tumors (Figure 
10B), demonstrating that high affinity T-cell priming is essential to allow a significant 
tumor control in case of low affinity tumor antigen recognition.  Nevertheless, antigen 
affinity recognition in the tumor still impacts on tumor control, as OT-1 cells still 
controlled better N4 than T4 expressing tumors (Figure 10B).  
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In agreement with the better tumor control, increased OT-1 cell numbers were found in 
B16.N4 compared to B16.T4 tumors 14 and 21 days post-tumor engraftment (Figure 
10C), but no differences were seen in B16.N4 compared to B16.T4 tumor dLN (Figure 
10D). Moreover, higher BrdU+ OT-1 cell frequencies, with higher BrdU incorporation 
per cell, were found in B16.N4 tumors at day 21 suggesting increased OT-1 cell 
proliferation in B16.N4 tumors.  However, at day 14, although OT-1 numbers were higher 
in B16.N4 tumors (Figure 10C), there was no difference in BrdU incorporation (Figure 
10E, 10F and 10G), suggesting that T-cell affinity may also affect T-cell survival in the 
tumor, as previously shown in acute infections (Wensveen et al., 2010). To test that, we 
Figure 9. Low affinity CD8+ T cell priming leads to earlier but curtailed expansion. A. Experimental design. 106 
or 104 OT-1 cells were i.v. transferred to C57BL/6 mice. The same day mice were s.c. vaccinated with N4 or T4 peptide 
in combination with CpG or infected with 2000 CFU Lm.N4 or Lm.T4 i.v. Blood was harvested every day (every 
second day from each mouse) during 11 days and on day 21. B. Percentage of OT-1 cells in total CD8+ T-cells, 
n=5/group. C. Percentage of effector (CD44high CD62L-) cells in total OT-1 cells. D. Representative histogram and 
quantification of PD-1 MFI of OT-1 cells. A 2-way ANOVA followed by Sidak’s multiple comparison test was 
performed. 
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measured expression levels of CD127 and CD25 that were shown to be important for 
CD8+ T-cell survival (Schluns, Kieper, Jameson, & Lefrancois, 2000; Wensveen et al., 
2010). Indeed, we observed increased CD127high MPEC frequencies (Figure 10H), as well 
as increased CD25 (IL-2Rα) and CD122 (IL-2Rβ) expression in OT-1 cells from B16.N4 
Figure 10. OT-1 cells control better high affinity antigen expressing tumors. A. Scheme of the experimental design. 
2·105 B16.N4 and B16.T4 cells were s.c. engrafted on each side of C57BL/6J mice. After 6 days, 105 naïve OT-1 cells 
were transferred and s.c. vaccination with N4-CpG was performed one day later. B. Tumor growth curves represented 
as tumor size relative to tumor volume at day 6. Dots represent the mean ± SD. n=9 in OT-1 + N4 vacc group and n=5 
in mice with only vaccination. C. Number of OT-1 cells per mm3 14 and 21 days post-tumor engraftment. D. Number 
of total OT-1 cells in B16.N4 and B16.T4 inguinal tumor dLN. E. Representative histograms of intracellular BrdU 
staining of OT-1 cells from B16.N4 (red) and B16.T4 (blue) tumors. Endogenous CD8+ from a mouse not receiving 
BrdU is represented as control (grey). F.  Percentage of BrdU+ cells in OT-1 cells in B16.N4 and B16.T4 tumors. G.  
BrdU MFI of BrdU+ OT-1 cells in tumors. H. Percentage of MPECs and TEs in total CD44high OT-1 cells in B16.N4 
and B16.T4 tumors. I. Representative histograms of CD25 and CD122 in OT-1 cells from spleen (black, dashed), 
B16.N4 (red, continuous) and B16.T4 (blue, dotted) tumors on day 14 and 21. Lower panels show quantification of 
CD25 MFI on CD25+ OT-1 cells and CD122 MFI on total OT-1 cells. Dots represent individual mice and lines connect 
the two tumors of each mouse. A 2-way ANOVA followed by Tukey’s multiple comparison test was performed in 
panel B, a paired t-test or Wilcoxon matched-pairs signed rank test after Shapiro-Wilk normality test in panels C, D, F, 
G and I and a 2-way RM ANOVA followed by Sidak’s multiple comparison test in panel H.   
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tumors compared to B16.T4 tumors (Figure 10I). Thus, increased tumor control of 
B16.N4 tumors was probably associated with increased proliferation and responsiveness 
to homeostatic cytokines upon high affinity antigen recognition. 
 
Low affinity antigen recognition leads to decreased and slower acquisition of activation 
markers including inhibitory receptors. 
Tumor infiltrating OT-1 cells expressed increased CD44 compared to those found in the 
spleen. However, OT-1 cells in B16.T4 tumors had lower CD44 expression levels than 
in B16.N4 tumors, both at 14 and 21 days post-tumor engraftment (Figure 11A). 
Therefore, within the tumor, OT-1 cells upregulate CD44 in a T-cell affinity dependent 
manner.  
 
The expression level of CD45RB, a CD45 isoform highly expressed in naïve cells but 
downregulated in effector and memory T-cells (Hermiston, Xu, & Weiss, 2003), was also 
modulated in a T cell affinity dependent, although in the opposite way of CD44 (Figure 
11B).  
 
Similar to the observations made when comparing OT-1 and OT-3 cells, decreased MPEC 
frequencies were observed in OT-1 cells from low affinity B16.T4 compared to high 
affinity B16.N4 tumors (Figure 10H). Thus, T-cell affinity impacts MPEC CD8+ T-cell 
formation both upon peripheral priming and in the tumor.  
 
As previously described for melanoma patients TILs (Ahmadzadeh et al., 2009), PD-1 
expression was higher in tumor-infiltrating OT-1 cells compared to those from the 
periphery (Figure 8E and Figure 11C). However, PD-1 expression was lower in B16.T4 
compared to B16.N4 tumors at day 14 and 21 (Figure 11C). Similarly, expression levels 
of CTLA-4 and CD39 T-cell exhaustion markers were strongly decreased in OT-1 cells 
from B16.T4 tumors compared to B16.N4 tumors (Figure 11D and 11E).  
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Altogether, T-cell affinity affects CD8+ T-cell differentiation in the tumor.  Low affinity 
antigen recognition leads to decreased acquisition of activation and differentiation 
markers including inhibitory receptors. Thus, despite numeric differences, low affinity T-
cells are interesting for therapeutic purposes as they may be less susceptible to negative 
regulators despite their decreased tumor control.  
 
 
 
 
 
Figure 11. Decreased expression of activation markers upon low affinity antigen recognition in the tumor. A-E. 
Representative histograms of CD44, CD45RB, PD-1, CTLA-4 and CD39 in OT-1 cells from spleen (black, dashed), 
B16.N4 (red, continuous) and B16.T4 (blue, dotted) tumors and endogenous naïve CD8+ T-cells (filled grey) 14 and 
21 days post-tumor engraftment. Bellow quantification of each marker’s MFI can be found. A paired t-test or Wilcoxon 
matched-pairs signed rank test was performed after Shapiro-Wilk normality test. 
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Intratumoral low affinity antigen recognition leads to decreased Granzyme B production 
but preserves cytokine production capacity 
Decreased expression of inhibitory receptors by OT-1s in B16.T4 versus B16.N4 tumors 
suggests decreased susceptibility to T-cell suppression. Therefore, we assessed at day 14 
the ability of OT-1 cells from spleen and B16.N4 or B16.T4 tumors to produce cytokines 
and express granzyme B after in vitro restimulation with N4 peptide. As expected, IFNγ+ 
and TNFα+ OT-1 cell frequencies were lower in tumors than in the spleen (Figure 12A 
and 12B), although the cytokine levels on per cell basis appeared similar in all locations 
(Figure 12C). Interestingly, when comparing B16.N4 and B16.T4 tumors, higher 
frequencies of IFNγ-producing OT-1 T-cells were found in T4 tumors (Figure 12A and 
12B). Similar results were obtained when measuring TNFα (Figure 12D and 12E). 
However, unlike cytokine production, both the frequencies and expression levels of 
granzyme B in OT-1 cells were instead decreased in T4 compared N4 tumors (Figure 12F 
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Figure 12. Increased cytokine producing OT-1 cells but reduced Granzyme B+ cells in B16.T4 compared to 
B16.N4 tumors. A. Representative dot plots of OT-1 cells from spleen, B16.N4 and B16.T4 tumors in vitro 
restimulated with N4 peptide 14 and 21 days post-tumor engraftment. B, D and F. Percentage of IFNγ+, TNFα+ and 
Granzyme B+ cells in OT-1 cells. C, E and G. IFNγ, TNFα and Granzyme B MFI in IFNγ+, TNFα+ and Granzyme B+ 
OT-1 cells respectively. Dots represent individual mice and bars the mean ± SD (n=5). A 1 way-ANOVA or Kruskal-
Wallis test followed by Tukey’s multiple comparison or Dunn’s multiple comparison test were performed respectively 
after Shapiro-Wilk normality test. 
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and 12G), suggesting that cytotoxic activity might be less affected by immunosuppression 
via PD-1 signaling, which correlates with higher tumor control of N4 tumors. Although 
cytokine production was further decreased when restimulating day 21 tumor infiltrating 
OT-1 cells, higher frequencies of IFNγ+ and TNFα+ cells were still found in OT-1 cells 
from B16.T4 compared to B16.N4 tumors (Figure 12B and 12D). Interestingly, 
frequencies of granzyme B+ OT-1 cells remained lower in OT-1 cells from B16.T4 
compared to B16.N4 tumors (Figure 12F and 12G). 
Therefore, stimulation of CD8+ T cells by low affinity antigen expressed by the tumor led 
to decreased cytotoxicity but preserved the ability to produce cytokines upon 
restimulation.  
 
CD8+ T-cells from both high and low affinity ligand expressing tumors show similar re-
expansion capacity in recall tumor-free responses  
To evaluate whether increased B16.N4 tumor control was due to increased OT-1 cell 
numbers that could compensate their exhausted profile, we assessed the fitness of B16.N4 
or B16.T4 OT-1 TILs by analyzing their re-expansion capacity upon antigen reencounter 
in a tumor free infection settings. To this end, 5000 OT-1 cells sorted from spleen, 
B16.N4 or B16.T4 tumors were transferred to naïve C57BL/6 mice which were infected 
with 2000 CFU of Lm-N4 (Figure 13A). As control, a group of mice received 5000 naïve 
OT-1 cells and Lm-N4.  
 
Strikingly, OT-1 cells from day 14 or day 21 B16.N4 and B16.T4 tumors re-expanded to 
a similar extent upon Lm-N4 infection (Figure 13B). When comparing OT-1 cells from 
day 14 tumors and spleen, we observed that OT-1 cells from tumors expanded three times 
less than OT-1 cells from spleen of the same tumor bearing mice (Figure 13B). However, 
such difference may be due to the higher frequency of CM OT-1 cells in the spleen at day 
14, as at day 21, when only effector cells remained in spleen and tumors (Figure 13C), 
OT-1 cells showed the same re-expansion capacity regardless of their tissue origin (Figure 
13B). Thus, effector OT-1 cells from the periphery or from high and low affinity tumors 
show the same re-expansion capacity in secondary tumor-free responses.  
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Moreover, 8 days-post infection, the differences in CD44, PD-1 and CTLA-4 expression 
levels between OT-1 cells from spleen, B16.N4 and B16.T4 tumors in primary hosts 
(Figure 11) were lost upon re-expansion in the secondary host (Figure 13E and 13F). 
Remarkably, PD-1 expression levels in secondary hosts receiving OT-1 TILs were much 
lower than within the tumors during the primary response (Figure 13E). Yet, PD-1 
expression levels in secondary hosts receiving OT-1 cells from tumor bearing mice were 
higher compared to mice receiving naive OT-1 cells. In addition, while increase MPEC 
OT-1 cell frequencies were found in B16.N4 compared to B16.T4 tumors in primary hosts 
(Figure 10H), there were no longer differences in MPECs and TE OT-1 cell frequencies 
in secondary hosts (Figure 13D). TE frequencies were much higher in secondary hosts’ 
spleens compared to primary hosts’ day 14 and day 21 tumors (Figure 13D). Thus, upon 
a high affinity secondary acute infection, there is a major reset of OT-1 cells originally 
primed in tumor-bearing mice.  
 
While day 14 OT-1 cells from N4 and T4 tumors showed reduced cytokine and increased 
Granzyme B production upon in vitro N4 peptide re-stimulation as compared to those 
from spleen (Figure 12), similar frequencies of IFNγ, TNFα and Granzyme B-producing 
OT-1 cells were found upon Lm-N4 infection of secondary hosts from all groups (Figure 
13G). Nonetheless, like in the in vitro re-stimulated OT-1 cells from primary hosts 
(Figure 12), the frequencies of IFNγ, TNFα and Granzyme B producing OT-1 cells were 
lower in mice receiving day 21 compared to day 14 tumor-infiltrating OT-1 cells (Figure 
13G). Thus, prolonged exposure to the tumor-microenvironment dampens CD8+ T-cells 
capacity to produce IFNγ, TNFα and Granzyme B even upon rechallenge in a tumor-free 
environment.  
Figure 13. Tumor infiltrating OT-1 cells from B16.N4 and B16.T4 tumors show similar re-expansion capacity in 
secondary tumor-free responses but decreased cytokine production when exposed for a longer time to the tumor 
microenvironment. A. Scheme of the experimental design. 14 or 21 days post-tumor engraftment 5000 OT-1 cells 
from spleen, B16.N4 or B16.T4 tumors were transferred into naive C57BL/6 mice. The same day secondary hosts were 
infected with 2000 CFU of Lm-N4. As controls, a group of mice received 5000 naive OT-1 cells and Lm-N4 infection. 
B.  Fold expansion of day 14 or day 21 OT-1 cells in spleen of secondary hosts, 8 days post-infection. C. Percentage 
of naive, CM and effector cells in OT-1 cells 14 and 21 days post-tumor engraftment pre-transfer (Pre) and 8 days post-
infection in secondary hosts (Post). D. Percentage of MPECs and TEs in CD44high OT-1 cells 14 and 21 days post-
tumor engraftment pre-transfer and 8 days post-infection in secondary hosts. E.  Representative histograms of CD44, 
PD-1 and CTLA-4 of naive OT-1 cells (grey, filled) or OT-1 cells from spleen (black, dashed), B16.N4 (red, 
continuous) and B16.T4 (blue, dotted) tumors at day 14 or day 21 pre-transfer (Pre) or 8 days post- infection in 
secondary hosts (Post). F. Quantification of CD44, PD-1 and CTLA-4 MFI. G. Percentage of IFNγ+, TNFα+ and 
Granzyme B+ OT-1 cells in OT-1 cells from spleen of secondary hosts in vitro restimulated with N4 peptide. Dots 
represent individual mice and bars the mean ± SD. n=1 pre-transfer and n=8 post-infection. A 2-way ANOVA followed 
by Sidak’s multiple comparison test was performed in panels B and G, a 2-way RM ANOVA followed by Tukey’s 
multiple comparison test in panels C and D, and a 1 way-ANOVA or Kruskal-Wallis test followed by Tukey’s multiple 
comparison or Dunn’s multiple comparison test after Shapiro-Wilk normality test in panel F. 
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Altogether, prolonged exposure to the tumor microenvironment, regardless of the affinity 
for the ligand, decreases the capacity of CD8+ T-cells to produce IFNγ, TNFα and 
Granzyme B. Yet, the re-expansion capacity of tumor infiltrating CD8+ T-cells in 
secondary tumor-free responses is preserved over time and is similar to the expansion 
amplitude of effector CD8+ T-cells from the periphery.  
 
Anti-PD-1 treatment enhances tumor control of both high and low affinity antigen 
expressing tumors.  
To address the impact of anti-PD-1 blockade on T-cells activated by high or low affinity 
tumor antigen, mice were engrafted with B16.N4 and B16.T4 tumors. On day 6 post 
tumor graft, 105 naïve OT-1 or irrelevant P14 cells were transferred and one day later N4-
CpG vaccine was administered. Anti-PD-1 or isotype control (ISO) antibodies were given 
three times, every three days from day 10 post-tumor engraftment (Figure 14A). PD-1 
blockade enhanced OT-1 cell mediated tumor control of both B16.N4 and B16.T4 tumors, 
by 2.4 and 1.6 times compared to isotype control treated mice respectively (Figure 14B). 
These anti-tumor responses correlated with increased OT-1 numbers 21 days post- tumor 
engraftment in the spleen (Figure 14C), as well as to a lesser extent in tumors (Figure 
14D) of anti-PD-1 compared to isotype control treated mice. In addition, in situ 
proliferation of OT-1 cells was enhanced in B16.N4 tumors of anti-PD-1 treated mice 
(Figure 14E and 14F), but not T4 tumors. However, when mice were grafted only with 
B16.T4 tumors, anti-PD-1 treatment further enhanced tumor control (by 2.8) (Figure 
15B) and increased OT-1 proliferation was also observed (Figure 15C and 15D), 
suggesting some preferential anti-PD-1 effect in N4 tumors in B16.N4 and B16.T4 double 
tumor bearing mice.  
 
At the peak of the response, at day 14 post-tumor engraftment, higher PD-1 expression 
levels were observed in OT-1 cells from spleen of anti-PD-1 treated mice, indicating an 
enhanced activation of OT-1 cells during peripheral priming (Figure 14G). At the same 
timepoint in the tumor, PD-1 levels were ten times higher than in the spleen, as a result 
from chronic stimulation, but with no difference between anti-PD-1 treated and untreated 
mice (Figure 14G). Strikingly however, one week later lower PD-1 expression levels were 
found in tumors of anti-PD-1 treated mice, while there was no more difference in PD-1 
expression levels in the spleen (Figure 14G). This lower PD-1 expression in tumor 
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infiltrating OT-1 cells would suggest a decreased susceptibility to PD-L1/L2 mediated 
immunosuppression and enhanced functionality of T-cells. Thus, we checked whether 
cytokine production capacity of OT-1 cells was increased in anti-PD-1 treated mice. 
Interestingly, selectively increased IFNγ+ frequencies were observed in OT-1 cells from 
Figure 14. Anti-PD-1 enhances B16.N4 and B16.T4 tumor control. A. Scheme of the experimental design. 2·105 
B16.N4 and B16.T4 cells were s.c. engrafted on each side of C57BL/6J mice. After 6 days, 105 naïve OT-1 or P14 cells 
were transferred and s.c. vaccination with N4-CpG was performed one day later. On days 10, 13 and 16 anti-PD-1 or 
isotype control (ISO) Abs were administered i.p. B. Tumor growth curves. Dots represent the mean tumor volume in 
mm3 ± SD, n=8/group. C. Number of OT-1 cells in spleen. D. Number of OT-1 cells per mm3 of tumor in B16.N4 and 
B16.T4 tumors. E. Percentage of BrdU+ cells in OT-1 cells from tumors. F. BrdU MFI of BrdU+ OT-1 cells in tumors. 
G. Representative histograms and PD-1 MFI quantification of OT-1 cells from spleen and tumors. H. Percentage of 
IFNγ+, TNFα+ and Granzyme B+ cells in OT-1 cells from B16.N4 or B16.T4 tumors in vitro restimulated with N4 
peptide 21 days post-tumor engraftment. Dots represent individual mice and the bar the mean ± SD. In black, isotype 
control antibody (ISO) and in purple anti-PD-1 antibody treated mice. A 2-way RM ANOVA followed by Tukey’s 
multiple comparison test were performed in panel B and an unpaired t-test or Mann-Whitney test after Shapiro-Wilk 
normality test in panels C-H. 
IS
O
αP
D
-1
0.0
5.0×105
1.0×106
1.5×106
2.0×106
N
um
be
r o
f O
T-
1 
ce
lls ****
Spleen
IS
O
αP
D
-1
D21
6 8 10 12 14 16 18 2021
0
200
400
600
Day post-tumor engraftment
Tu
m
or
 v
ol
um
e 
(m
m
3 )
N4 Tumor
*
****
OT-1 + ISO (N4)
OT-1 + aPD-1 (N4)
P14 + aPD-1 (N4)
6 8 10 12 14 16 18 2021
Day post-tumor engraftment
T4 Tumor
*
OT-1 + ISO (T4)
OT-1 + aPD-1 (T4)
P14 + aPD-1 (T4)
Naive CD8
OT-1	(ISO)
OT-1	(!PD-1)
Spleen N4 Tumor T4 Tumor
A B
C E
G
H
PD-1
D F
IS
O
αP
D
-1
 0
5×104
1×105
5.0×105
1.0×106
1.5×106
N
um
be
r o
f O
T-
1/
m
m
3 
tu
m
or
N4 Tumor
IS
O
αP
D
-1
 
T4 Tumor
*
IS
O
αP
D
-1
0
1000
2000
3000
4000
N4 Tumor
**
IS
O
αP
D
-1
T4 Tumor
**
IS
O
αP
D
-1
0
10
20
30
40
50
%
 IF
N
γ +
 O
T1
 c
el
ls **
N4 Tumor
IS
O
αP
D
-1
T4 Tumor
IS
O
αP
D
-1
0
5
10
15
20
%
 T
N
Fα
+ 
O
T-
1 
ce
lls
N4 Tumor
IS
O
αP
D
-1
T4 Tumor
IS
O
αP
D
-1
 0
20
40
60
80
100
%
 G
ra
nz
ym
e 
B
+
 O
T-
1 
ce
lls
N4 Tumor
IS
O
αP
D
-1
 
T4 Tumor
IS
O
αP
D
-1
 0
20
40
60
80
%
 B
rd
U
+ 
O
T-
1 
ce
lls *
N4 Tumor
IS
O
αP
D
-1
 
T4 Tumor
IS
O
αP
D
-1
 0
500
1000
1500
M
FI
 B
rd
U
, 
B
rd
U
+ 
O
T-
1 
ce
lls
*
N4 Tumor
IS
O
αP
D
-1
 
T4 Tumor
IS
O
αP
D
-1
0
200
400
600
M
FI
 P
D
-1
 
D14
***
D21
IS
O
αP
D
-1
0
1000
2000
3000
4000
N4 Tumor
IS
O
αP
D
-1
T4 Tumor
D14
B16.N4	and	
B16.T4	tumors
105	OT-1	or	P14	cell	transfer
D7D0
N4-CpG
D6
N4 T4
D10 D13 D16
αPD-1/ISO	
D14 D21
† †
D21
D21
PhD Thesis   Amaia Martínez Usatorre 
 61 
B16.N4 tumors on day 21, while no differences were observed in B16.T4 tumors (Figure 
14H). Nonetheless, in single B16.T4 tumor bearing mice increased IFNγ+ frequencies 
were also observed in anti-PD-1 treated mice (Figure 15E).  
 
Altogether, anti-PD-1 treatment enhanced tumor control of both high and low affinity 
antigen-expressing tumors by increasing peripheral expansion of OT-1 cells resulting in 
higher OT-1 numbers in the tumor. Moreover, at a late tumor stage, OT-1 TILs displayed 
lower PD-1 expression levels and enhanced cell proliferation as well as higher IFNγ+ 
production. 
  
Figure 15. Anti-PD-1 treatment enhances proliferation and cytokine production of OT-1 cells in tumors of 
B16.T4 tumor bearing mice.  A. Experimental design. B16.T4 single tumor bearing mice received 105 OT-1 cells on 
day 6 and N4-CpG s.c vaccination the day after. Anti-PD-1 or ISO control antibodies were given on days 10, 13 and 
16 i.p. B. Tumor growth curves expressed as mean tumor volume ± SD, n=6/group. C. Percentage of BrdU+ cells in 
OT-1 cells from B16.T4 tumors. D. BrdU MFI of BrdU+ OT-1 cells. E. Percentage of IFNγ+, TNFα+ and Granzyme B+ 
cells in OT-1 cells from B16.T4 tumors in vitro restimulated with N4 peptide. Dots represent individual mice and the 
bar the mean. In black ISO and in purple anti-PD-1 treated mice. A two way ANOVA followed by Sidak’s multiple 
comparison test was performed in panel B and an unpaired t-test or Mann-Whitney test was performed after Shapiro-
Wilk normality test in panels C-E. 
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Discussion 
The weak immunogenicity of cancer cells is one of the hurdles in achieving clinically 
effective anti-tumor T-cell responses. Indeed, most TAAs are self-proteins and therefore 
tumor-reactive T-cells found in cancer patients generally recognize their antigen with low 
avidity (McMahan & Slansky, 2007). The advent of affordable whole exome sequencing 
has made possible the routine identification of mutant protein antigens (neo-antigen), for 
which specific high avidity CD8+ T-cells may be found in blood and tumors of cancer 
patients (Gros et al., 2016) (Yarchoan, Johnson, Lutz, Laheru, & Jaffee, 2017). Thus, high 
and low avidity TAA-specific T-cells likely contribute to the overall anti-tumor response 
but their respective relevance is only partially understood. Moreover, the response of high 
and low affinity CD8+ T-cells to cancer vaccines and ICB therapies has not been studied.  
 
Our comparison of high and low affinity T-cell responses by modulating either the TCR 
or the antigen affinity revealed that the TCR affinity for the peptide vaccine greatly 
impacts the magnitude of CD8+ T-cells’ peripheral expansion, as previously shown in 
bacterial infections (Zehn et al., 2009). Curtailed expansion of low affinity primed CD8+ 
T-cells was accompanied by reduced early PD-1 expression and effector CD8+ T-cell 
frequencies in dLNs. Moreover, low affinity priming by systemic vaccination hampered 
effective control of tumors expressing either high or low affinity antigen.  In contrast, 
high affinity priming led to a significant retardation of tumor growth regardless of the 
antigen recognition strength in the tumor microenvironment. These observations support 
the use of high affinity altered-peptide ligands to optimize therapeutic cancer vaccines 
(Jandus et al., 2009; Murahashi et al., 2016; Reed et al., 2015).  
  
Although high affinity peripheral priming allowed tumor control of low affinity ligand 
expressing tumors, our results clearly show that the magnitude of tumor control is 
dependent on the affinity of tumor-associated antigen recognition by T cells recruited to 
the tumor. This was probably due to decreased in situ OT-1 cell expansion and Granzyme 
B expression in low affinity tumors. Yet, OT-1 cells infiltrating the low affinity antigen 
expressings tumors exhibited lower inhibitory receptor expression levels and higher 
cytokine producing cell frequencies than those thriving in the high affinity antigen 
expressing tumors. These results suggest increased functionality of low affinity 
stimulated tumor infiltrating CD8+ T-cells.  Notwithstanding, tumor infiltrating OT-1 
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cells showed the same re-expansion capacity in secondary tumor free acute responses 
regardless of the affinity for the antigen ligand expressed by the tumor.  This outcome is 
similar to recent observations made in the model of specific CD8+ T-cell exhaustion in 
the context of LCMV cl13 chronic infection. Indeed, while low affinity stimulated CD8+ 
T-cells showed lower PD-1 expression levels in a primary chronic virus infection, high 
and low affinity stimulated CD8+ T-cells maintained the same re-expansion capacity in a 
secondary acute viral infection (Utzschneider, Alfei, et al., 2016). Thus, chronic high and 
low affinity stimulation whether in an infection or in the tumor, do not impair re-
expansion capacity of CD8+ T-cells in secondary acute responses. 
 
Interestingly the CD8+ T-cell exhausted phenotype acquired in the tumor 
microenvironment appears to be reversible upon secondary acute infection. This contrasts 
with previous observations in the LCMV cl13 chronic infection model where chronically 
stimulated CD8+ T-cells retained high PD-1 levels in a secondary acute infection 
(Utzschneider et al., 2013), probably due to permanent demethylation of the PD-1 locus 
(Youngblood et al., 2011). Therefore, it would be interesting to analyse whether 
epigenetic regulation of the PD-1 locus may explain the differences observed between 
the two models. In this regard, a recent report showed that T-cells in mouse spontaneous 
liver tumors may acquire the exhausted functional state by transitioning through two 
successive discrete chromatin states. One plastic dysfunctional state that is reversible and 
a fixed one in which cells become resistant to reprogramming (Philip et al., 2017). 
Whether this sequence of events occurs in chronically TILs on a regular basis in all types 
of tumors remain to be elucidated. 
 
In the transplantable tumor model analyzed here, prolonged exposure to the tumor 
microenvironment led to decreased frequencies of cytokine and Granzyme B-producing 
OT-1 cells in both high and low affinity ligand expressing tumors. Unfortunately, while 
early (day 14) tumor infiltrating OT-1 cell transfer to a tumor-free environment restored 
cytokine and Granzyme B production capacity, a late (day 21) OT-1 cell transfer 
diminished OT-1 cells functionality in the secondary response. In the chronic LCMV cl13 
infection similar observations were made. Albeit similar re-expansion, chronically 
stimulated CD8+ T-cells maintained reduced cytokine production in secondary acute viral 
responses compared to CD8+ T-cells from acute infections (Utzschneider et al., 2013). 
Altogether, chronic antigen stimulation regardless the affinity to the ligand leads to 
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decreased cytokine production but preserved re-expansion upon re-challenge with the 
antigen conveyed by acute infection settings. 
 
Signaling through the PD-1 receptor is one of the immunosuppressive signals that CD8+ 
T-cells encounter in the tumor. Pre-clinical and clinical studies have shown that antibody-
mediated PD-1 blockade greatly ameliorates the outcome of cancer patients especially in 
the case of immunogenic tumors (Hirano et al., 2005; Iwai, Terawaki, & Honjo, 2005; 
Leach et al., 1996; Topalian et al., 2012; van Elsas, Hurwitz, & Allison, 1999). Our data 
showed that αPD-1 treatment improves the therapeutic outcome in both high and low 
affinity antigen expressing melanoma tumors by enhancing CD8+ T-cell numbers and 
functionality in the tumor. Hence, low affinity TAA-specific CD8+ T-cells may also well 
contribute to the anti-tumor activity observed in αPD-1 treated metastatic melanoma 
patients (Topalian et al., 2012).  
 
Altogether, our results suggest that early vaccination with high affinity altered peptide 
ligands or neo-antigens, in combination with αPD-1 may be a clinically effective strategy 
to boost endogenous low affinity TAA-specific CD8+ T-cell responses, as well as neo-
antigen specific CD8+ T-cell responses. In support of this notion, it is noteworthy that a 
recent study showed that melanoma patients with tumor recurrences after vaccination 
with neo-antigens had complete tumor responses following treatment with αPD-1. This 
was accompanied by broadening of the neo-antigen specific T-cell repertoires (Ott et al., 
2017). 
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PART 2: ROLE AND REGULATION OF MIR-155 ON CD8+ 
T CELL ANTI-TUMOR RESPONSES  
Introduction 
High tumor infiltration of memory CD8+ T-cell has been associated with better clinical 
outcome in different types of human cancer (Fridman, Pages, Sautes-Fridman, & Galon, 
2012). Nonetheless, tumors manage to evade immune control through multiple 
mechanisms (Beatty & Gladney, 2015). Therefore, efforts are being made to better 
understand the complex relationship between the immune system and the tumor and to 
develop new therapies. It is particularly crucial for cancers like melanoma, which are 
immunogenic but generally resistant to radiotherapy and conventional chemotherapy 
(Trinh, 2008). For instance, re-infusion of autologous tumor reactive T cells expanded ex 
vivo has shown encouraging results in malignant melanoma patients (Dudley et al., 2005; 
Dudley et al., 2008). However, trafficking, survival and persistence of re-infused T cells 
need to be optimized, and genetic engineering of T cells is a novel approach currently 
explored to improve T cell qualities. In particular, genetic manipulation of specific 
microRNAs may allow improvement of T cell fitness (Ji, Hocker, & Gattinoni, 2016).   
 
Micro-RNAs are ~22nt long non-coding RNAs found in multicellular organisms that 
regulate protein expression at post-transcriptional level. miRNAs can target hundreds of 
mRNAs and regulate different biological processes including immune cell differentiation 
and function, thereby playing a role in the outcome of immune responses (Baltimore, 
Boldin, O'Connell, Rao, & Taganov, 2008). Recent work from our group showed that 
miRNAs and in particular miR-155 are regulated during human CD8+ T cell 
differentiation and thus may play an important role on CD8+ T cell function (Salaun et 
al., 2011).  
 
miR-155 resides in the non-coding B-cell integration cluster (BIC), which was first 
characterized as a proto-oncogene associated with lymphoma development (Tam et al., 
1997). MiR-155 upregulation is also observed in solid tumors, including breast, lung, 
pancreatic and thyroid cancers (Greither et al., 2010; Iorio et al., 2005; Nikiforova, Tseng, 
Steward, Diorio, & Nikiforov, 2008; Yanaihara et al., 2006). However, it also plays an 
essential role in the immune system (Rodriguez et al., 2007). It is upregulated upon 
antigen receptor stimulation in B and T cells (Haasch et al., 2002; Rodriguez et al., 2007), 
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as well as upon stimulation of Toll-like receptors in macrophages and DCs (Lind et al., 
2015; O'Connell et al., 2007), via activation of NF-κB and AP-1 transcription factors 
(Kluiver et al., 2007; Yin et al., 2008). We and others have shown in miR-155 deficient 
mice that miR-155 is required for effector CD8+ T cell responses against viruses and 
tumors (Dudda et al., 2013; Gracias et al., 2013). Furthermore, overexpression of miR-
155 enhanced murine CD8+ T cell anti-tumor responses (Dudda et al., 2013), suggesting 
that miR-155 is important for tumor-infiltrating CD8+ T cells fitness.  However, little is 
known about the parameters that regulate miR-155 expression levels in CD8+ T cells of 
cancer patients.  
 
In this study, we measured miR-155 expression levels in tumor-infiltrating CD8+ T cells 
isolated from melanoma patients and murine tumors and compared them to miR-155 
levels in CD8+ T cells from peripheral blood or murine lymphoid tissues. We observed 
that sustained antigen recognition leads to affinity-dependent miR-155 upregulation 
within the tumor, which correlates with increased CD8+ T cell tumor infiltration.  
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Material and methods 
Mice 
C57BL/6 mice were obtained from Envigo, OT-1 transgenic mice from The Jackson 
Laboratory (Stock no 003831), OT-3 transgenic mice from Prof. Zehn (Enouz et al., 2012) 
and P14 transgenic mice from Prof. Oxenius. Mice were at least 7 weeks old at the 
beginning of the experiment and were maintained in conventional facilities of the 
University of Lausanne. This study was approved by the Veterinary Authorities of the 
Swiss Canton Vaud (authorization n°1850) and performed in accordance with Swiss 
ethical guidelines.  
 
Melanoma tumor models 
105 B16.OVA or 2·105 B16.N4-GFP and 2·105 B16.T4-GFP cells (described in previous 
part) were subcutaneously (s.c) engrafted on each flank of C57BL/6 mice.  After six days, 
CD45.1 105 OT-1 or 106 OT-3 T cells were intravenously (i.v) transferred. One day later 
mice were s.c. vaccinated with 10µg SIINFEKL (N4) peptide (Protein and Peptide 
Chemistry Facility, UNIL) and 50µg CpG (ODN 1826, U133-L01A) (Trilink 
Biotechnologies). Spleens and tumors were harvested 14 and 21 days post-tumor 
engraftment. Spleens were mashed through a 100µm diameter filter (Falcon) and red 
blood cells were lysed with RBC lysis buffer (Qiagen). Tumors were dissociated with 
Tumor Dissociation Kit (Milenyi Biotec) following manufacturer’s instructions.  
 
Immune checkpoint blockade 
B16.N4 and B16.T4 tumor bearing mice received 200µg of αPD-1 (clone RMP-1-14, Rat 
IgG2a, BioXCell) or 2A3 isotype control (Rat IgG2a, BioXCell) on day 10, 13 and 16 
post-tumor engraftment.  
 
MiR-155 overexpression in P14 cells 
P14 cells were isolated from spleens of P14 transgenic mice with EasySep Mouse T cell 
isolation kit (Stem cell, 19851A) and activated with 1:1 aCD3/CD28 Dynabeads 
(Thermo Fisher, 11452D) in 10% fetal calf serum (FCS, Dominique Dutscher, S1810-
500), 50IU/mL/50ug/mL Penicilin/Streptomycin (Gibco, 15070-063), 0.05mM 2ß-
mercaptoethanol (Gibco, 31350-010), 10mM HEPES (Amimed, 5-31F00-H), 2mM L-
Glutamine (Amimed, 5-10K100-H), 1mM Sodium Pyruvate (Gibco, 11360-039) and 1x 
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Non-essential amino acids (Thermo Fisher, 11140-035) in RPMI 1640 with Glutamax 
(Gibco, 61870-010) (mouse T cell media) with 50U/mL rhIL-2 (Glaxo-IMB). Two days 
post-activation, P14 cells were transduced with MDHI-SCR-GFP or MDHI-miR-155-
GFP retroviral vectors (provided by Dr. Gattinoni). One day later, media was replaced by 
10U/mL IL-2, 10ng/mL r-human-IL-7 (Reprotech, 200-07) and 10ng/mL r-human-IL-15 
(Reprotech, 200-15) containing mouse T cell media. Five days post-activation, media 
with 10ng/mL IL-7/IL15 was added and two days later, GFP+ P14-SCR/miR-155 cells 
were FACS-sorted and transferred into B6 mice.    
 
LCMV infection 
103 naïve CD45.1 P14 T cells, 5·103 P14-SCR-GFP+ or 5·103 P14 miR-155-GFP+ cells 
were intravenously (i.v) transferred into CD45.2 B6 mice. One day later, mice were i.v 
infected with 2x106 pfu of wt LCMV cl13 or 1:3 mixture of wt cl13 and A3 cl13 strains 
(mix infection). Both LCMV strains were provided by Prof. Dietmar Zehn.  
 
LCMV virus titration  
50uL of blood were harvested 6 and 20 days post-infection and frozen at -80°C. Serial 
dilutions of thawed blood were made with 10% FCS (Dominique Dutscher, S1810-500), 
50IU/mL/50ug/mL Penicilin/Streptomycin (Gibco, 15070-063), 0.05mM 2ß-
mercaptoethanol (Gibco, 31350-010), 10mM HEPES (Amimed, 5-31F00-H), in DMEM 
with Glutamax (Gibco, 31966-021) (cDMEM) in duplicates and 200uL of each dilution 
was mixed with 200uL of 1.6·105 Vero cells. After 3h incubation at 37°C, 400uL of 2x 
DMEM methylcellulose was overlaid and cells were further cultured at 37°C. 72h later, 
cells were fixed with 4% paraformaldehyde (PFA), permeabilized with 1x Triton, washed 
with 5% FCS in PBS and stained with Rat anti-LCMV nucleoprotein (clone VLA-4) 
(BE0106, BioXcell) for 1h at RT. After two washes with 2% FCS in PBS, Goat-anti-Rat-
HRP secondary antibody was added to the cells (112-035-167, Jackson 
ImmunoResearch) and incubated for 1h at RT. Cells were then washed twice with 2% 
FCS in PBS and o-Phenylenediamine dihydrochloride (OPD) (P9187, Sigma-Aldrich) 
was added for 15’ at RT. Finally, cells were washed twice with PBS and number of 
plaques were counted.  
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Ex vivo stimulation of P14 cells 
Mouse splenocytes were stimulated with 5ug/mL gp3333-41 (KAVYNFATM) peptide or 
10ng/mL Phorbol 12-myristate 13-acetate (PMA) (Sigma-Aldrich) + 500ng/mL 
Ionomycin (Sigma-Aldrich) for 30min at 37°C in cDMEM. BD GolgiPlug and GolgiStop 
(BD Bioscience) was added to the cells and incubated for another 4h at 37°C before cell 
staining.  
 
Human samples   
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donor (HD) 
blood (Service régional vaudois de transfusion sanguine de la Croix-Rouge Suisse) by 
density gradient centrifugation on Lymphoprep (Axis-Shield PoC AS). Total CD8+ T 
cells from HDs PB leucocytes were obtained by magnetic bead enrichment with Human 
CD8+ T Cell Isolation Kit (Miltenyi Biotec) or CD8 Dynabeads (Life technologies) 
following manufacturer’s instructions.  
Liquid nitrogen stored peripheral blood (PB) lymphocytes, non-infiltrated lymph nodes 
(NLNs), tumor infiltrated lymph nodes (TILNs) and tumors of malignant melanoma 
patients were thawed in 10µg/mL DNase I (SIGMA-ALDRICH), 10% fetal calf serum 
(FCS), antibiotic mixture (5mg/mL Penicillin, 5mg/mL Streptomycin, 10mg/mL 
Neomycin (Invitrogen)), 0.05mM 2ß-mercaptoethanol (Invitrogen) in RPMI medium 
(Invitrogen). Melanoma patients’ clinical data is found in Table 1. 
 
In vitro miR-155 expression kinetic in αCD3/αCD28 beads activated naive CD8+ T cells  
130000 sorted naive CD8+ T cells from HDs were placed in a round-bottom 96 well plate 
in 50ng/mL IL-2, 8% human serum, 100U/mL Penicillin (Gibco), 100µg/mL 
Streptomycin (Gibco), 0.1mg/mL Kanamycin (Gibco), 2mM L-glutamine (Gibco), 1% in 
volume non-essential amino acids (Gibco), 1mM Na Pyruvate (Gibco), 0.05mM 2ß-
mercaptoethanol (Sigma) in RPMI medium (Gibco) (human T cell media). Cells were 
activated with 1:2 αhCD3/αhCD28 coated Dynabeads (Life technologies) and collected 
in RNAlater (AM7020, Lifetechnologies) every 24h during 5 days for RNA extraction 
and qPCR analysis.  
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Multimer stimulation and T cell avidity measurement of Melan-A26-35 CD8+-T cells by 
NTAmers 
50000 HLA-A2/Melan-A MART-126-35 (EAAGIGILTV) specific CD8+ T cell clones from 
melanoma patient LAU986 were in vitro stimulated with 1µg/mL HLA-A2/Melan-
AMART1 26-35 (A27L) (ELAGIGILTV) multimers in human T cell media in 96-well plates for 
24h before RNA extraction and miR-155 qPCR.  
T cell avidity of Melan-AMART126-35 CD8+ T cell clones was measured by NTAmer 
staining as previously described (Hebeisen et al., 2015). Briefly, CD8+ T cell clones were 
stained in 50 µL of 0.2% BSA, 5 mM EDTA in PBS for 45 minutes at 4°C with HLA-
A*0201 NTAmers loaded with Melan-A MART-126-35 (A27L) peptide containing Cy5-labeled 
and biotinylated HLA-monomers multimerized through streptavidin-PE. After washing 
at 4°C, cells were resuspended in FACS buffer and dissociation kinetics was assessed at 
4°C using LSR-II flow cytometer (BD Biosciences). Upon 30 seconds of acquisition 
(baseline), imidazole (100mM) was added and Cy5 fluorescence was measured during 5 
to 10 minutes.  
 
Surface and intracellular antibody staining for flow cytometry 
Human HDs peripheral blood CD8+ T cells and melanoma patients lymphocytes from 
PB, NLNs, TILNs and tumors were stained with anti-human(αh)-CD3-AlexaFluor700 
(cl.UCHT1, Biolegend) αhCD4-PE (cl.RPA-T4, BD Biosciences), αhCD8-APC-
Alexa750 (cl.B9.11, Beckman Coulter), αhCCR7-BrilliantViolet421 (cl.G043H7, 
Biolegend) and αhCD45RA-ECD (cl.2H4LDH11LDB9, Beckman Coulter).  
Mouse splenocytes and dissociated tumor samples were stained with CD3-A700 
(cl.17A2, eBioscience), CD8-PE-TexasRed (cl.MCD0817, Life technologies), CD45.1 
FITC (cl.A20.1, FACS facility UNIL), CD45.2 APCeF780 (cl.104, eBioscience), PD-1-
APC (cl29F.1A12, eBioscience), CD44-PacificBlue (cl.IM781, FACS facility UNIL) and 
CD62L-PE-Cy5 (cl.MEL-14, eBioscience) after H2-Db/LCMV gp276-286 
(SGVENPGGYCL) multimer staining when necessary. For intracellular staining of 
cytokines, cells were fixed with Fixation Buffer (420801, Biolegend) and permeabilized 
with Intracellular Staining Permeabilization Wash Buffer (421002, Biolegend) according 
to manufacturer’s instructions. Cells were then stained with IFNγ-PerCp-Cy5.5 
(cl.XM61.2, eBioscience), TNFα-Pacific Blue (cl. MP6-XT22, Biolegend), IL-2-PE-Cy7 
(cl. JES6-SH4, eBioscience), and GranzymeB-PE-TexasRed (GRB17, Molecular probe). 
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For dead cell discrimination, cells were stained with LIVE/DEADÒ Aqua fluorescent 
reactive dye (Vivid) (Invitrogen) after surface antibody staining and before fixation for 
intracellular staining. All stainings were performed in darkness at 4°C for 20’ in 2% FCS, 
2mM EDTA in PBS (sorting buffer), except the staining with Vivid, which was 
performed in PBS and the intracellular staining which was done in Intracellular Staining 
Permeabilization Wash Buffer (421002, Biolegend). Multimer staining was performed in 
darkness at 4°C for 60’ in sorting buffer. Before and between each staining step, cells 
were washed with sorting buffer and finally, cells were resuspended in sorting buffer for 
flow cytometry analysis with LSRI-II flow cytometer (BD) or flow cytometry cell sorting 
(FACS) with Aria III (BD). Sorted cells were collected in RNA later (AM7020, Life 
Technologies). 
 
Quantitative PCR (qPCR) 
Total RNA was extracted with mirVana kit (Ambion). Mature human miRNA-155 (hsa-
miR-155) and RNU44 small nucleolar RNA or mature mouse miR-155 (mmu-miR-155) 
and snoRNA202 were individually reverse transcribed (30 min at 16°C, 30 min at 42°C, 
5 min at 85°C) with TaqMan RT MicroRNA Kit (Applied Biosystems) following 
manufacturer’s instructions. cDNA was amplified using Universal PCR Master Mix, No 
AmpEraseÒ UNG (Roche) and hsa-miR-155, RNU44, mmu-miR-155, and snoRNA202 
specific TaqMan primers (Applied Biosystems) in MicroAmpÒ Fast Optical 96-Well 
Reaction Plate (Applied Biosystems) on a 7500 Fast Real-Time PCR System (Applied 
Biosystems) (40 cycles of 15s at 95°C and 60s at 60°C).  Single specific qPCRs were 
performed in duplicates. RNU44 Ct of human samples and snoRNA202 Ct of mouse 
samples was subtracted to hsa-miR-155 Ct and mmu-miR155 Ct respectively to calculate 
relative expression (∆Ct). Expression fold change relative to a reference sample was 
calculated using the following formula: !"#$	&ℎ()*+	,+#(-./+	-"	(	,+!+,+)&+ = 22(∆56789:;<2∆56=<><=<?@<). 
MiR-155 in situ hybridization (ISH)  
Multiplex ISH assay for miR-155 and U6 RNAs was performed as described (Sempere, 
2014; Sempere et al., 2010). Briefly, tissue sections were incubated for 90 min at 45oC in 
standard hybridization solution with 100 nM of dual terminal tag miR-155 (5’FAM-
tT+TA+AT+GCT+AAT+CGT+GAT+AG+GG+GTt-3’FAM) and U6(5’-biotin-
tCGTGTATCCTTGCGCAGGGGCCATGCTAATCTTCTCTGTt-3’biotin) probes and 
PhD Thesis   Amaia Martínez Usatorre 
 72 
washed three times with 0.5X Saline Sodium Citrate buffer (SSC) for 10 min at 
hybridization temperature. Probe signal was revealed by consecutive rounds of 
horseradish peroxidase-mediated deposition of tyramide-conjugated fluorescein (miR-
155 probe) and tyramide-conjugated rhodamine (U6 probe) using standard protocol on 
an automated Dako Autostainer Link 48 (Dako North America, Inc, Carpinteria, CA). 
Multiplex IHC assay for CD8 and Ki-67 was performed on consecutive tissues to ISH 
assay as described (Ensink et al., 2015). Briefly, slides were pre-treated with standard 
program with citrate buffer pH=6 for heat-induced epitope retrieval on Dako PT Link. 
Primary antibody signal (1:200 dilution of mouse anti-CD8 ([4B11], BioRad, 
MCA1817); 1:400 dilution of rabbit anti-Ki-67 ([SP6], Spring Bioscience, M3064)) was 
revealed with appropriate combination of HRP-conjugated anti-host species goat 
secondary antibodies and tyramide-conjugated dyes as above. All tissue slides were 
counterstained with DAPI. Images were acquired and multispectrally separated using the 
Vectra Automated Quantitative Pathology Imaging System (PerkinElmer, Waltham, 
MA). PerkinElmer InForm software package was used for DAPI-based cell segmentation, 
for quantitating expression of miR-155 with H-score function, and for enumerating Ki-
67+ and CD8+ cells with cell phenotyping algorithm.  
 
Statistical analysis 
Flow cytometry data were analyzed with FlowJo (TreeStar). Graphs and statistical 
analysis were made with Prism (GraphPad Software). Specific statistical analyses are 
described in figure’s captions. Overall, normality of data distribution was analyzed by 
Shapiro-Wilk normality test. Comparison between two unpaired groups was performed 
by parametric Student’s t-test or non-parametric Mann-Whitney test. For multiple 
comparison, a parametric 1-way ANOVA or non-parametric Krustal-Wallis test was 
performed followed by Tukey’s multiple comparison test or Dunn’s multiple comparison 
test respectively. Simultaneous analysis of two variables among multiple groups was 
performed by 2-way ANOVA or 2-way repeated measurements (RM) ANOVA followed 
by Tukey’s multiple comparison test. Long-rank Mantel-Cox test was applied for survival 
curves and Pearson’s correlation coefficients were calculated for correlation analysis. P-
values are coded as *p:<0,05; **:p<0,01; ***:p<0,001 and ****:p<0,0001 in figures. 
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LAU Sex Age PB NLNs TILNs Tumor Treatment Survival 
(months) 
TNM at 
sampling 
108 F 40 20.07.94 20.07.94 20.07.94 - 09.94, IFNα. 
08.95, adoptive T cell transfer. 
267 (A) pTx N3 M0, 
IIIC 
18 F 72 15.05.96 19.06.96 19.06.96 - - 10 (D) ? 
115 F 45 13.10.94 14.09.94 14.09.94 - 15.09.94 ILP (TNFa, Melphalan,  
IFNg), 22.02.1995 chemotherapy (DTIC 
+ tamoxifen) 
77 (A) T3b N3 Mx 
162 F 55 15.05.96 03.05.95 03.05.95 - 02.96 chemotherapy (cisplatin, IL-2,  
IFNα) 
32 (A) pT2 N0 M0 
211 M 80 29.05.97 14.08.96 14.08.96 - 14.08.1996 (TNFa, Melphalan) 29 (D) T? N2 M0 
147 F 38 10.02.05 08.02.95 08.02.95 - 01.11.01, peptide-based 
immunotherapy, 21.08.2002 
vaccination, 21.10.2002 chemotherapy 
266 (A). T3a N2 M0 
42 M 51 24.04.96 - 25.01.95 07.11.96 11.98 peptide-based immunotherapy 210 (D). T4a N1 M0 
(25.01.1996) 
then T4a N1 
M0 
(07.11.1996) 
993 M 57 06.10.04 - - 06.10.04 U.K 14 (D) pT1a pN3 M0 
820 M 76 15.12.04 - - 16.12.04 U.K 58 (A) T2a N1 M0 
1299 M 53 24.10.08 - 24.10.08 - U.K 14 (A) Tx N1b M0 
1318 F 81 21.01.09 - 21.01.09 - 2010 Temodal 36 (D) pT4b pN3 
pM1a 
99 F 32 10.09.96 - - 16.07.97 DTIC/fotemustine, IFN, Temodal 26 (D) pT4 N0 M0 
1256 F 36 15.07.08 
and 
12.11.07 
- 19.02.09 - Chemotherapy 1 (D) pTx N3 M0 
372 M 59 3.11.99 - 03.11.99 - Radiotherapy, chemotherapy 
(DTIC/CDDP) and IFNα 
9 (D) T4a N3 M0 
1259 F 46 03.10.07 - 03.10.07 - Radiotherapy 14 (D) pTx N2 M0 
392 F 33 24.07.00 - 01.03.00 - 27.09.04- 13.04.05 peptide-based 
immunotherapy 
66 (D) pT3a N3 M0 
991 M 60 15.09.04 - 15.09.04 - Radiotherapy 4 (D) pT4a pN2a 
380 F 63 22.12.99 - 22.12.99 - None 206 (A) Tx pN1b M0 
161 F 65 - 22.03.95 22.03.95 - peptide-based immunotherapy and 
chemotherapy 
15 (D) pT2b pN3 M0 
1359 M 76 02.10.09 - 28.07.10 - None 38 (D) pT1 pN2a M0 
1255 M 87 08.08.07 - 08.08.07 - None 31 (A) pT2b pN2 M0 
576 M 57 25.04.01 - 25.04.01 - U.K 60 (D) pT1 N1 M0 
Table 1. Clinical data of melanoma patients. LAU: code number of patients. Sex, F: female and M: male. Age: age at sampling. PB: 
peripheral blood, NLNs: non-infiltrated lymph nodes, TILNs: tumor-infiltrated lymph nodes and tumor sampling date. Survival in months 
from date of sampling, A: alive, D: dead. TNM: classification of malignant tumors. T: size or direct extent of the primary tumor. N: degree 
of spread to regional lymph nodes. M: presence of distant metastasis. Xx: X parameter cannot be assessed, X0: absence of X parameter. X1, 
X2, X3 size or extension of X parameter. U.K: Unknown. 
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Results 
Tumor-specific effector CD8+ T cells retain high miR-155 expression levels in B16 
melanoma tumors  
We previously published that miR-155 overexpression in tumor-specific CD8+ T cells 
enhances their ability to control tumor growth (Dudda et al., 2013), suggesting that miR-
155 expression is important for CD8+ T cell mediated anti-tumor responses. Therefore, 
we analyzed miR-155 expression levels in tumor-infiltrating CD8+ T cells upon peptide-
CpG vaccination. C57BL/6 (B6) mice were engrafted with B16.OVA tumors and after 6 
days, OT-1 cells were transferred. One day later, N4 peptide and CpG were administered 
subcutaneously (s.c) (Figure 16A). Seven days post-vaccination (day 14), qPCR analysis 
of ex vivo endogenous effector CD8+ T cells and effector OT-1 cells showed higher miR-
155 expression levels in the tumor than in the spleen (Figure 16B). Similar high miR-155 
expression levels were detected in TILs one week later (Figure 16B). Thus, in the tumor 
microenvironment, effector CD8+ T-cells upregulate and maintain high miR-155 
expression levels.  
 
miR-155, a marker of antigen recognition 
A major difference between the spleen and the tumor is the presence of specific antigen. 
OT-1 cells and tumor-specific CD8+ T cells within the endogenous tumour-infiltrating 
CD8+ T cell population are chronically exposed to antigens expressed by tumors. To 
assess whether chronic antigen exposure is the cause of increased miR-155 expression in 
tumor-infiltrating CD8+ T cells we assessed miR-155 expression in CD8+ T cells from a 
chronic viral infection. For that we used the clone-13 (cl13) lymphocytic 
choriomeningitis virus (LCMV) chronic viral infection mouse model. Gp33 LCMV 
antigen specific naïve CD8+ T cells (P14) were transferred into B6 mice and 7 and 21 
days after infection, miR-155 expression levels were analyzed in ex vivo sorted P14 and 
endogenous gp276-specific CD8+ T cells from the spleen (Figure 16C). Already at day 7, 
P14 and gp276-specific CD8+ T cells showed respectively 20 and 15 times higher miR-
155 expression levels than naïve CD8+ T cells (Figure 16D), similarly to our observations 
in tumor infiltrating CD8+ T cells (Figure 16B). Such high miR-155 expression levels 
were also observed three weeks post-infection, indicating that chronic antigen exposure 
leads to increased miR-155 expression. Of note, P14 cells tend to have higher miR-155 
expression levels than gp276 specific CD8+ T cells. Such difference could be due to T 
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cell affinity differences: while P14 cells are high affinity monoclonal cells, gp276tet+ 
cells are polyclonal cells with probably a range of different affinities.  Antigen 
presentation differences could also explain the difference in miR-155 expression levels 
as the affinity of gp33 peptide to MHC class I molecules is higher than the affinity of 
gp276 peptide and is reflected in epitope immunodominance (van der Most et al., 1998; 
Wherry et al., 2003). 
D7 D2
1
0
10
20
30
40
R
el
at
iv
e 
m
iR
-1
55
 e
xp
re
ss
io
n
P14 (WT)
gp276 (WT)
en
do
O
T-
1
en
do
O
T-
1
en
do
O
T-
1
en
do
O
T-
10
10
20
30
R
el
at
iv
e 
m
iR
-1
55
 e
xp
re
ss
io
n
Spleen Tumor Spleen Tumor
D14 D21
B16.OVA
*
**
**
* ***
D7 D2
1
0
10
20
30
40
R
el
at
iv
e
 m
iR
-1
55
 e
xp
re
ss
io
n
P14 (WT)
P14 (MIX)
**
*
A B
C D
F
D7 D2
1
0
10
20
30
40
gp276 (WT)
gp276 (MIX)
E G
2·106	pfu	LCMV	cl13
D7 D21
1000	P14	
cells	(CD45.1)
D0D-1
B6	(CD45.2)	
LCMV	cl13	WT or	
MIX	infection
D7 D21
1000	P14	
cells	(CD45.1)
D0D-1
B6	(CD45.2)	
cl13	wt cl13	w/o	gp33
gp33	+
gp276	+++
cl13	wt gp33	+++gp276	+++LCMV	cl13	WT
LCMV	cl13	MIX
105 OT-1	or	
(CD45.1)
D7
D21
105 B16.OVA
D6D0
B6	(CD45.2)	
D14
SIINFEKL	+	CpG
Figure 16. miR-155 expression levels reflect antigen exposure. A. Scheme of the experimental design. Six days after 
B16.OVA tumor engraftment, 105 CD45.1 OT-1 were transferred into CD45.2 B6 mice. One day later mice were s.c. 
vaccinated with N4-CpG. B. miR-155 expression levels in endogenous CD8+ effector and effector OT-1 cells from 
spleen and B16.OVA tumors 14 and 21 days post-tumor engraftment. C. Scheme of the experimental design. CD45.2 
B6 mice were i.v infected with 2x106 pfu LCMV cl13 one day after 103 CD45.1 P14 T cell transfer. D. miR-155 
expression levels in P14 and endogenous gp276+ CD8+ T cells from the spleen 7 and 21 days after wt cl13 LCMV 
infection. E. Scheme of the experimental design. CD45.2 B6 mice were infected with 2x106 pfu of wt LCMV cl13 or 
1:3 mixture of wt cl13 and A3 cl13 strains (mix infection) one day after 103 CD45.1 P14 T cell transfer. F. miR-155 
expression levels in P14 cells 7 and 21 days after wt or mix LCMV cl13 infection. G. miR-155 expression levels in 
endogenous gp276+ CD8+ T cells after wt or mix LCMV cl13 infection. Bars represent mean of miR-155 expression 
as fold change relative to levels in host naïve CD8+ T cells from the spleen. In panel B, each dot represents miR-155 
expression levels of pooled cells from 5 mice. In panel D, F and G, each dot represents cells of individual mice.  A 2-
way ANOVA followed by Sidak’s multiple comparison test was performed on non-normalized DCt data.  
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To confirm the role of antigen exposure on the regulation of miR-155 expression, P14 
cells exposed to different gp33 antigen doses but same inflammatory environment were 
analyzed. Mice were infected with wild-type (wt) cl13 LCMV or a 1:3 mixture of wt cl13 
LCMV and cl13 A3 LCMV strain, which lacks the gp33 epitope (Figure 16E). Although 
miR-155 expression levels at day 7 were similar in effector P14 cells from wt and mix 
infection, at day 21, effector P14 cells from the mix infection showed reduced miR-155 
expression (Figure 16F).  gp276 specific CD8+ T cells, on the contrary, showed same 
miR-155 expression levels in wt and mix infection (Figure 16G). To confirm that only 
gp33 antigen load and not total viral load differ between wt and mix infection, total 
LCMV cl13 virus titers were measured in blood of wt and mix infected mice. Indeed, 
similar virus titers were observed in wt and mix infected mice (Figure 17A). Therefore, 
the use of the mix LCMV cl13 model allowed us confirming that in the same 
inflammatory environment, the amount and frequency of antigen exposure determines 
CD8+ T cells miR-155 expression levels.    
 
miR-155-overexpression enhances CD8+ T cells expansion and cytotoxicity in LCMV 
cl13 chronic infection 
CD8+ T cells from tumors and chronic viral infections display an exhaustion profile 
characterized by increased expression of inhibitory receptors such as PD-1 and reduced 
cytokine production after in vitro restimulation (Baitsch et al., 2011; Moskophidis, 
Lechner, Pircher, & Zinkernagel, 1993; Wherry et al., 2007; Zippelius et al., 2004) 
(Figure 11 and 12). Chronic antigen stimulation has been proposed as one of the main T 
cell exhaustion drivers (Wherry et al., 2003). Indeed, using the LCMV mix infection 
model, it was previously shown that in the same inflammatory environment, antigen 
exposure plays an important role in the acquisition of an exhausted phenotype by CD8+ 
T cells (Utzschneider, Alfei, et al., 2016). Along these results, we also observed that P14 
cells from the mix infection showed reduced PD-1 expression (Figure 17B and 17C) and 
increased cytokine production upon in vitro peptide restimulation compared to P14 cells 
from wt infection (Figure 17D and 17E). Thus, increased miR-155 expression levels were 
accompanied by decreased P14 cell functionality 21 days after wt infection. To further 
determine whether high miR-155 expression levels are detrimental and linked to the 
exhausted phenotype observed in the P14 cells after wt LCMV cl13 infection we analyzed 
the functionality of miR-155-overexpressing P14 cells after wt or mix LCMV infection. 
To this aim, naïve P14 cells were in vitro activated and transduced with MDHI-miR-155-
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GFP or MDHI-SCR-GFP retroviral vectors. Seven days post-transduction, 5000 sorted 
P14 GFP+ cells were transferred to naïve B6 mice and the same day, mice were infected 
with LCMV wt or mix infection.  
 
QPCR analysis of ex vivo sorted P14-GFP+ cells confirmed that P14-miR-155 cells 
expressed higher miR-155 expression levels than SCR-transduced cells during chronic 
LCMV infection (Figure 18A). In both infection models, miR-155-overexpressing P14 
Figure 17. Low antigen dose leads to enhanced functionality of P14 cells upon chronic LMCV cl13 infection. A. 
LCMV cl13 viral titers expressed as plaque forming units per mL of blood of mix and wt infected mice 6 and 20 days 
post-infection. B. Representative histograms of PD-1 expression of P14 cells from wt or mix infection, seven and 21 
days post-infection. C. PD-1 MFI quantification. D and E. Representative histograms and quantification of IFNγ+, 
TNFα+ and IL-2+ P14 cell percentage in total P14 cells after in vitro gp33 peptide re-stimulation of splenocytes, 7 and 
21 days after infection respectively. Lines represent the mean and symbols individual mice. An unpaired t-test or Mann-
Whitney non-parametric test was performed after Shapiro-Wilk normality test.  
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cells showed increased expansion by day 7 post-infection and were still detectable at day 
21 in contrast to P14-SCR cells (Figure 18B), while viral titers were similar in the blood 
of all mice (Figure 18C). However, on day 7, PD-1 expression levels were higher in miR-
155 overexpressing P14 cells (Figure 18D). This could indicate a stronger activation but 
also increased exhaustion of miR-155 overexpressing P14 cells. Thus, we checked their 
capacity to produce cytokines upon ex vivo peptide restimulation. While IFNg production 
was similar, decreased TNFa producing cell frequencies were observed in P14-miR-155 
compared to P14 SCR cells. However, this was only observed in the WT LCMV cl13 
infection and the amount of TNFa produced per cell was similar (Figure 18E and 18F). 
Thus, miR-155 overexpression did not lead to striking differences in IFNg and TNFa 
production 7 post infection. In contrast, increased granzyme B production was observed 
in P14-miR-155 compared to P14-SCR cells (Figure 18E and 18F). Therefore, miR-155 
overexpression leads to increased cytotoxic capacity, expansion and probably survival of 
CD8+ T cells in chronic infection regardless of the antigen dose.   
 
 
 
Figure 18. miR-155 overexpression 
enhances P14 cell expansion and 
cytotoxic potential in LCMV cl13 wt 
and mix infection. A. Mir-155 
expression levels of P14-miR-155-GFP+ 
or P14-SCR-GFP+ cells before transfer or 
7 and 21 days post-infection represented 
as fold upregulation relative to levels in 
naïve P14 cells. B. Percentage of P14-
SCR or P14-miR-155 cells in total CD8+ 
T cells. C. LCMV cl13 viral titers 
expressed as pfu per mL of blood of mix 
and wt infected mice 6 and 20 days post-
infection. D. PD-1 MFI of P14-miR-155 
or P14-SCR cells in the spleen 7 days 
post-infection. E.   Percentage of IFNg+, 
TNFa+ and Granzyme B+ cells in total 
P14-SCR or P15-miR-155 cells upon in 
vitro gp33 stimulation of splenocytes 7 
days-post infection. F. IFNγ, TNFα and 
Granzyme B MFI in IFNγ+, TNFα+ and 
Granzyme B+ P14-SCR or P14-miR-155 
cells. Dots represent individual mice and 
the line the mean ± SD. A 2-way ANOVA 
followed by Sidak’s multiple comparison 
test was performed except in the right 
panel (D21) of figure A where an 
unpaired t-test was performed after 
Shapiro-Wilk normality test. n.d. Non-
detected, <0,005% in CD8+cells 
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MiR-155 expression levels in low affinity tumors positively correlate with tumor control 
Most TAAs are self-antigens (Byrne et al., 2011). Therefore, only low avidity specific 
CD8+ T cells recognizing these antigens overcome thymic selection and are found in 
cancer patients. Nonetheless, tumor neo-antigens arisen from somatic mutations have 
recently been described in cancer patients’ tumors as well as CD8+ T cells able to 
recognize them (Gros et al., 2016; Robbins et al., 2013). In contrast to TAA-specific 
CD8+ T cells, neo-antigen specific CD8+ T cells could potentially recognize their antigen 
with high affinity due to the absence of central tolerance. Thus, we wondered whether 
miR-155 expression levels differ between high and low avidity T cells that can likely be 
found in cancer patients. To address this, naïve high avidity OT-1 or low avidity OT-3 
OVA-specific CD8+ T cells (Enouz et al., 2012) were transferred to B16.OVA bearing 
mice and miR-155 expression levels were analyzed in spleen and tumors after N4-CpG 
vaccination. While naïve OT-1 and OT-3 cells expressed similar miR-155 expression 
levels (Figure 19A), effector OT-3 cells expressed lower miR-155 expression levels than 
OT-1 cells in spleen and tumors at day 14 post tumor engraftment. On day 21, OT-3 cells 
maintained lower miR-155 expression levels than OT-1 cells in the tumor, whereas there 
did not differ anymore in the spleen. Nonetheless, like OT-1 cells, OT-3 cells consistently 
showed higher miR-155 expression levels in tumors than in spleen (Figure 19B).   
 
It was shown that the strength of the TCR-ligand interaction affects the expansion and 
differentiation of CD8+ T cells upon infection (Knudson, Goplen, Cunningham, Daniels, 
& Teixeiro, 2013; Zehn et al., 2009). Likewise, we observed in the first part of my thesis 
a decreased expansion and effector differentiation of OT-3 cells compared to OT-1 cells 
upon N4-CpG vaccination in B16.OVA tumor-bearing mice (Figure 6C and 6E).  Thus, 
to exclude intrinsic differences between OT-1 and OT-3 cells during peripheral T cell 
priming which could explain the differences in miR-155 expression, we compared miR-
155 expression levels of OT-1 cells isolated from B16.N4 and B16.T4 tumors after N4-
CpG s.c vaccination. At day 14 and 21 post-tumor engraftment, sorted OT-1 cells showed 
increased miR-155 expression in B16.N4 tumors and to a lower extent in B16.T4, 
compared to miR-155 expression levels in the spleen OT-1 cells (Figure 19C). Moreover, 
at day 14, OT-1 cells from B16.N4 tumors tent to have higher miR-155 expression levels 
than OT-1 cells from B16.T4 tumors. The difference was significant at day 21 (Figure 
19C), indicating that antigen recognition affinity impacts on miR-155 expression. As a 
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conclusion, tumor-specific CD8+ T cells   upregulate miR-155 in the tumor in a T cell 
affinity-dependent manner.   
 
We also noticed that there was low miR-155 expression variability among OT-1 cells 
from B16.N4 tumors, whereas the variability was high in B16.T4 tumors (SD -DCt 0.40 
vs 1.18). Interestingly, miR-155 expression levels in those low affinity tumors negatively 
correlated with tumor volume (Figure 19D). Overall, miR-155 expression levels in tumor 
infiltrating OT-1 cells likely reflects the activation state of the cells as we previously 
showed that antigen recognition is one of the main drivers of miR-155 upregulation. 
However, when we analyzed expression levels of miR-21, another miRNA upregulated 
upon T cell activation (Salaun et al., 2011; Wu et al., 2007), we did not observe any 
correlation with tumor volume (Figure 19E), suggesting that miR-155 expression levels 
Figure 19. miR-155 expression levels in tumor infiltrating effector OT-1 cells is T cell affinity dependent and 
positively correlates with tumor control in B16.T4 tumors A. miR-155 expression levels in naive OT-1 and OT-
3 cells. B. Relative miR-155 expression levels in effector OT-1 and OT-3 cells from spleen and B16.OVA tumors 
14 and 21 days post-tumor engraftment. C. Relative miR-155 expression levels in effector OT-1 cells from spleen 
and B16.N4 or B16.T4 tumors. D and E. Relationship between tumor volume and miR-155 or miR-21 expression 
levels respectively. Bars represent the mean and symbols individual mice except in Figure B where each dot 
represents a pool of 5 mice. In red B16.N4 and in blue B16.T4 tumors. miR-155 expression levels are expressed as 
-ΔCt of miR-155 and snoRNA202. Relative miR-155 expression levels are expressed as fold change relative to levels 
in host naïve CD8+ T cells from the spleen. An unpaired t-test or Mann-Whitney non-parametric test was performed 
after Shapiro-Wilk normality test in panels A, a 2-way ANOVA followed by Sidak’s multiple comparison test in 
panel B, a 1-way ANOVA followed by Tukey’s multiple comparison test in panel C and a Pearson’s correlation in 
panels D and E. All statistical tests were performed in non-normalized -ΔCt data.  
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may be an important indicator of CD8+ T cell fitness in low affinity antigen expressing 
tumors. 
 
Anti-PD-1 treatment enhances tumor-infiltrating CD8+ T cells miR-155 expression levels 
Tumor infiltrating CD8+ T cells become dysfunctional due to the highly 
immunosuppressive tumor microenvironment. Signaling through PD-1 receptor is one of 
the critical inhibitory signals that CD8+ T cells encounter in the tumor. In fact, it has been 
shown that PD-1 blockade enhances CD8+ T cell functionality (Wong et al., 2007) leading 
to impressive clinical responses in metastatic melanoma patients (Topalian et al., 2012). 
When we measured miR-155 expression levels in tumor infiltrating OT-1 cells of anti-
PD-1 treated mice, we observed increased miR-155 expression levels in B16.N4 tumors 
after anti-PD-1 treatment and a tendency in B16.T4 tumors (Figure 20A). miR-21 levels 
were however similar despite the treatment (Figure 20B). Anti-PD-1 treated mice showed 
improved tumor control due to enhanced OT-1 cell infiltration and functionality (Figure 
14). Thus, increased miR-155 expression levels in CD8+ T cells from anti-PD-1 treated 
mice are in line with our hypothesis that miR-155 expression levels correlate with 
enhanced CD8+ T cell fitness.  
 
miR-155 expression is regulated during human CD8+ T cell activation and differentiation 
The role of miR-155 in mouse CD8+ T cells has been largely studied by us and others 
(Dudda et al., 2013; Gracias et al., 2013; Ji et al., 2015). In contrast, little is known about 
the modulation of miR-155 in human CD8+ T cells. 
 
We previously reported that miRNA expression profiles differ among the different CD8+ 
T cells subsets from healthy donors (HDs) (Salaun et al., 2011). miR-155, in particular, 
was found to be upregulated in EM compared to naïve CD8+ T cells.  Here, we sorted 
naïve, CM, EM and EMRA CD8+ T cells from a different cohort of HDs and confirmed 
Figure 20. Anti-PD-1 treatment 
leads to increased miR-155 
expression in CD8+ TILs. A and B. 
Relative miR-155 or miR-21 
expression levels of effector OT-1 
cells from B16.N4 or B16.T4 
tumors of mice treated with anti-
PD-1 or isotype control Ab. An 
unpaired t-test or Mann-Whitney 
non-parametric test was performed 
after Shapiro-Wilk normality test in 
panels A, F and G. N
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that peripheral blood (PB) EM and EMRA CD8+ T cells have higher miR-155 expression 
levels as compared to naïve and CM CD8+ T cells (Figure 21A and 21B). Therefore, HDs 
PB CD8+ T cells show different miR-155 expression levels depending on differentiation 
stage, whereby EM and EMRA CD8+ T cells are the ones with the highest expression 
levels.   
 
This differential miR-155 expression suggests that miR-155 is regulated during human 
CD8+ T differentiation. Indeed, in vitro activation of naïve CD8+ T cells from 4 HDs with 
αCD3/αCD28 coated beads showed a strong miR-155 upregulation until day 2. 
Thereafter, miR-155 levels tent to decrease with a big variability between donors, but 
activated cells retained higher miR-155 expression levels than resting naïve CD8+ T cells 
(Figure 21C).  
Peripheral CD8+ T cell subsets from melanoma patients and HDs show similar miR-155 
expression levels 
Previous data from the group (Dudda et al., 2013) and my results presented above 
convincingly demonstrate that miR-155 is important for CD8+ T cell mediated anti-tumor 
response in the B16 mouse melanoma tumor model. Thus, we aimed to detect a similar 
association in cancer patients by analyzing miR-155 expression levels in melanoma 
patients’ CD8+ T cells.  
 
miR-155 expression levels in PB CD8+ T cell subsets were similar in melanoma patients 
and HDs (Figure 21C). Nonetheless, naïve CD8+ T cells miR-155 expression levels were 
highly variable in HDs and patients with no association with sex or age (Figure 21E and 
21F). However, there was a direct correlation between miR-155 expression levels in naïve 
cells and EM or EMRA subsets from the same donor (Figure 21G), indicating that the 
higher the basal miR-155 levels, the higher the levels found in EM and EMRA CD8+ T 
cells. Altogether, miR-155 expression levels are variable among individuals but 
expression profiles between HDs and melanoma patients polyclonal PB CD8+ T cell 
subsets are similar. 
 
miR-155 upregulation in melanoma patients Melan-A CD8+ T cells is T cell avidity 
dependent 
miR-155 expression in bulk CD8+ T cells from melanoma patients PB may not reflect 
miR-155 expression of tumor-specific CD8+ T cells as they are found in relatively low 
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frequencies in the blood (Pittet et al., 1999). Therefore, we determined miR-155 
expression levels in HLA-A2/Melan-A26-35 specific CD8+ T cell clones originally isolated 
from PB of metastatic melanoma patients. Melan-A26-35 -specific CD8+ T clones were 
stimulated with multimers containing the high-affinity ELAGIGLTV (ELA) analog 
peptide. In parallel, Melan-A CD8+ T cells binding avidity for the peptide/MHC was 
measured with HLA-A2/ELA NTAmers as previously described (Hebeisen et al., 2015). 
24h after multimer stimulation, miR-155 was upregulated in Melan-A26-35  specific CD8+ 
T cell clones and expression levels in each clone correlated with its avidity for the ligand 
as measured by the NTAmer technology (Figure 21H). Thus, in line with our observations 
in mouse CD8+ T cells, TCR stimulation of human tumor specific CD8+ T cells leads to 
avidity dependent miR-155 upregulation.  
 
Figure 21. miR-155 is upregulated upon activation and EM differentiation in a T cell avidity dependent manner 
in human CD8+ T cells. A. Naïve, CM, EM and EMRA CD8+ T cell subset gating strategy based on CCR7 and 
CD45RA expression. B. Relative miR-155 expression levels of PB HDs CD8+ T cell subsets expressed as fold change 
relatively to levels in naïve cells. C. Relative miR-155 expression kinetics in HDs naïve CD8+ T cells activated with 
1:2 αCD3/αCD28 coated beads. D. miR-155 expression levels in HDs and melanoma patients PB CD8+ T cell subsets. 
E. HDs or patients naïve CD8+ T cell miR-155 expression levels grouped by sex. F. Relationship between HDs or 
patients naïve CD8+ T cell miR-155 expression levels and age (n=26; p=0.1836, n.s.; r=-0.269). G. Relationship 
between miR-155 expression levels in PB naïve CD8+ T cells and PB EM/EMRA CD8+ T cells (n=46; p=0.009; 
r=0.379). H. Correlation between miR-155 expression levels in Melan-A CD8+ T cell clones stimulated with Melan-
AMART-126–35 (A27L) multimers and T cell avidity measured by NTAmer dissociation kinetics. In black melanoma patients’ 
samples and in grey HDs. Dots represent individual HD or patients except in figure H were dots represent individual 
clones.  Lines in panels D and E represent the mean and the linear regression in panels F, G and H. A Friedman’s test 
followed by Dunn’s multiple comparison test was performed in panels B and C, a 2-way ANOVA followed by Sidak’s 
multiple comparison test in panel D, an unpaired t-test in figure E after Shapiro-Wilk normality test and a Spearman’s 
correlation in panels F-H.  
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miR-155 is upregulated in EM CD8+ T cells isolated from TILNs and melanoma tumors 
As tumor specific murine OT-1 cells showed high miR-155 expression levels, we 
analyzed miR-155 expression levels in ex vivo sorted CD8+ T cell subsets from tumors, 
tumor infiltrated lymph nodes (TILNs) and non-infiltrated lymph nodes (NLNs) from 
melanoma patients. qPCR analysis revealed that EM CD8+ T cells had higher miR-155 
expression levels in TILNs and tumors than in PB. CM CD8+ T cells showed a similar 
trend but to a lower extent than EM CD8+ T cells (Figure 22A and 22B). Many factors 
could contribute to the differences in miR-155 expression levels in tumors and TILNs 
compared to PB CD8+ T cells. However, when we compared miR-155 expression levels 
in NLNs to levels in TILNs CD8+ T cell subsets, we found that EM CD8+ T cells in TILNs 
showed higher miR-155 expression levels than in NLNs (Figure 22C). Thus, the presence 
of cancer cells plays a role in EM CD8+ T cells miR-155 upregulation in melanoma 
patients. In fact, miR-155 expression levels were very low and similar between PB and 
NLNs CD8+ T cell subsets (Figure 22D). The only exception was patient LAU117, who 
showed higher miR-155 expression levels in NLNs EM CD8+ T cells compared to levels 
in PB EM CD8+ T cells. However, NLNs are LNs from melanoma patients, in which 
tumor cells are not detectable but often belong to the same LN chain as TILNs, obtained 
during radical lymphadenectomy of patients positive for tumor invaded sentinel lymph 
node. Therefore, despite being tumor free, soluble factors from afferent TILNs could have  
 
Figure 22. miR-155 expression levels are higher in EM CD8+ T cells of metastatic tumors and TILNs compared 
to non-infiltrated tissues. Relative miR-155 expression levels in PB, TILNs (A and C), tumors (B) and NLNs (C and 
D) CD8+ T cell subsets of melanoma patients. Symbols represent individual patients miR-155 expression levels 
measured by qPCR and represented as fold change relatively to levels in PB naïve CD8+ T cells. Lines represent the 
mean. A 2-way ANOVA followed by Tukey’s multiple comparison test data was performed on non-normalized DCt.   
arrived and modified NLNs microenvironment. In addition, it has been shown that T cells 
can migrate to efferent LNs (Braun et al., 2011). Thus, the possibility that TILNs EM 
cells with high miR-155 expression levels have migrated from TILNs to NLNs should 
also be considered. In fact, antigen experienced EM CD8+ T cell frequencies were higher 
in melanoma patients NLNs compared to healthy donors LNs (Figure 23), indicating that 
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melanoma patients NLNs differ from healthy LNs, and that the tumor could also be the 
trigger of the high miR-155 expression levels in NLNs, as observed in the patient 
LAU117.  
 
High miR-155 expression levels correlate with increased EM CD8+ T cell frequencies in 
melanoma patients TILNs 
MiR-155 expression levels in EM CD8+ T cells from TILNs and tumors were very 
variable among patients. Interestingly, we observed a positive correlation between TILNs 
EM CD8+ T cells miR-155 expression levels and the percentage of EM CD8+ T cells in 
TILNs (Figure 24A). High EM CD8+ T cells frequencies in TILNs correlated at the same 
time with better overall survival (OS) (Figure 24B), as it has been shown in other cancer 
Figure 23. Higher percentages of EM CD8+ T cell subsets are found in tumors and tumor-infiltrated tissues 
compared to non-infiltrated ones. A. Circles represent CD8+ T cell subsets percentages means in total CD8+ T cells 
in PB, NLNs, TILNs and tumors expressed as parts of whole. B. CD8+ T cell subsets percentages in total CD8+ T cells 
in PB, NLNs, TILNs and tumors.  Dots represent individuals and the bar the mean. C.  CD8+ T cell subset percentages 
in total CD8+ T cells in melanoma patients NLNs compared to healthy donors LNs. A 2-way-ANOVA followed by a 
paired Tukey’s multiple comparison test was performed in panel B and a 2-way ANOVA followed by a paired Sidak’s 
multiple comparison test in panel C.   
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patients cohorts (Angell & Galon, 2013). These correlations suggest that miR-155 
expression levels could be a marker of good prognosis in melanoma patients, although 
mir-155 expression levels did not directly correlate with prolonged OS (Figure 24C). 
These observations indicate that other parameters apart from miR-155 expression were 
involved in the increased TILNs EM CD8+ T cell infiltrates which associated with longer 
OS in this cohort of melanoma patients.  
 
MiR-155 expression by immune cells in TILNs and tumor tissue sections of melanoma 
patients 
Fresh or frozen tumor and TILNs samples are rarely available from melanoma patients. 
Moreover, miR-155 qPCR analysis on sorted EM CD8+ T cells is time-sensitive, 
resource-intensive and technically-demanding to be applied in standard diagnostic or 
prognostic assessments. In contrast, formalin-fixed paraffin embedded (FFPE) tumor and 
TILNs biospecimens are often available as they are obtained for standard diagnosis. 
Therefore, in collaboration with Prof. Lorenzo Sempere in Van Andel Research Institute 
(Michigan, USA), we performed an automated miR-155 in situ hybridization (ISH) in a 
collection of FFPE sections from patients’ tumors and TILNs, which matched samples 
already analyzed by qPCR (Figure 22). We observed evidence of miR-155 expression in 
CD8+ cells, but also in other infiltrating cells of small diameter, which likely 
corresponded to other lymphocyte subsets. Overall, the small-diameter cells showed the 
highest miR-155 expression levels, while larger cells such as cancer cells displayed low 
miR-155 expression levels (Figure 25A and 25D), as seen by qPCR on sorted cells 
(Figure 25E). Interestingly, most miR-155+ small immune cells were in the peri-tumoral 
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Figure 24. High EM CD8+ T-cell frequencies characterized by high miR-155 expression levels correlate with 
prolonged overall survival in melanoma patients. A. Correlation between EM CD8+ T cell percentage in total live 
cells in TILNs and EM CD8+ T cells miR-155 expression levels expressed as –ΔCt of miR-155 and RNU44.  Symbols 
represent individual patients. B and C. Survival curves of melanoma patients segregated according to the median EM 
CD8+ T cell percentage in TILNs and median of miR-155 expression levels. A Pearson’s correlation was performed 
in panel A and a Long-rank Mantel-Cox test in panels B and C.  
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region, and the miR-155 H-score was variable among different areas of the same section 
as well as among tumors, as we previously reported by qPCR (Figure 22A and 22B). Of 
note, we could also detect CD8+ cells in the intra-tumoral regions (Figures 25A, 25B and 
25C) with evidence of a small subset of in situ proliferating Ki-67+ CD8+ cells in some 
tumors (Figure 25A, 25B and 25D). Thus, we were able to provide proof-of-principle for 
automated miR-155 staining in melanoma tissue sections which could be used for high-
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Figure 25. Mir-155 expression analysis on melanoma patients’ FFPE sections. A. Representative pictures of miR-
155 and U6 ISH co-detection, CD8 and Ki-67 co-staining and hematoxylin and eosin (H&E) staining on melanoma 
patients TILNs/tumor consecutive sections. B. mir-155 staining intensity coded as low (yellow), medium (orange) and 
high (red) per cell on the top panel and CD8+ and Ki-67+ cells marked in green and purple respectively on the bottom 
panel. Intra-tumoral (intraT) and peri-tumoral (periT) regions are distinguished; heatmaps in C show quantification in 
each tissue field per region. D. miR-155 staining intensity represented in arbitrary units (a.u) vs nucleus size determined 
by number of pixels (left) or U6 endogenous control staining intensity in a.u (right) at the top and CD8 staining intensity 
represented in arbitrary units (a.u) vs nucleus size (left) or Ki-67 staining intensity in a.u (right) on the bottom on 
multiple tissue fields from same TILN specimen. E. qPCR miR-155 expression analysis on normal melanocytes, 
melanoma cell lines or sorted naive EM CD8+ T cells from PB, TILNs and tumors of melanoma patients.  A one-way 
ANOVA followed by Tukey’s multiple comparison test was performed in panel E. 
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throughput analysis and patient stratification. Follow up correlative studies in larger 
patient cohorts will be required to calibrate a miR-155-based score that would integrate 
tissue heterogeneity as well as subclonal expression variety.  
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Discussion 
We have demonstrated that antigen dose impacts on CD8+ T cells endogenous miR-155 
expression levels. Therefore, miR-155 expression levels in CD8+ T cells reflect in situ 
antigen stimulation and could be used as a marker of CD8+ T cell responsiveness. For 
instance, the high miR-155 expression levels observed in B16.OVA endogenous bulk 
CD8+ TILs suggest that, in addition to the epitopes of the OVA protein, CD8+ TILs cells 
recognize probably other endogenous tumor antigens. In addition, we propose that high 
miR-155 expression levels in melanoma patients TILNs EM CD8+ T cells indicate the 
presence of antigen responding EM CD8+ T cells.  
 
The fact that miR-155 expression levels reflect antigen-reactive CD8+ T cells may 
promote the correlation between miR-155 expression levels and CD8+ T cells frequencies 
in melanoma patients TILNs.  In fact, our results are in line with previous observations 
in HIV infected individuals where miR-155 expression levels in PB CD8+ T cells 
correlated with increased CD8+ T cell numbers as well as their activation state determined 
by high PD-1 and CD38 expression (Jin C et al. HIV Medicine 2017). 
 
Increased survival of CD8+ T cells with miR-155 expression levels may also explain the 
positive correlation between miR-155 expression levels and EM CD8+ T cell infiltration 
in melanoma patients TILN. Previous experiments in the lab showed that lack of miR-
155 impaired CD8+ T cell proliferation and survival in acute viral infections (Dudda et 
al. 2013, Immunity). Accordingly, it was later shown that enhanced tumor control of miR-
155 overexpressing CD8+ T cells was due to increased responsiveness to IL-7 and IL-15 
homeostatic cytokines (Ji et al., 2015), which are essential cytokines for survival and 
homeostatic proliferation of memory T cells (Surh & Sprent, 2008). Moreover, Ji et al. 
reported that miR-155 overexpressing CD8+ T cells showed increased functionality in 
tumors. While enhanced survival of miR-155 overexpressing CD8+ T cells was due to 
increased Stat5 signaling, Akt signaling was responsible for the increased functionality. 
SOCS1 and PTPN2 Stat5 signaling negative regulators and Ship1 Akt inhibitor were 
identified as responsible miR-155 targets respectively (Ji et al., 2015).  
Nonetheless, miRNA-mRNA targeting effects should be carefully addressed and should 
not be generalized to all cell contexts. Indeed, it was shown that the effect of miR-155-
SOCS1 regulation axis is cell and context dependent (L. F. Lu et al., 2015). While SOCS1 
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regulation by miR-155 is dispensable for acute antiviral CD8+ T cell responses, it is 
essential for CD8+ T cells maintenance in chronic viral infections (L. F. Lu et al., 2015), 
indicating that SOCS1 targeting effect depends on whether CD8+ T cells are chronically 
exposed to the antigen or not.  
As tumor infiltrating CD8+ T cells are chronically exposed to the antigen, increased EM 
CD8+ T cell infiltrates in melanoma patients with high miR-155 expression levels could 
involve SOCS1 targeting. In fact, silencing of SOCS1 could recapitulate enhanced tumor 
control of miR-155 overexpressing CD8+ T cells in B16 tumor bearing mice (Dudda et 
al., 2013). In addition, we can speculate that the increased persistence of miR-155 
overexpressing transduced P14 cells in LCMV cl13 wt and mix infection models also 
depends on increased survival capacity by SOCS1 targeting.  
 
We did not observe increased IFNg production of miR-155 overexpressing CD8+ T cells 
in LCMV cl13 chronic infection as previously shown in tumors and acute infections (Ji 
Y et al. PNAS 2015, Gracias et al. Nat Immunology 2013). However, increased 
Granzyme B expression was detected, suggesting that miR-155 enhanced not only cell 
survival but also cytotoxicity in chronic viral infection.  
 
Moreover, we reported that miR-155 upregulation by tumor-specific CD8+ T cells is T 
cell affinity dependent. Thus, high miR-155 expression levels in melanoma patients 
TILNs EM CD8+ T cells could also indicate that those EM CD8+ T cell recognize the 
antigen with higher affinity than EM CD8+ T cells from patients with low miR-155 
expression levels. In fact, we saw in the first part of this thesis that high compared to low 
affinity stimulation in the tumor leads to increased tumor control due to increased CD8+ 
T cells expansion/survival and cytotoxicity (Figure 9). Furthermore, miR-155 
quantification upon antigen stimulation could be an inexpensive method to compare the 
affinity of different CD8+ T cell clones, avoiding the technical challenging SPR 
measurements.   
 
Altogether, as miR-155 expression levels reflect responsiveness and affinity for the 
antigen as well as survival and effector function potential, it could be used as an overall 
marker of tumor infiltrating CD8+ T cells fitness. Therefore, it could be included in the 
recently defined “Immunoscore” term used to classify cancer patients, that may have 
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superior prognostic value to the American Joint Committee on Cancer/ Union for 
International Cancer Control TNM-classification (Angell and Galon 2013).  
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GENERAL CONCLUSIONS AND PERSPECTIVES 
We have demonstrated that the interaction strength between the TCR and the pMHC 
finely controls CD8+ T cells expansion and differentiation by modulating the levels of 
intracellular molecular regulators such as miR-155. Naïve T cells are constantly 
stimulated with weak self-pMHC interactions (Malissen & Bongrand, 2015) due to TCRs 
cross-reactivity (Birnbaum et al., 2014; Mazza et al., 2007). Thus, restraining T cell 
activation upon low affinity TCR triggering is essential to prevent autoimmunity.  
However, this regulation is unfavorable for CD8+ T cell anti-tumor responses that mostly 
rely on low affinity tumor antigen recognition. We have seen in the B16 mouse melanoma 
model that a way to overcome such limitation is the use of cancer vaccines containing 
high affinity altered peptide ligands in combination with CpG. This approach enabled 
sufficient peripheral CD8+ T cell activation and expansion to control B16 tumors 
expressing a low affinity antigen. Thus, optimizing the affinity of the peptide ligand in 
the vaccine formulation is our next priority. Currently, in silico tools allow prediction of 
peptide-MHC-I binding affinities. However, it was shown that despite inducing increased 
Melan-A T cell frequencies, vaccination with a high affinity HLA-A2 binder 
ELAGIGILTV-Melan-A analog peptide led to inferior T cell responses compared to the 
native, low affinity HLA-A2 binder, EAAGIGILTV Melan-A peptide (Speiser et al., 
2008). This was probably due to increased ELAGIGILTV analog peptide presentation by 
DCs and consecutive activation of low avidity T cells (Bullock, Mullins, & Engelhard, 
2003). Adjustment of the immunization dose to have limiting amounts of antigen during 
the in vivo T cell priming could be a strategy to prioritize selection of high avidity T cells. 
Another hypothesis is that the TCR repertoire activated by the analog peptide is not 
entirely cross-reactive with the native peptide. In fact, it was shown that vaccination with 
the gp100209-217(T210M) analog peptide, which has increased binding affinity for HLA-A2 
(Parkhurst et al., 1996), elicits high frequencies of specific CD8+ T cells, yet only about 
half of them react to the native peptide (Rosenberg et al., 2005). Thus, we should 
emphasize the need of altered peptide ligands with increased affinity for the TCRs of the 
tumor-specific CD8+ T cells. One approach to identify such peptides could be to test the 
ability of TAA derived altered peptide ligands to induce T cell affinity dependent 
responses such as Granzyme B production, proliferation and miR-155 upregulation in 
tumor infiltrating CD8+ T cells from cancer patients. 
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Combination of high affinity cancer vaccines with ICB therapies may be particularly 
necessary for low affinity antigen expressing tumor targeting.  Anti-PD-1 treatment 
enhanced tumor control of low affinity antigen expressing tumors. However, combination 
of PD-1 blocking antibodies with other checkpoint inhibitors such as anti-CTLA-4, may 
further enhance tumor control (Curran, Montalvo, Yagita, & Allison, 2010). In fact, anti-
PD-1 and anti-CTLA-4 double blockade showed improved treatment outcome without an 
escalation of adverse events compared to single therapies in melanoma patients (Wolchok 
et al., 2013).  
   
ICB therapies aim to block inhibitory signals of the tumor microenvironment to unleash 
full functionality of T cells. In fact, we have reported here that tumor infiltrating CD8+ T 
cells retain full capacity to reexpand in tumor-free inflammatory environments, proving 
that functionality of CD8+ T cells is rescuable, particularly at early timepoints, when 
cytokine production capacity is also recovered.  However, it remains to be elucidated 
whether all tumor-infiltrating CD8+ T cells or a specific subpopulation is the one 
maintaining the reexpansion and functional capacity. In fact, it was shown in chronic viral 
infections, a condition in which CD8+ T cells are chronically exposed to the antigen and 
inflammation as in tumors, that TCF-1 transcription factor expressing virus specific CD8+ 
T cells are the memory-like CD8+ T cells sustaining the anti-viral response and 
responding to anti-PD-1 treatment (Utzschneider, Charmoy, et al., 2016). Thus, we now 
aim to determine whether this memory-like CD8+ T cell population is also present in 
tumors. In addition, we would like to identify specific surface markers of this population 
that would enable their selection for adoptive T cell transfer as well as definition of 
predictive biomarkers for ICB therapies. 
 
Not only the presence of memory-like CD8+ T cells but miR-155 expression levels may 
also be used as a biomarker of CD8+ T cells fitness and responsiveness to anti-PD-1 
treatment. Active CD8+ T produce IFNγ which upregulates PD-L1 expression on cancer 
cells (Dong et al., 2002) and it has been shown that PD-L1 expression in tumor biopsies 
correlates with anti-PD-1 response rates in cancer patients (Daud et al., 2016). In addition, 
it has been suggested that presence of PD-1+ activated CD8+ T cells is also a predictive 
biomarker of anti-PD-1 treatment (Huang et al., 2017). Thus, success of anti-PD-1 
treatment relies on the presence of reactive CD8+ T cells that we showed to be 
characterized by high miR-155 expression levels. Nonetheless, a large-scale analysis 
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needs to be performed to confirm the predictive value of CD8+ T cells miR-155 
expression levels in melanoma patients and other cancer patients.  
 
Studies in preclinical models have shown that miR-155 overexpression enhances anti-
tumor responses by increasing CD8+ T cells survival and effector functions (Dudda et al., 
2013; Ji et al., 2015). We also demonstrated here that miR-155 overexpression enhances 
persistence of transduced cells in chronic viral infections. Thus, miR-155 overexpression 
may be beneficial in ACT therapies involving ex vivo T cell transduction with tumor-
specific TCRs, for instance, to enhance persistence of transferred cells, a hurdle still to 
overcome in the field of ACT therapy (Dudley & Rosenberg, 2003). Nonetheless, 
experiments presented in the thesis of my colleague Gwennaëlle Monnot showed that 
CD8+ T cells do not always equally benefit from miR-155 overexpression, whereby low 
affinity CD8+ T cells may particularly profit from its overexpression (Monnot et al. 
manuscript in preparation). Silencing of negative regulators of the TCR signaling such as 
CD5, cbl-b or SHP-2 could be additionally combined with miR-155 overexpression when 
engineering T cells for ACT to increase the sensitivity of low affinity tumor specific T 
cells to the antigen (Hollander, 1984; Hui et al., 2017; Loeser et al., 2007; Presotto et al., 
2017; Tabbekh et al., 2011). In addition, safety restraints such as expression of suicide 
genes may also be considered to prevent off-target related toxicities (Straathof, Spencer, 
Sutton, & Rooney, 2003).  
 
PhD Thesis   Amaia Martínez Usatorre 
 96 
  
PhD Thesis   Amaia Martínez Usatorre 
 97 
ACKNOWLEDGMENTS 
I would like to thank my thesis director Prof. Pedro Romero for always believing in me 
and giving me the opportunity to perform a PhD in his group. His constant support as 
well as given opportunity design and perform experiments independently was essential 
to develop research skills and complete this thesis. I am also incredibly grateful to my co-
director Alena Donda who has carefully followed all the steps of this thesis and has 
always been there when I needed. I thank Dr. Camilla Jandus for her guidance during my 
Master project and thesis. She has always been very helpful and brought many ideas to 
the project. I thank Prof. Margot Thome and Prof. Salvatore Valitutti for their scientific 
input as members of the jury of my thesis.  I am also grateful for the scientific input and 
great collaboration with Prof. Dietmar Zehn and Lorenzo Sempere.  
I thank the animal take cares, in particular Lisa Arlandi and Helena María Vicente Da 
Silva Abreu, for the good care they took of all mice.  The FACS facility, specially Danny 
Labes and Romain Bedel, for their technical support with flow cytometers and many 
hours of cell sorting. Elsa Ferreira and Nazlisha Nuredini, for their laboratory support. 
Our computer technician Vincent Coutaz for solving all the many little issues with 
computers, internet, software and printers.  I thank the lab technicians, Leyder Lozano, 
Candice Stoudmann and Silvia Ferreira for keeping in order the lab, genotyping mice and 
helping with big experiments.  My many current and past lab colleagues/friends Sara 
Labiano, Benjamin Tschumi, Lianjun Zhang, Mathias Wenes, Nina Dumauthioz, Guerric 
Samson, Gwennaëlle Monnot and Natalia Botelho for their constant support and help 
with experiments as well as for the great environment in the lab and many outdoor 
activities.  
I thank my friends Laura Carretero, Andrea García Garijo, Navina Rajah, Harmonie 
Dehaene, Carole Binsfeld, Giulia Vanoni, Efe Erdes, Wilson Castro, Alejandra Gomez 
Cadena and Mirko Schnider for the many great times together during the past five years, 
for always been there when I needed, in the good and bad times. I specially thank my 
family for their constant support and love despite the distance. Finally, I thank Santiago 
Carmona for believing in me more than anyone, for his support, love and happiness 
brought to my life.  
PhD Thesis   Amaia Martínez Usatorre 
 98 
  
PhD Thesis   Amaia Martínez Usatorre 
 99 
REFERENCES 
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., 
White, D. E., & Rosenberg, S. A. (2009). Tumor antigen-specific CD8 T cells 
infiltrating the tumor express high levels of PD-1 and are functionally impaired. 
Blood, 114(8), 1537-1544. doi:10.1182/blood-2008-12-195792 
Akers, S. N., Odunsi, K., & Karpf, A. R. (2010). Regulation of cancer germline antigen 
gene expression: implications for cancer immunotherapy. Future Oncol, 6(5), 
717-732. doi:10.2217/fon.10.36 
Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A., Behjati, S., Biankin, A. 
V., . . . Stratton, M. R. (2013). Signatures of mutational processes in human 
cancer. Nature, 500(7463), 415-421. doi:10.1038/nature12477 
Altfeld, M., van Lunzen, J., Frahm, N., Yu, X. G., Schneider, C., Eldridge, R. L., . . . 
Walker, B. D. (2002). Expansion of pre-existing, lymph node-localized CD8+ T 
cells during supervised treatment interruptions in chronic HIV-1 infection. J Clin 
Invest, 109(6), 837-843. doi:10.1172/JCI14789 
Anderson, G., & Takahama, Y. (2012). Thymic epithelial cells: working class heroes for 
T cell development and repertoire selection. Trends Immunol, 33(6), 256-263. 
doi:10.1016/j.it.2012.03.005 
Anderton, S. M., Radu, C. G., Lowrey, P. A., Ward, E. S., & Wraith, D. C. (2001). 
Negative selection during the peripheral immune response to antigen. J Exp Med, 
193(1), 1-11.  
Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., 
. . . Coffin, R. S. (2015). Talimogene Laherparepvec Improves Durable Response 
Rate in Patients With Advanced Melanoma. J Clin Oncol, 33(25), 2780-2788. 
doi:10.1200/JCO.2014.58.3377 
Angell, H., & Galon, J. (2013). From the immune contexture to the Immunoscore: the 
role of prognostic and predictive immune markers in cancer. Curr Opin Immunol, 
25(2), 261-267. doi:10.1016/j.coi.2013.03.004 
Appay, V., van Lier, R. A., Sallusto, F., & Roederer, M. (2008). Phenotype and function 
of human T lymphocyte subsets: consensus and issues. Cytometry A, 73(11), 975-
983. doi:10.1002/cyto.a.20643 
Arcangeli, S., Rotiroti, M. C., Bardelli, M., Simonelli, L., Magnani, C. F., Biondi, A., . . 
. Varani, L. (2017). Balance of Anti-CD123 Chimeric Antigen Receptor Binding 
Affinity and Density for the Targeting of Acute Myeloid Leukemia. Mol Ther, 
25(8), 1933-1945. doi:10.1016/j.ymthe.2017.04.017 
Badovinac, V. P., Porter, B. B., & Harty, J. T. (2004). CD8+ T cell contraction is 
controlled by early inflammation. Nat Immunol, 5(8), 809-817. 
doi:10.1038/ni1098 
Baitsch, L., Baumgaertner, P., Devevre, E., Raghav, S. K., Legat, A., Barba, L., . . . 
Speiser, D. E. (2011). Exhaustion of tumor-specific CD8(+) T cells in metastases 
from melanoma patients. J Clin Invest, 121(6), 2350-2360. doi:10.1172/JCI46102 
Bala, S., Marcos, M., Kodys, K., Csak, T., Catalano, D., Mandrekar, P., & Szabo, G. 
(2011). Up-regulation of microRNA-155 in macrophages contributes to increased 
tumor necrosis factor {alpha} (TNF{alpha}) production via increased mRNA 
half-life in alcoholic liver disease. J Biol Chem, 286(2), 1436-1444. 
doi:10.1074/jbc.M110.145870 
Balasse, E., Gatouillat, G., Patigny, D., Andry, M. C., & Madoulet, C. (2009). In vivo 
anti-melanoma activities of the Melan-A/MART-1(101-115) T CD4+ cell 
peptide. Vaccine, 27(44), 6107-6109. doi:10.1016/j.vaccine.2009.07.109 
PhD Thesis   Amaia Martínez Usatorre 
 100 
Baltimore, D., Boldin, M. P., O'Connell, R. M., Rao, D. S., & Taganov, K. D. (2008). 
MicroRNAs: new regulators of immune cell development and function. Nat 
Immunol, 9(8), 839-845. doi:10.1038/ni.f.209 
Banerjee, A., Gordon, S. M., Intlekofer, A. M., Paley, M. A., Mooney, E. C., Lindsten, 
T., . . . Reiner, S. L. (2010). Cutting edge: The transcription factor eomesodermin 
enables CD8+ T cells to compete for the memory cell niche. J Immunol, 185(9), 
4988-4992. doi:10.4049/jimmunol.1002042 
Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 
116(2), 281-297.  
Bartel, D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell, 
136(2), 215-233. doi:10.1016/j.cell.2009.01.002 
Beatty, G. L., & Gladney, W. L. (2015). Immune escape mechanisms as a guide for cancer 
immunotherapy. Clin Cancer Res, 21(4), 687-692. doi:10.1158/1078-0432.CCR-
14-1860 
Berger, C. T., Frahm, N., Price, D. A., Mothe, B., Ghebremichael, M., Hartman, K. L., . 
. . Brander, C. (2011). High-functional-avidity cytotoxic T lymphocyte responses 
to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. J 
Virol, 85(18), 9334-9345. doi:10.1128/JVI.00460-11 
Besser, M. J., Shapira-Frommer, R., Treves, A. J., Zippel, D., Itzhaki, O., Hershkovitz, 
L., . . . Schachter, J. (2010). Clinical responses in a phase II study using adoptive 
transfer of short-term cultured tumor infiltration lymphocytes in metastatic 
melanoma patients. Clin Cancer Res, 16(9), 2646-2655. doi:10.1158/1078-
0432.CCR-10-0041 
Besser, M. J., Shapira-Frommer, R., Treves, A. J., Zippel, D., Itzhaki, O., Schallmach, 
E., . . . Schachter, J. (2009). Minimally cultured or selected autologous tumor-
infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in 
metastatic melanoma patients. J Immunother, 32(4), 415-423. 
doi:10.1097/CJI.0b013e31819c8bda 
Bethune, J., Artus-Revel, C. G., & Filipowicz, W. (2012). Kinetic analysis reveals 
successive steps leading to miRNA-mediated silencing in mammalian cells. 
EMBO Rep, 13(8), 716-723. doi:10.1038/embor.2012.82 
Birnbaum, M. E., Mendoza, J. L., Sethi, D. K., Dong, S., Glanville, J., Dobbins, J., . . . 
Garcia, K. C. (2014). Deconstructing the peptide-MHC specificity of T cell 
recognition. Cell, 157(5), 1073-1087. doi:10.1016/j.cell.2014.03.047 
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., . . . 
Wherry, E. J. (2009). Coregulation of CD8+ T cell exhaustion by multiple 
inhibitory receptors during chronic viral infection. Nat Immunol, 10(1), 29-37. 
doi:10.1038/ni.1679 
Blank, C., Gajewski, T. F., & Mackensen, A. (2005). Interaction of PD-L1 on tumor cells 
with PD-1 on tumor-specific T cells as a mechanism of immune evasion: 
implications for tumor immunotherapy. Cancer Immunol Immunother, 54(4), 
307-314. doi:10.1007/s00262-004-0593-x 
Boland, C. R., & Goel, A. (2010). Microsatellite instability in colorectal cancer. 
Gastroenterology, 138(6), 2073-2087 e2073. doi:10.1053/j.gastro.2009.12.064 
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., . . . Brahmer, 
J. R. (2015). Nivolumab versus Docetaxel in Advanced Nonsquamous Non-
Small-Cell Lung Cancer. N Engl J Med, 373(17), 1627-1639. 
doi:10.1056/NEJMoa1507643 
PhD Thesis   Amaia Martínez Usatorre 
 101 
Bos, R., & Sherman, L. A. (2010). CD4+ T-cell help in the tumor milieu is required for 
recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res, 70(21), 
8368-8377. doi:10.1158/0008-5472.CAN-10-1322 
Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., . . . 
Wigginton, J. M. (2012). Safety and activity of anti-PD-L1 antibody in patients 
with advanced cancer. N Engl J Med, 366(26), 2455-2465. 
doi:10.1056/NEJMoa1200694 
Braun, A., Worbs, T., Moschovakis, G. L., Halle, S., Hoffmann, K., Bolter, J., . . . Forster, 
R. (2011). Afferent lymph-derived T cells and DCs use different chemokine 
receptor CCR7-dependent routes for entry into the lymph node and intranodal 
migration. Nat Immunol, 12(9), 879-887. doi:10.1038/ni.2085 
Brinckerhoff, L. H., Thompson, L. W., & Slingluff, C. L., Jr. (2000). Melanoma vaccines. 
Curr Opin Oncol, 12(2), 163-173.  
Brooks, D. G., Trifilo, M. J., Edelmann, K. H., Teyton, L., McGavern, D. B., & Oldstone, 
M. B. (2006). Interleukin-10 determines viral clearance or persistence in vivo. Nat 
Med, 12(11), 1301-1309. doi:10.1038/nm1492 
Bullock, T. N., Mullins, D. W., & Engelhard, V. H. (2003). Antigen density presented by 
dendritic cells in vivo differentially affects the number and avidity of primary, 
memory, and recall CD8+ T cells. J Immunol, 170(4), 1822-1829.  
Burnet, M. (1957). Cancer; a biological approach. I. The processes of control. Br Med J, 
1(5022), 779-786.  
Byrne, K. T., Cote, A. L., Zhang, P., Steinberg, S. M., Guo, Y., Allie, R., . . . Turk, M. J. 
(2011). Autoimmune melanocyte destruction is required for robust CD8+ memory 
T cell responses to mouse melanoma. J Clin Invest, 121(5), 1797-1809. 
doi:10.1172/JCI44849 
Caballero, O. L., & Chen, Y. T. (2009). Cancer/testis (CT) antigens: potential targets for 
immunotherapy. Cancer Sci, 100(11), 2014-2021. doi:10.1111/j.1349-
7006.2009.01303.x 
Cai, X., Yin, Y., Li, N., Zhu, D., Zhang, J., Zhang, C. Y., & Zen, K. (2012). Re-
polarization of tumor-associated macrophages to pro-inflammatory M1 
macrophages by microRNA-155. J Mol Cell Biol, 4(5), 341-343. 
doi:10.1093/jmcb/mjs044 
Cancer Genome Atlas, N. (2012). Comprehensive molecular characterization of human 
colon and rectal cancer. Nature, 487(7407), 330-337. doi:10.1038/nature11252 
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. 
A., . . . Linette, G. P. (2015). Cancer immunotherapy. A dendritic cell vaccine 
increases the breadth and diversity of melanoma neoantigen-specific T cells. 
Science, 348(6236), 803-808. doi:10.1126/science.aaa3828 
Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., . . . Sharma, 
P. (2010). Preoperative CTLA-4 blockade: tolerability and immune monitoring in 
the setting of a presurgical clinical trial. Clin Cancer Res, 16(10), 2861-2871. 
doi:10.1158/1078-0432.CCR-10-0569 
Caskey, M., Lefebvre, F., Filali-Mouhim, A., Cameron, M. J., Goulet, J. P., Haddad, E. 
K., . . . Sekaly, R. P. (2011). Synthetic double-stranded RNA induces innate 
immune responses similar to a live viral vaccine in humans. J Exp Med, 208(12), 
2357-2366. doi:10.1084/jem.20111171 
Castle, J. C., Kreiter, S., Diekmann, J., Lower, M., van de Roemer, N., de Graaf, J., . . . 
Sahin, U. (2012). Exploiting the mutanome for tumor vaccination. Cancer Res, 
72(5), 1081-1091. doi:10.1158/0008-5472.CAN-11-3722 
PhD Thesis   Amaia Martínez Usatorre 
 102 
Chan, A. C., Dalton, M., Johnson, R., Kong, G. H., Wang, T., Thoma, R., & Kurosaki, T. 
(1995). Activation of ZAP-70 kinase activity by phosphorylation of tyrosine 493 
is required for lymphocyte antigen receptor function. EMBO J, 14(11), 2499-
2508.  
Chang, J. T., Palanivel, V. R., Kinjyo, I., Schambach, F., Intlekofer, A. M., Banerjee, A., 
. . . Reiner, S. L. (2007). Asymmetric T lymphocyte division in the initiation of 
adaptive immune responses. Science, 315(5819), 1687-1691. 
doi:10.1126/science.1139393 
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., . . . 
Group, B.-S. (2011). Improved survival with vemurafenib in melanoma with 
BRAF V600E mutation. N Engl J Med, 364(26), 2507-2516. 
doi:10.1056/NEJMoa1103782 
Chavez-Galan, L., Arenas-Del Angel, M. C., Zenteno, E., Chavez, R., & Lascurain, R. 
(2009). Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol 
Immunol, 6(1), 15-25. doi:10.1038/cmi.2009.3 
Chen, X., Du, Y., Lin, X., Qian, Y., Zhou, T., & Huang, Z. (2016). CD4+CD25+ 
regulatory T cells in tumor immunity. Int Immunopharmacol, 34, 244-249. 
doi:10.1016/j.intimp.2016.03.009 
Chiang, C. L., Kandalaft, L. E., Tanyi, J., Hagemann, A. R., Motz, G. T., Svoronos, N., . 
. . Coukos, G. (2013). A dendritic cell vaccine pulsed with autologous 
hypochlorous acid-oxidized ovarian cancer lysate primes effective broad 
antitumor immunity: from bench to bedside. Clin Cancer Res, 19(17), 4801-4815. 
doi:10.1158/1078-0432.CCR-13-1185 
Cobb, B. S., Hertweck, A., Smith, J., O'Connor, E., Graf, D., Cook, T., . . . 
Merkenschlager, M. (2006). A role for Dicer in immune regulation. J Exp Med, 
203(11), 2519-2527. doi:10.1084/jem.20061692 
Coffey, R. J., Jr., Shipley, G. D., & Moses, H. L. (1986). Production of transforming 
growth factors by human colon cancer lines. Cancer Res, 46(3), 1164-1169.  
Cole, D. K., Pumphrey, N. J., Boulter, J. M., Sami, M., Bell, J. I., Gostick, E., . . . 
Jakobsen, B. K. (2007). Human TCR-binding affinity is governed by MHC class 
restriction. J Immunol, 178(9), 5727-5734.  
Cornish, A. L., Chong, M. M., Davey, G. M., Darwiche, R., Nicola, N. A., Hilton, D. J., 
. . . Alexander, W. S. (2003). Suppressor of cytokine signaling-1 regulates 
signaling in response to interleukin-2 and other gamma c-dependent cytokines in 
peripheral T cells. J Biol Chem, 278(25), 22755-22761. 
doi:10.1074/jbc.M303021200 
Costinean, S., Zanesi, N., Pekarsky, Y., Tili, E., Volinia, S., Heerema, N., & Croce, C. 
M. (2006). Pre-B cell proliferation and lymphoblastic leukemia/high-grade 
lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A, 103(18), 
7024-7029. doi:10.1073/pnas.0602266103 
Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., . . . 
Slingluff, C. L., Jr. (1994). Identification of a peptide recognized by five 
melanoma-specific human cytotoxic T cell lines. Science, 264(5159), 716-719.  
Crawford, F., Kozono, H., White, J., Marrack, P., & Kappler, J. (1998). Detection of 
antigen-specific T cells with multivalent soluble class II MHC covalent peptide 
complexes. Immunity, 8(6), 675-682.  
Cui, W., Liu, Y., Weinstein, J. S., Craft, J., & Kaech, S. M. (2011). An interleukin-21-
interleukin-10-STAT3 pathway is critical for functional maturation of memory 
CD8+ T cells. Immunity, 35(5), 792-805. doi:10.1016/j.immuni.2011.09.017 
PhD Thesis   Amaia Martínez Usatorre 
 103 
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010). PD-1 and CTLA-4 
combination blockade expands infiltrating T cells and reduces regulatory T and 
myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A, 107(9), 
4275-4280. doi:10.1073/pnas.0915174107 
Curtsinger, J. M., Valenzuela, J. O., Agarwal, P., Lins, D., & Mescher, M. F. (2005). 
Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion 
and differentiation. J Immunol, 174(8), 4465-4469.  
Daud, A. I., Wolchok, J. D., Robert, C., Hwu, W. J., Weber, J. S., Ribas, A., . . . Hamid, 
O. (2016). Programmed Death-Ligand 1 Expression and Response to the Anti-
Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol, 
34(34), 4102-4109. doi:10.1200/JCO.2016.67.2477 
Denli, A. M., Tops, B. B., Plasterk, R. H., Ketting, R. F., & Hannon, G. J. (2004). 
Processing of primary microRNAs by the Microprocessor complex. Nature, 
432(7014), 231-235. doi:10.1038/nature03049 
Djuranovic, S., Nahvi, A., & Green, R. (2012). miRNA-mediated gene silencing by 
translational repression followed by mRNA deadenylation and decay. Science, 
336(6078), 237-240. doi:10.1126/science.1215691 
Doering, T. A., Crawford, A., Angelosanto, J. M., Paley, M. A., Ziegler, C. G., & Wherry, 
E. J. (2012). Network analysis reveals centrally connected genes and pathways 
involved in CD8+ T cell exhaustion versus memory. Immunity, 37(6), 1130-1144. 
doi:10.1016/j.immuni.2012.08.021 
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., . . . Chen, 
L. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential 
mechanism of immune evasion. Nat Med, 8(8), 793-800. doi:10.1038/nm730 
Donia, M., Junker, N., Ellebaek, E., Andersen, M. H., Straten, P. T., & Svane, I. M. 
(2012). Characterization and comparison of 'standard' and 'young' tumour-
infiltrating lymphocytes for adoptive cell therapy at a Danish translational 
research institution. Scand J Immunol, 75(2), 157-167. doi:10.1111/j.1365-
3083.2011.02640.x 
Draheim, C. C., McCubbin, J. A., & Williams, D. P. (2002). Differences in cardiovascular 
disease risk between nondiabetic adults with mental retardation with and without 
Down syndrome. Am J Ment Retard, 107(3), 201-211. doi:10.1352/0895-
8017(2002)107<0201:DICDRB>2.0.CO;2 
Dudda, J. C., Salaun, B., Ji, Y., Palmer, D. C., Monnot, G. C., Merck, E., . . . Romero, P. 
(2013). MicroRNA-155 is required for effector CD8+ T cell responses to virus 
infection and cancer. Immunity, 38(4), 742-753. 
doi:10.1016/j.immuni.2012.12.006 
Dudley, M. E., & Rosenberg, S. A. (2003). Adoptive-cell-transfer therapy for the 
treatment of patients with cancer. Nat Rev Cancer, 3(9), 666-675. 
doi:10.1038/nrc1167 
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, 
D. J., . . . Rosenberg, S. A. (2002). Cancer regression and autoimmunity in patients 
after clonal repopulation with antitumor lymphocytes. Science, 298(5594), 850-
854. doi:10.1126/science.1076514 
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. 
P., . . . Rosenberg, S. A. (2005). Adoptive cell transfer therapy following non-
myeloablative but lymphodepleting chemotherapy for the treatment of patients 
with refractory metastatic melanoma. J Clin Oncol, 23(10), 2346-2357. 
doi:10.1200/JCO.2005.00.240 
PhD Thesis   Amaia Martínez Usatorre 
 104 
Dudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., . . . 
Rosenberg, S. A. (2008). Adoptive cell therapy for patients with metastatic 
melanoma: evaluation of intensive myeloablative chemoradiation preparative 
regimens. J Clin Oncol, 26(32), 5233-5239. doi:10.1200/JCO.2008.16.5449 
Dutoit, V., Rubio-Godoy, V., Dietrich, P. Y., Quiqueres, A. L., Schnuriger, V., Rimoldi, 
D., . . . Valmori, D. (2001). Heterogeneous T-cell response to MAGE-A10(254-
262): high avidity-specific cytolytic T lymphocytes show superior antitumor 
activity. Cancer Res, 61(15), 5850-5856.  
Eis, P. S., Tam, W., Sun, L., Chadburn, A., Li, Z., Gomez, M. F., . . . Dahlberg, J. E. 
(2005). Accumulation of miR-155 and BIC RNA in human B cell lymphomas. 
Proc Natl Acad Sci U S A, 102(10), 3627-3632. doi:10.1073/pnas.0500613102 
Enouz, S., Carrie, L., Merkler, D., Bevan, M. J., & Zehn, D. (2012). Autoreactive T cells 
bypass negative selection and respond to self-antigen stimulation during infection. 
J Exp Med, 209(10), 1769-1779. doi:10.1084/jem.20120905 
Ensink, E., Sinha, J., Sinha, A., Tang, H., Calderone, H. M., Hostetter, G., . . . Haab, B. 
B. (2015). Segment and fit thresholding: a new method for image analysis applied 
to microarray and immunofluorescence data. Anal Chem, 87(19), 9715-9721. 
doi:10.1021/acs.analchem.5b03159 
Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., . 
. . Ribas, A. (2018). High response rate to PD-1 blockade in desmoplastic 
melanomas. Nature, 553(7688), 347-350. doi:10.1038/nature25187 
Fabian, M. R., & Sonenberg, N. (2012). The mechanics of miRNA-mediated gene 
silencing: a look under the hood of miRISC. Nat Struct Mol Biol, 19(6), 586-593. 
doi:10.1038/nsmb.2296 
Faroudi, M., Utzny, C., Salio, M., Cerundolo, V., Guiraud, M., Muller, S., & Valitutti, S. 
(2003). Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell 
interaction: manifestation of a dual activation threshold. Proc Natl Acad Sci U S 
A, 100(24), 14145-14150. doi:10.1073/pnas.2334336100 
Fidler, I. J. (1973). Selection of successive tumour lines for metastasis. Nat New Biol, 
242(118), 148-149.  
Fortier, M. H., Caron, E., Hardy, M. P., Voisin, G., Lemieux, S., Perreault, C., & Thibault, 
P. (2008). The MHC class I peptide repertoire is molded by the transcriptome. J 
Exp Med, 205(3), 595-610. doi:10.1084/jem.20071985 
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., . . . 
Honjo, T. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel 
B7 family member leads to negative regulation of lymphocyte activation. J Exp 
Med, 192(7), 1027-1034.  
Fridman, W. H., Pages, F., Sautes-Fridman, C., & Galon, J. (2012). The immune 
contexture in human tumours: impact on clinical outcome. Nat Rev Cancer, 12(4), 
298-306. doi:10.1038/nrc3245 
Gabrilovich, D. (2004). Mechanisms and functional significance of tumour-induced 
dendritic-cell defects. Nat Rev Immunol, 4(12), 941-952. doi:10.1038/nri1498 
Gattinoni, L., Speiser, D. E., Lichterfeld, M., & Bonini, C. (2017). T memory stem cells 
in health and disease. Nat Med, 23(1), 18-27. doi:10.1038/nm.4241 
Gauthier, J., & Yakoub-Agha, I. (2017). Chimeric antigen-receptor T-cell therapy for 
hematological malignancies and solid tumors: Clinical data to date, current 
limitations and perspectives. Curr Res Transl Med, 65(3), 93-102. 
doi:10.1016/j.retram.2017.08.003 
PhD Thesis   Amaia Martínez Usatorre 
 105 
Gerlach, C., van Heijst, J. W., Swart, E., Sie, D., Armstrong, N., Kerkhoven, R. M., . . . 
Schumacher, T. N. (2010). One naive T cell, multiple fates in CD8+ T cell 
differentiation. J Exp Med, 207(6), 1235-1246. doi:10.1084/jem.20091175 
Germain, R. N. (2002). T-cell development and the CD4-CD8 lineage decision. Nat Rev 
Immunol, 2(5), 309-322. doi:10.1038/nri798 
Gil, D., Schamel, W. W., Montoya, M., Sanchez-Madrid, F., & Alarcon, B. (2002). 
Recruitment of Nck by CD3 epsilon reveals a ligand-induced conformational 
change essential for T cell receptor signaling and synapse formation. Cell, 109(7), 
901-912.  
Gracias, D. T., Stelekati, E., Hope, J. L., Boesteanu, A. C., Doering, T. A., Norton, J., . . 
. Katsikis, P. D. (2013). The microRNA miR-155 controls CD8(+) T cell 
responses by regulating interferon signaling. Nat Immunol, 14(6), 593-602. 
doi:10.1038/ni.2576 
Graves, P., & Zeng, Y. (2012). Biogenesis of mammalian microRNAs: a global view. 
Genomics Proteomics Bioinformatics, 10(5), 239-245. 
doi:10.1016/j.gpb.2012.06.004 
Greither, T., Grochola, L. F., Udelnow, A., Lautenschlager, C., Wurl, P., & Taubert, H. 
(2010). Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic 
tumors is associated with poorer survival. Int J Cancer, 126(1), 73-80. 
doi:10.1002/ijc.24687 
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., . . . Rosenberg, 
S. A. (2016). Prospective identification of neoantigen-specific lymphocytes in the 
peripheral blood of melanoma patients. Nat Med, 22(4), 433-438. 
doi:10.1038/nm.4051 
Gross, G., Waks, T., & Eshhar, Z. (1989). Expression of immunoglobulin-T-cell receptor 
chimeric molecules as functional receptors with antibody-type specificity. Proc 
Natl Acad Sci U S A, 86(24), 10024-10028.  
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., . . . Schreiber, 
R. D. (2014). Checkpoint blockade cancer immunotherapy targets tumour-
specific mutant antigens. Nature, 515(7528), 577-581. doi:10.1038/nature13988 
Haasch, D., Chen, Y. W., Reilly, R. M., Chiou, X. G., Koterski, S., Smith, M. L., . . . 
Trevillyan, J. M. (2002). T cell activation induces a noncoding RNA transcript 
sensitive to inhibition by immunosuppressant drugs and encoded by the proto-
oncogene, BIC. Cell Immunol, 217(1-2), 78-86.  
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 
144(5), 646-674. doi:10.1016/j.cell.2011.02.013 
Hassel, J. C., Heinzerling, L., Aberle, J., Bahr, O., Eigentler, T. K., Grimm, M. O., . . . 
Gutzmer, R. (2017). Combined immune checkpoint blockade (anti-PD-1/anti-
CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat 
Rev, 57, 36-49. doi:10.1016/j.ctrv.2017.05.003 
Hebeisen, M., Schmidt, J., Guillaume, P., Baumgaertner, P., Speiser, D. E., Luescher, I., 
& Rufer, N. (2015). Identification of Rare High-Avidity, Tumor-Reactive CD8+ 
T Cells by Monomeric TCR-Ligand Off-Rates Measurements on Living Cells. 
Cancer Res, 75(10), 1983-1991. doi:10.1158/0008-5472.CAN-14-3516 
Hermiston, M. L., Xu, Z., & Weiss, A. (2003). CD45: a critical regulator of signaling 
thresholds in immune cells. Annu Rev Immunol, 21, 107-137. 
doi:10.1146/annurev.immunol.21.120601.140946 
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., . . . Chen, L. 
(2005). Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates 
cancer therapeutic immunity. Cancer Res, 65(3), 1089-1096.  
PhD Thesis   Amaia Martínez Usatorre 
 106 
Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., . . . Dranoff, 
G. (2008). Immunologic and clinical effects of antibody blockade of cytotoxic T 
lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc 
Natl Acad Sci U S A, 105(8), 3005-3010. doi:10.1073/pnas.0712237105 
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., 
. . . Urba, W. J. (2010). Improved survival with ipilimumab in patients with 
metastatic melanoma. N Engl J Med, 363(8), 711-723. 
doi:10.1056/NEJMoa1003466 
Hollander, N. (1984). Immunotherapy of lymphoid and nonlymphoid tumors with 
monoclonal anti-Lyt-1 antibodies. J Immunol, 133(5), 2801-2805.  
Hu, R., Kagele, D. A., Huffaker, T. B., Runtsch, M. C., Alexander, M., Liu, J., . . . 
O'Connell, R. M. (2014). miR-155 promotes T follicular helper cell accumulation 
during chronic, low-grade inflammation. Immunity, 41(4), 605-619. 
doi:10.1016/j.immuni.2014.09.015 
Huang, C. Y., Chiang, S. F., Ke, T. W., Chen, T. W., Lan, Y. C., You, Y. S., . . . Chao, 
K. S. C. (2017). Cytosolic high-mobility group box protein 1 (HMGB1) and/or 
PD-1+ TILs in the tumor microenvironment may be contributing prognostic 
biomarkers for patients with locally advanced rectal cancer who have undergone 
neoadjuvant chemoradiotherapy. Cancer Immunol Immunother. 
doi:10.1007/s00262-017-2109-5 
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., . . . Lo, 
R. S. (2016). Genomic and Transcriptomic Features of Response to Anti-PD-1 
Therapy in Metastatic Melanoma. Cell, 165(1), 35-44. 
doi:10.1016/j.cell.2016.02.065 
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., . . . Vale, R. D. 
(2017). T cell costimulatory receptor CD28 is a primary target for PD-1-mediated 
inhibition. Science, 355(6332), 1428-1433. doi:10.1126/science.aaf1292 
Hunter, C., Smith, R., Cahill, D. P., Stephens, P., Stevens, C., Teague, J., . . . Wooster, R. 
(2006). A hypermutation phenotype and somatic MSH6 mutations in recurrent 
human malignant gliomas after alkylator chemotherapy. Cancer Res, 66(8), 3987-
3991. doi:10.1158/0008-5472.CAN-06-0127 
Ichii, H., Sakamoto, A., Arima, M., Hatano, M., Kuroda, Y., & Tokuhisa, T. (2007). Bcl6 
is essential for the generation of long-term memory CD4+ T cells. Int Immunol, 
19(4), 427-433. doi:10.1093/intimm/dxm007 
Ichii, H., Sakamoto, A., Hatano, M., Okada, S., Toyama, H., Taki, S., . . . Tokuhisa, T. 
(2002). Role for Bcl-6 in the generation and maintenance of memory CD8+ T 
cells. Nat Immunol, 3(6), 558-563. doi:10.1038/ni802 
Inoges, S., Rodriguez-Calvillo, M., Zabalegui, N., Lopez-Diaz de Cerio, A., Villanueva, 
H., Soria, E., . . . Programa para el Estudio y Tratamiento de Hemopatias Malignas 
study, g. (2006). Clinical benefit associated with idiotypic vaccination in patients 
with follicular lymphoma. J Natl Cancer Inst, 98(18), 1292-1301. 
doi:10.1093/jnci/djj358 
Intlekofer, A. M., Takemoto, N., Wherry, E. J., Longworth, S. A., Northrup, J. T., 
Palanivel, V. R., . . . Reiner, S. L. (2005). Effector and memory CD8+ T cell fate 
coupled by T-bet and eomesodermin. Nat Immunol, 6(12), 1236-1244. 
doi:10.1038/ni1268 
Iorio, M. V., Ferracin, M., Liu, C. G., Veronese, A., Spizzo, R., Sabbioni, S., . . . Croce, 
C. M. (2005). MicroRNA gene expression deregulation in human breast cancer. 
Cancer Res, 65(16), 7065-7070. doi:10.1158/0008-5472.CAN-05-1783 
PhD Thesis   Amaia Martínez Usatorre 
 107 
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992). Induced expression of PD-1, a 
novel member of the immunoglobulin gene superfamily, upon programmed cell 
death. EMBO J, 11(11), 3887-3895.  
Iwai, Y., Terawaki, S., & Honjo, T. (2005). PD-1 blockade inhibits hematogenous spread 
of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. 
Int Immunol, 17(2), 133-144. doi:10.1093/intimm/dxh194 
Iwashima, M., Irving, B. A., van Oers, N. S., Chan, A. C., & Weiss, A. (1994). Sequential 
interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science, 
263(5150), 1136-1139.  
Jablonski, K. A., Gaudet, A. D., Amici, S. A., Popovich, P. G., & Guerau-de-Arellano, 
M. (2016). Control of the Inflammatory Macrophage Transcriptional Signature by 
miR-155. PLoS One, 11(7), e0159724. doi:10.1371/journal.pone.0159724 
Jager, E., Karbach, J., Gnjatic, S., Neumann, A., Bender, A., Valmori, D., . . . Knuth, A. 
(2006). Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral 
and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl 
Acad Sci U S A, 103(39), 14453-14458. doi:10.1073/pnas.0606512103 
Jandus, C., Martínez-Usatorre, A., Vigano, S., Zhang, L., & Romero, P. (2017). The Vast 
Universe of T Cell Diversity: Subsets of Memory Cells and Their Differentiation. 
Methods Mol Biol, 1514, 1-17. doi:10.1007/978-1-4939-6548-9_1 
Jandus, C., Speiser, D., & Romero, P. (2009). Recent advances and hurdles in melanoma 
immunotherapy. Pigment Cell Melanoma Res, 22(6), 711-723. 
doi:10.1111/j.1755-148X.2009.00634.x 
Janeway, C. (2001). Immunobiology : the immune system in health and disease (5th ed.). 
London ; New York, NY, US: Garland Pub. 
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global 
cancer statistics. CA Cancer J Clin, 61(2), 69-90. doi:10.3322/caac.20107 
Ji, Y., Hocker, J. D., & Gattinoni, L. (2016). Enhancing adoptive T cell immunotherapy 
with microRNA therapeutics. Semin Immunol, 28(1), 45-53. 
doi:10.1016/j.smim.2015.11.006 
Ji, Y., Wrzesinski, C., Yu, Z., Hu, J., Gautam, S., Hawk, N. V., . . . Gattinoni, L. (2015). 
miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by 
enhancing responsiveness to homeostatic gammac cytokines. Proc Natl Acad Sci 
U S A, 112(2), 476-481. doi:10.1073/pnas.1422916112 
Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., . 
. . Rosenberg, S. A. (2009). Gene therapy with human and mouse T-cell receptors 
mediates cancer regression and targets normal tissues expressing cognate antigen. 
Blood, 114(3), 535-546. doi:10.1182/blood-2009-03-211714 
Josefowicz, S. Z., Lu, L. F., & Rudensky, A. Y. (2012). Regulatory T cells: mechanisms 
of differentiation and function. Annu Rev Immunol, 30, 531-564. 
doi:10.1146/annurev.immunol.25.022106.141623 
Joshi, N. S., Cui, W., Chandele, A., Lee, H. K., Urso, D. R., Hagman, J., . . . Kaech, S. 
M. (2007). Inflammation directs memory precursor and short-lived effector 
CD8(+) T cell fates via the graded expression of T-bet transcription factor. 
Immunity, 27(2), 281-295. doi:10.1016/j.immuni.2007.07.010 
Joshi, N. S., Cui, W., Dominguez, C. X., Chen, J. H., Hand, T. W., & Kaech, S. M. (2011). 
Increased numbers of preexisting memory CD8 T cells and decreased T-bet 
expression can restrain terminal differentiation of secondary effector and memory 
CD8 T cells. J Immunol, 187(8), 4068-4076. doi:10.4049/jimmunol.1002145 
Kaech, S. M., & Cui, W. (2012). Transcriptional control of effector and memory CD8+ 
T cell differentiation. Nat Rev Immunol, 12(11), 749-761. doi:10.1038/nri3307 
PhD Thesis   Amaia Martínez Usatorre 
 108 
Kaech, S. M., Tan, J. T., Wherry, E. J., Konieczny, B. T., Surh, C. D., & Ahmed, R. 
(2003). Selective expression of the interleukin 7 receptor identifies effector CD8 
T cells that give rise to long-lived memory cells. Nat Immunol, 4(12), 1191-1198. 
doi:10.1038/ni1009 
Kallies, A., Xin, A., Belz, G. T., & Nutt, S. L. (2009). Blimp-1 transcription factor is 
required for the differentiation of effector CD8(+) T cells and memory responses. 
Immunity, 31(2), 283-295. doi:10.1016/j.immuni.2009.06.021 
Kalos, M., & June, C. H. (2013). Adoptive T cell transfer for cancer immunotherapy in 
the era of synthetic biology. Immunity, 39(1), 49-60. 
doi:10.1016/j.immuni.2013.07.002 
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., . . 
. Investigators, I. S. (2010). Sipuleucel-T immunotherapy for castration-resistant 
prostate cancer. N Engl J Med, 363(5), 411-422. doi:10.1056/NEJMoa1001294 
Kim, J., Modlin, R. L., Moy, R. L., Dubinett, S. M., McHugh, T., Nickoloff, B. J., & 
Uyemura, K. (1995). IL-10 production in cutaneous basal and squamous cell 
carcinomas. A mechanism for evading the local T cell immune response. J 
Immunol, 155(4), 2240-2247.  
Kim, V. N., Han, J., & Siomi, M. C. (2009). Biogenesis of small RNAs in animals. Nat 
Rev Mol Cell Biol, 10(2), 126-139. doi:10.1038/nrm2632 
Kirberg, J., Bruno, L., & von Boehmer, H. (1993). CD4+8- help prevents rapid deletion 
of CD8+ cells after a transient response to antigen. Eur J Immunol, 23(8), 1963-
1967. doi:10.1002/eji.1830230835 
Kluiver, J., van den Berg, A., de Jong, D., Blokzijl, T., Harms, G., Bouwman, E., . . . 
Kroesen, B. J. (2007). Regulation of pri-microRNA BIC transcription and 
processing in Burkitt lymphoma. Oncogene, 26(26), 3769-3776. 
doi:10.1038/sj.onc.1210147 
Knudson, K. M., Goplen, N. P., Cunningham, C. A., Daniels, M. A., & Teixeiro, E. 
(2013). Low-affinity T cells are programmed to maintain normal primary 
responses but are impaired in their recall to low-affinity ligands. Cell Rep, 4(3), 
554-565. doi:10.1016/j.celrep.2013.07.008 
Kohlhaas, S., Garden, O. A., Scudamore, C., Turner, M., Okkenhaug, K., & Vigorito, E. 
(2009). Cutting edge: the Foxp3 target miR-155 contributes to the development 
of regulatory T cells. J Immunol, 182(5), 2578-2582. 
doi:10.4049/jimmunol.0803162 
Kopp, K. L., Ralfkiaer, U., Gjerdrum, L. M., Helvad, R., Pedersen, I. H., Litman, T., . . . 
Woetmann, A. (2013). STAT5-mediated expression of oncogenic miR-155 in 
cutaneous T-cell lymphoma. Cell Cycle, 12(12), 1939-1947. 
doi:10.4161/cc.24987 
Kozomara, A., & Griffiths-Jones, S. (2014). miRBase: annotating high confidence 
microRNAs using deep sequencing data. Nucleic Acids Res, 42(Database issue), 
D68-73. doi:10.1093/nar/gkt1181 
Krummel, M. F., & Allison, J. P. (1995). CD28 and CTLA-4 have opposing effects on 
the response of T cells to stimulation. J Exp Med, 182(2), 459-465.  
Krummey, S. M., Martinez, R. J., Andargachew, R., Liu, D., Wagener, M., Kohlmeier, J. 
E., . . . Ford, M. L. (2016). Low-Affinity Memory CD8+ T Cells Mediate Robust 
Heterologous Immunity. J Immunol, 196(6), 2838-2846. 
doi:10.4049/jimmunol.1500639 
Kvistborg, P., Shu, C. J., Heemskerk, B., Fankhauser, M., Thrue, C. A., Toebes, M., . . . 
Schumacher, T. N. (2012). TIL therapy broadens the tumor-reactive CD8(+) T 
cell compartment in melanoma patients. Oncoimmunology, 1(4), 409-418.  
PhD Thesis   Amaia Martínez Usatorre 
 109 
Lanzavecchia, A., & Sallusto, F. (2002). Progressive differentiation and selection of the 
fittest in the immune response. Nat Rev Immunol, 2(12), 982-987. 
doi:10.1038/nri959 
Larkin, J., Ascierto, P. A., Dreno, B., Atkinson, V., Liszkay, G., Maio, M., . . . Ribas, A. 
(2014). Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N 
Engl J Med, 371(20), 1867-1876. doi:10.1056/NEJMoa1408868 
Larkin, J., Minor, D., D'Angelo, S., Neyns, B., Smylie, M., Miller, W. H., Jr., . . . Weber, 
J. (2017). Overall Survival in Patients With Advanced Melanoma Who Received 
Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A 
Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol, 
JCO2016718023. doi:10.1200/JCO.2016.71.8023 
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., . . . Diaz, 
L. A., Jr. (2015). PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N 
Engl J Med, 372(26), 2509-2520. doi:10.1056/NEJMoa1500596 
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996). Enhancement of antitumor 
immunity by CTLA-4 blockade. Science, 271(5256), 1734-1736.  
Lederberg, J. (1959). Genes and antibodies. Science, 129(3364), 1649-1653.  
Lee, E. J., Gusev, Y., Jiang, J., Nuovo, G. J., Lerner, M. R., Frankel, W. L., . . . 
Schmittgen, T. D. (2007). Expression profiling identifies microRNA signature in 
pancreatic cancer. Int J Cancer, 120(5), 1046-1054. doi:10.1002/ijc.22394 
Legat, A., Maby-El Hajjami, H., Baumgaertner, P., Cagnon, L., Abed Maillard, S., 
Geldhof, C., . . . Speiser, D. E. (2016). Vaccination with LAG-3Ig (IMP321) and 
Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic 
Melanoma Patients-Report of a Phase I/IIa Clinical Trial. Clin Cancer Res, 22(6), 
1330-1340. doi:10.1158/1078-0432.CCR-15-1212 
Leiter, U., Eigentler, T., & Garbe, C. (2014). Epidemiology of skin cancer. Adv Exp Med 
Biol, 810, 120-140.  
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996). CD28/B7 system of T cell 
costimulation. Annu Rev Immunol, 14, 233-258. 
doi:10.1146/annurev.immunol.14.1.233 
Lewis, B. P., Shih, I. H., Jones-Rhoades, M. W., Bartel, D. P., & Burge, C. B. (2003). 
Prediction of mammalian microRNA targets. Cell, 115(7), 787-798.  
Lienard, D., Rimoldi, D., Marchand, M., Dietrich, P. Y., van Baren, N., Geldhof, C., . . . 
Speiser, D. E. (2004). Ex vivo detectable activation of Melan-A-specific T cells 
correlating with inflammatory skin reactions in melanoma patients vaccinated 
with peptides in IFA. Cancer Immun, 4, 4.  
Lind, E. F., Millar, D. G., Dissanayake, D., Savage, J. C., Grimshaw, N. K., Kerr, W. G., 
& Ohashi, P. S. (2015). miR-155 Upregulation in Dendritic Cells Is Sufficient To 
Break Tolerance In Vivo by Negatively Regulating SHIP1. J Immunol, 195(10), 
4632-4640. doi:10.4049/jimmunol.1302941 
Linette, G. P., Zhang, D., Hodi, F. S., Jonasch, E. P., Longerich, S., Stowell, C. P., . . . 
Haluska, F. G. (2005). Immunization using autologous dendritic cells pulsed with 
the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ 
immunity. Clin Cancer Res, 11(21), 7692-7699. doi:10.1158/1078-0432.CCR-
05-1198 
Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J. J., . . . 
Hannon, G. J. (2004). Argonaute2 is the catalytic engine of mammalian RNAi. 
Science, 305(5689), 1437-1441. doi:10.1126/science.1102513 
PhD Thesis   Amaia Martínez Usatorre 
 110 
Liu, S., Yang, Y., & Wu, J. (2011). TNFalpha-induced up-regulation of miR-155 inhibits 
adipogenesis by down-regulating early adipogenic transcription factors. Biochem 
Biophys Res Commun, 414(3), 618-624. doi:10.1016/j.bbrc.2011.09.131 
Loeser, S., Loser, K., Bijker, M. S., Rangachari, M., van der Burg, S. H., Wada, T., . . . 
Penninger, J. M. (2007). Spontaneous tumor rejection by cbl-b-deficient CD8+ T 
cells. J Exp Med, 204(4), 879-891. doi:10.1084/jem.20061699 
Lu, D., Nakagawa, R., Lazzaro, S., Staudacher, P., Abreu-Goodger, C., Henley, T., . . . 
Vigorito, E. (2014). The miR-155-PU.1 axis acts on Pax5 to enable efficient 
terminal B cell differentiation. J Exp Med, 211(11), 2183-2198. 
doi:10.1084/jem.20140338 
Lu, L. F., Gasteiger, G., Yu, I. S., Chaudhry, A., Hsin, J. P., Lu, Y., . . . Rudensky, A. Y. 
(2015). A Single miRNA-mRNA Interaction Affects the Immune Response in a 
Context- and Cell-Type-Specific Manner. Immunity, 43(1), 52-64. 
doi:10.1016/j.immuni.2015.04.022 
Lu, L. F., Thai, T. H., Calado, D. P., Chaudhry, A., Kubo, M., Tanaka, K., . . . Rudensky, 
A. Y. (2009). Foxp3-dependent microRNA155 confers competitive fitness to 
regulatory T cells by targeting SOCS1 protein. Immunity, 30(1), 80-91. 
doi:10.1016/j.immuni.2008.11.010 
Lu, T., Ramakrishnan, R., Altiok, S., Youn, J. I., Cheng, P., Celis, E., . . . Gabrilovich, D. 
(2011). Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic 
T cells in mice. J Clin Invest, 121(10), 4015-4029. doi:10.1172/JCI45862 
Lu, Y. C., Yao, X., Crystal, J. S., Li, Y. F., El-Gamil, M., Gross, C., . . . Robbins, P. F. 
(2014). Efficient identification of mutated cancer antigens recognized by T cells 
associated with durable tumor regressions. Clin Cancer Res, 20(13), 3401-3410. 
doi:10.1158/1078-0432.CCR-14-0433 
Malissen, B., & Bongrand, P. (2015). Early T cell activation: integrating biochemical, 
structural, and biophysical cues. Annu Rev Immunol, 33, 539-561. 
doi:10.1146/annurev-immunol-032414-112158 
Mann, M., Barad, O., Agami, R., Geiger, B., & Hornstein, E. (2010). miRNA-based 
mechanism for the commitment of multipotent progenitors to a single cellular 
fate. Proc Natl Acad Sci U S A, 107(36), 15804-15809. 
doi:10.1073/pnas.0915022107 
Mantovani, A., Sozzani, S., Locati, M., Allavena, P., & Sica, A. (2002). Macrophage 
polarization: tumor-associated macrophages as a paradigm for polarized M2 
mononuclear phagocytes. Trends Immunol, 23(11), 549-555.  
Martinez-Nunez, R. T., Louafi, F., & Sanchez-Elsner, T. (2011). The interleukin 13 (IL-
13) pathway in human macrophages is modulated by microRNA-155 via direct 
targeting of interleukin 13 receptor alpha1 (IL13Ralpha1). J Biol Chem, 286(3), 
1786-1794. doi:10.1074/jbc.M110.169367 
Masopust, D., Kaech, S. M., Wherry, E. J., & Ahmed, R. (2004). The role of 
programming in memory T-cell development. Curr Opin Immunol, 16(2), 217-
225. doi:10.1016/j.coi.2004.02.005 
Matloubian, M., Concepcion, R. J., & Ahmed, R. (1994). CD4+ T cells are required to 
sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol, 
68(12), 8056-8063.  
Matsushita, H., Vesely, M. D., Koboldt, D. C., Rickert, C. G., Uppaluri, R., Magrini, V. 
J., . . . Schreiber, R. D. (2012). Cancer exome analysis reveals a T-cell-dependent 
mechanism of cancer immunoediting. Nature, 482(7385), 400-404. 
doi:10.1038/nature10755 
PhD Thesis   Amaia Martínez Usatorre 
 111 
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., . . . Grupp, 
S. A. (2014). Chimeric antigen receptor T cells for sustained remissions in 
leukemia. N Engl J Med, 371(16), 1507-1517. doi:10.1056/NEJMoa1407222 
Mazza, C., Auphan-Anezin, N., Gregoire, C., Guimezanes, A., Kellenberger, C., Roussel, 
A., . . . Malissen, B. (2007). How much can a T-cell antigen receptor adapt to 
structurally distinct antigenic peptides? EMBO J, 26(7), 1972-1983. 
doi:10.1038/sj.emboj.7601605 
McCoy, C. E., Sheedy, F. J., Qualls, J. E., Doyle, S. L., Quinn, S. R., Murray, P. J., & 
O'Neill, L. A. (2010). IL-10 inhibits miR-155 induction by toll-like receptors. J 
Biol Chem, 285(27), 20492-20498. doi:10.1074/jbc.M110.102111 
McMahan, R. H., & Slansky, J. E. (2007). Mobilizing the low-avidity T cell repertoire to 
kill tumors. Semin Cancer Biol, 17(4), 317-329. 
doi:10.1016/j.semcancer.2007.06.006 
Michie, A. M., Carlyle, J. R., Schmitt, T. M., Ljutic, B., Cho, S. K., Fong, Q., & Zuniga-
Pflucker, J. C. (2000). Clonal characterization of a bipotent T cell and NK cell 
progenitor in the mouse fetal thymus. J Immunol, 164(4), 1730-1733.  
Mingueneau, M., Sansoni, A., Gregoire, C., Roncagalli, R., Aguado, E., Weiss, A., . . . 
Malissen, B. (2008). The proline-rich sequence of CD3epsilon controls T cell 
antigen receptor expression on and signaling potency in preselection CD4+CD8+ 
thymocytes. Nat Immunol, 9(5), 522-532. doi:10.1038/ni.1608 
Mombaerts, P., Iacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S., & Papaioannou, 
V. E. (1992). RAG-1-deficient mice have no mature B and T lymphocytes. Cell, 
68(5), 869-877.  
Moreau, H. D., Lemaitre, F., Terriac, E., Azar, G., Piel, M., Lennon-Dumenil, A. M., & 
Bousso, P. (2012). Dynamic in situ cytometry uncovers T cell receptor signaling 
during immunological synapses and kinapses in vivo. Immunity, 37(2), 351-363. 
doi:10.1016/j.immuni.2012.05.014 
Morgan, D. J., Kreuwel, H. T., Fleck, S., Levitsky, H. I., Pardoll, D. M., & Sherman, L. 
A. (1998). Activation of low avidity CTL specific for a self epitope results in 
tumor rejection but not autoimmunity. J Immunol, 160(2), 643-651.  
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. 
M., . . . Rosenberg, S. A. (2006). Cancer regression in patients after transfer of 
genetically engineered lymphocytes. Science, 314(5796), 126-129. 
doi:10.1126/science.1129003 
Moskophidis, D., Lechner, F., Pircher, H., & Zinkernagel, R. M. (1993). Virus persistence 
in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic 
effector T cells. Nature, 362(6422), 758-761. doi:10.1038/362758a0 
Muljo, S. A., Ansel, K. M., Kanellopoulou, C., Livingston, D. M., Rao, A., & Rajewsky, 
K. (2005). Aberrant T cell differentiation in the absence of Dicer. J Exp Med, 
202(2), 261-269. doi:10.1084/jem.20050678 
Murahashi, M., Hijikata, Y., Yamada, K., Tanaka, Y., Kishimoto, J., Inoue, H., . . . Tani, 
K. (2016). Phase I clinical trial of a five-peptide cancer vaccine combined with 
cyclophosphamide in advanced solid tumors. Clin Immunol. 
doi:10.1016/j.clim.2016.03.015 
Nazari-Jahantigh, M., Wei, Y., Noels, H., Akhtar, S., Zhou, Z., Koenen, R. R., . . . 
Schober, A. (2012). MicroRNA-155 promotes atherosclerosis by repressing Bcl6 
in macrophages. J Clin Invest, 122(11), 4190-4202. doi:10.1172/JCI61716 
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. 
A., . . . Go, W. Y. (2017). Axicabtagene Ciloleucel CAR T-Cell Therapy in 
PhD Thesis   Amaia Martínez Usatorre 
 112 
Refractory Large B-Cell Lymphoma. N Engl J Med, 377(26), 2531-2544. 
doi:10.1056/NEJMoa1707447 
Neilsen, P. M., Noll, J. E., Mattiske, S., Bracken, C. P., Gregory, P. A., Schulz, R. B., . . 
. Callen, D. F. (2013). Mutant p53 drives invasion in breast tumors through up-
regulation of miR-155. Oncogene, 32(24), 2992-3000. doi:10.1038/onc.2012.305 
Nikiforova, M. N., Tseng, G. C., Steward, D., Diorio, D., & Nikiforov, Y. E. (2008). 
MicroRNA expression profiling of thyroid tumors: biological significance and 
diagnostic utility. J Clin Endocrinol Metab, 93(5), 1600-1608. 
doi:10.1210/jc.2007-2696 
O'Connell, R. M., Kahn, D., Gibson, W. S., Round, J. L., Scholz, R. L., Chaudhuri, A. 
A., . . . Baltimore, D. (2010). MicroRNA-155 promotes autoimmune 
inflammation by enhancing inflammatory T cell development. Immunity, 33(4), 
607-619. doi:10.1016/j.immuni.2010.09.009 
O'Connell, R. M., Taganov, K. D., Boldin, M. P., Cheng, G., & Baltimore, D. (2007). 
MicroRNA-155 is induced during the macrophage inflammatory response. Proc 
Natl Acad Sci U S A, 104(5), 1604-1609. doi:10.1073/pnas.0610731104 
Okamura, K., Hagen, J. W., Duan, H., Tyler, D. M., & Lai, E. C. (2007). The mirtron 
pathway generates microRNA-class regulatory RNAs in Drosophila. Cell, 130(1), 
89-100. doi:10.1016/j.cell.2007.06.028 
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., . . . Wu, C. J. 
(2017). An immunogenic personal neoantigen vaccine for patients with 
melanoma. Nature, 547(7662), 217-221. doi:10.1038/nature22991 
Ozga, A. J., Moalli, F., Abe, J., Swoger, J., Sharpe, J., Zehn, D., . . . Stein, J. V. (2016). 
pMHC affinity controls duration of CD8+ T cell-DC interactions and imprints 
timing of effector differentiation versus expansion. J Exp Med, 213(12), 2811-
2829. doi:10.1084/jem.20160206 
Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. 
Nat Rev Cancer, 12(4), 252-264. doi:10.1038/nrc3239 
Parkhurst, M. R., Riley, J. P., Igarashi, T., Li, Y., Robbins, P. F., & Rosenberg, S. A. 
(2004). Immunization of patients with the hTERT:540-548 peptide induces 
peptide-reactive T lymphocytes that do not recognize tumors endogenously 
expressing telomerase. Clin Cancer Res, 10(14), 4688-4698. doi:10.1158/1078-
0432.CCR-04-0325 
Parkhurst, M. R., Salgaller, M. L., Southwood, S., Robbins, P. F., Sette, A., Rosenberg, 
S. A., & Kawakami, Y. (1996). Improved induction of melanoma-reactive CTL 
with peptides from the melanoma antigen gp100 modified at HLA-A*0201-
binding residues. J Immunol, 157(6), 2539-2548.  
Perez-Guijarro, E., Day, C. P., Merlino, G., & Zaidi, M. R. (2017). Genetically 
engineered mouse models of melanoma. Cancer, 123(S11), 2089-2103. 
doi:10.1002/cncr.30684 
Perret, R., Sierro, S. R., Botelho, N. K., Corgnac, S., Donda, A., & Romero, P. (2013). 
Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells 
enhance tumor immunity. Cancer Res, 73(22), 6597-6608. doi:10.1158/0008-
5472.CAN-13-0875 
Peske, J. D., Woods, A. B., & Engelhard, V. H. (2015). Control of CD8 T-Cell Infiltration 
into Tumors by Vasculature and Microenvironment. Adv Cancer Res, 128, 263-
307. doi:10.1016/bs.acr.2015.05.001 
Pfeifer, G. P., Denissenko, M. F., Olivier, M., Tretyakova, N., Hecht, S. S., & Hainaut, 
P. (2002). Tobacco smoke carcinogens, DNA damage and p53 mutations in 
PhD Thesis   Amaia Martínez Usatorre 
 113 
smoking-associated cancers. Oncogene, 21(48), 7435-7451. 
doi:10.1038/sj.onc.1205803 
Philip, M., Fairchild, L., Sun, L., Horste, E. L., Camara, S., Shakiba, M., . . . Schietinger, 
A. (2017). Chromatin states define tumour-specific T cell dysfunction and 
reprogramming. Nature, 545(7655), 452-456. doi:10.1038/nature22367 
Pipkin, M. E., Sacks, J. A., Cruz-Guilloty, F., Lichtenheld, M. G., Bevan, M. J., & Rao, 
A. (2010). Interleukin-2 and inflammation induce distinct transcriptional 
programs that promote the differentiation of effector cytolytic T cells. Immunity, 
32(1), 79-90. doi:10.1016/j.immuni.2009.11.012 
Pittet, M. J., Valmori, D., Dunbar, P. R., Speiser, D. E., Lienard, D., Lejeune, F., . . . 
Romero, P. (1999). High frequencies of naive Melan-A/MART-1-specific 
CD8(+) T cells in a large proportion of human histocompatibility leukocyte 
antigen (HLA)-A2 individuals. J Exp Med, 190(5), 705-715.  
Powell, D. J., Jr., Dudley, M. E., Robbins, P. F., & Rosenberg, S. A. (2005). Transition 
of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T 
cells in humans after adoptive cell transfer therapy. Blood, 105(1), 241-250. 
doi:10.1182/blood-2004-06-2482 
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., . . . Vogelzang, N. 
J. (2014). MPDL3280A (anti-PD-L1) treatment leads to clinical activity in 
metastatic bladder cancer. Nature, 515(7528), 558-562. doi:10.1038/nature13904 
Presotto, D., Erdes, E., Duong, M. N., Allard, M., Regamey, P. O., Quadroni, M., . . . 
Hebeisen, M. (2017). Fine-Tuning of Optimal TCR Signaling in Tumor-
Redirected CD8 T Cells by Distinct TCR Affinity-Mediated Mechanisms. Front 
Immunol, 8, 1564. doi:10.3389/fimmu.2017.01564 
Pui, J. C., Allman, D., Xu, L., DeRocco, S., Karnell, F. G., Bakkour, S., . . . Pear, W. S. 
(1999). Notch1 expression in early lymphopoiesis influences B versus T lineage 
determination. Immunity, 11(3), 299-308.  
Quigley, M., Pereyra, F., Nilsson, B., Porichis, F., Fonseca, C., Eichbaum, Q., . . . 
Haining, W. N. (2010). Transcriptional analysis of HIV-specific CD8+ T cells 
shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med, 16(10), 
1147-1151. doi:10.1038/nm.2232 
Radtke, F., Wilson, A., Stark, G., Bauer, M., van Meerwijk, J., MacDonald, H. R., & 
Aguet, M. (1999). Deficient T cell fate specification in mice with an induced 
inactivation of Notch1. Immunity, 10(5), 547-558.  
Rao, R. R., Li, Q., Odunsi, K., & Shrikant, P. A. (2010). The mTOR kinase determines 
effector versus memory CD8+ T cell fate by regulating the expression of 
transcription factors T-bet and Eomesodermin. Immunity, 32(1), 67-78. 
doi:10.1016/j.immuni.2009.10.010 
Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O., Vogl, D. T., 
Lacey, S. F., . . . June, C. H. (2015). NY-ESO-1-specific TCR-engineered T cells 
mediate sustained antigen-specific antitumor effects in myeloma. Nat Med, 21(8), 
914-921. doi:10.1038/nm.3910 
Reed, C. M., Cresce, N. D., Mauldin, I. S., Slingluff, C. L., Jr., & Olson, W. C. (2015). 
Vaccination with Melanoma Helper Peptides Induces Antibody Responses 
Associated with Improved Overall Survival. Clin Cancer Res, 21(17), 3879-3887. 
doi:10.1158/1078-0432.CCR-15-0233 
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., . . . 
Chan, T. A. (2015). Cancer immunology. Mutational landscape determines 
sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 348(6230), 
124-128. doi:10.1126/science.aaa1348 
PhD Thesis   Amaia Martínez Usatorre 
 114 
Robbins, P. F., Lu, Y. C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., . . . Rosenberg, 
S. A. (2013). Mining exomic sequencing data to identify mutated antigens 
recognized by adoptively transferred tumor-reactive T cells. Nat Med, 19(6), 747-
752. doi:10.1038/nm.3161 
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., . . . Ascierto, P. 
A. (2015). Nivolumab in previously untreated melanoma without BRAF 
mutation. N Engl J Med, 372(4), 320-330. doi:10.1056/NEJMoa1412082 
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., . . . Wolchok, J. 
D. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic 
melanoma. N Engl J Med, 364(26), 2517-2526. doi:10.1056/NEJMoa1104621 
Rodriguez, A., Vigorito, E., Clare, S., Warren, M. V., Couttet, P., Soond, D. R., . . . 
Bradley, A. (2007). Requirement of bic/microRNA-155 for normal immune 
function. Science, 316(5824), 608-611. doi:10.1126/science.1139253 
Romero, P., Banchereau, J., Bhardwaj, N., Cockett, M., Disis, M. L., Dranoff, G., . . . 
Coukos, G. (2016). The Human Vaccines Project: A roadmap for cancer vaccine 
development. Sci Transl Med, 8(334), 334ps339. 
doi:10.1126/scitranslmed.aaf0685 
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. 
T., . . . et al. (1988). Use of tumor-infiltrating lymphocytes and interleukin-2 in 
the immunotherapy of patients with metastatic melanoma. A preliminary report. 
N Engl J Med, 319(25), 1676-1680. doi:10.1056/NEJM198812223192527 
Rosenberg, S. A., & Restifo, N. P. (2015). Adoptive cell transfer as personalized 
immunotherapy for human cancer. Science, 348(6230), 62-68. 
doi:10.1126/science.aaa4967 
Rosenberg, S. A., Sherry, R. M., Morton, K. E., Scharfman, W. J., Yang, J. C., Topalian, 
S. L., . . . Steinberg, S. M. (2005). Tumor progression can occur despite the 
induction of very high levels of self/tumor antigen-specific CD8+ T cells in 
patients with melanoma. J Immunol, 175(9), 6169-6176.  
Rutishauser, R. L., Martins, G. A., Kalachikov, S., Chandele, A., Parish, I. A., Meffre, 
E., . . . Kaech, S. M. (2009). Transcriptional repressor Blimp-1 promotes CD8(+) 
T cell terminal differentiation and represses the acquisition of central memory T 
cell properties. Immunity, 31(2), 296-308. doi:10.1016/j.immuni.2009.05.014 
Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J. 
P., . . . Hacohen, N. (2017). Resistance to checkpoint blockade therapy through 
inactivation of antigen presentation. Nat Commun, 8(1), 1136. 
doi:10.1038/s41467-017-01062-w 
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B. P., Simon, P., Lower, M., . . . Tureci, 
O. (2017). Personalized RNA mutanome vaccines mobilize poly-specific 
therapeutic immunity against cancer. Nature, 547(7662), 222-226. 
doi:10.1038/nature23003 
Sahin, U., Tureci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., . . . 
Pfreundschuh, M. (1995). Human neoplasms elicit multiple specific immune 
responses in the autologous host. Proc Natl Acad Sci U S A, 92(25), 11810-11813.  
Salaun, B., Yamamoto, T., Badran, B., Tsunetsugu-Yokota, Y., Roux, A., Baitsch, L., . . 
. Romero, P. (2011). Differentiation associated regulation of microRNA 
expression in vivo in human CD8+ T cell subsets. J Transl Med, 9, 44. 
doi:10.1186/1479-5876-9-44 
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004). Central memory and effector 
memory T cell subsets: function, generation, and maintenance. Annu Rev 
Immunol, 22, 745-763. doi:10.1146/annurev.immunol.22.012703.104702 
PhD Thesis   Amaia Martínez Usatorre 
 115 
Salomon, D. S., Ciardiello, F., Valverius, E., Saeki, T., & Kim, N. (1989). Transforming 
growth factors in human breast cancer. Biomed Pharmacother, 43(9), 661-667.  
Sapoznik, S., Ortenberg, R., Galore-Haskel, G., Kozlovski, S., Levy, D., Avivi, C., . . . 
Markel, G. (2012). CXCR1 as a novel target for directing reactive T cells toward 
melanoma: implications for adoptive cell transfer immunotherapy. Cancer 
Immunol Immunother, 61(10), 1833-1847. doi:10.1007/s00262-012-1245-1 
Sarkar, S., Kalia, V., Haining, W. N., Konieczny, B. T., Subramaniam, S., & Ahmed, R. 
(2008). Functional and genomic profiling of effector CD8 T cell subsets with 
distinct memory fates. J Exp Med, 205(3), 625-640. doi:10.1084/jem.20071641 
Schluns, K. S., Kieper, W. C., Jameson, S. C., & Lefrancois, L. (2000). Interleukin-7 
mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol, 
1(5), 426-432. doi:10.1038/80868 
Schmid, D. A., Irving, M. B., Posevitz, V., Hebeisen, M., Posevitz-Fejfar, A., Sarria, J. 
C., . . . Rufer, N. (2010). Evidence for a TCR affinity threshold delimiting 
maximal CD8 T cell function. J Immunol, 184(9), 4936-4946. 
doi:10.4049/jimmunol.1000173 
Schmidt, J., Dojcinovic, D., Guillaume, P., & Luescher, I. (2013). Analysis, Isolation, 
and Activation of Antigen-Specific CD4(+) and CD8(+) T Cells by Soluble MHC-
Peptide Complexes. Front Immunol, 4, 218. doi:10.3389/fimmu.2013.00218 
Schumacher, T. N., & Schreiber, R. D. (2015). Neoantigens in cancer immunotherapy. 
Science, 348(6230), 69-74. doi:10.1126/science.aaa4971 
Schwartzentruber, D. J., Lawson, D., Richards, J., Conry, R. M., Miller, D., Triesman, J., 
. . . Hwu, P. (2009). A phase III multi-institutional randomized study of 
immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-
2 compared with high-dose IL-2 alone in patients with metastatic melanoma. 
Journal of Clinical Oncology, 27(18S), CRA9011-CRA9011. 
doi:10.1200/jco.2009.27.18s.cra9011 
Sempere, L. F. (2014). Fully automated fluorescence-based four-color multiplex assay 
for co-detection of microRNA and protein biomarkers in clinical tissue 
specimens. Methods Mol Biol, 1211, 151-170. doi:10.1007/978-1-4939-1459-
3_13 
Sempere, L. F., Preis, M., Yezefski, T., Ouyang, H., Suriawinata, A. A., Silahtaroglu, A., 
. . . Korc, M. (2010). Fluorescence-based codetection with protein markers reveals 
distinct cellular compartments for altered MicroRNA expression in solid tumors. 
Clin.Cancer Res., 16(16), 4246-4255.  
Sethupathy, P., Borel, C., Gagnebin, M., Grant, G. R., Deutsch, S., Elton, T. S., . . . 
Antonarakis, S. E. (2007). Human microRNA-155 on chromosome 21 
differentially interacts with its polymorphic target in the AGTR1 3' untranslated 
region: a mechanism for functional single-nucleotide polymorphisms related to 
phenotypes. Am J Hum Genet, 81(2), 405-413. doi:10.1086/519979 
Shank, B. R., Do, B., Sevin, A., Chen, S. E., Neelapu, S. S., & Horowitz, S. B. (2017). 
Chimeric Antigen Receptor T Cells in Hematologic Malignancies. 
Pharmacotherapy, 37(3), 334-345. doi:10.1002/phar.1900 
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & 
Schreiber, R. D. (2001). IFNgamma and lymphocytes prevent primary tumour 
development and shape tumour immunogenicity. Nature, 410(6832), 1107-1111. 
doi:10.1038/35074122 
Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 
348(6230), 56-61. doi:10.1126/science.aaa8172 
PhD Thesis   Amaia Martínez Usatorre 
 116 
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., 
Kalbasi, A., . . . Ribas, A. (2017). Primary Resistance to PD-1 Blockade Mediated 
by JAK1/2 Mutations. Cancer Discov, 7(2), 188-201. doi:10.1158/2159-
8290.CD-16-1223 
Shinkai, Y., Koyasu, S., Nakayama, K., Murphy, K. M., Loh, D. Y., Reinherz, E. L., & 
Alt, F. W. (1993). Restoration of T cell development in RAG-2-deficient mice by 
functional TCR transgenes. Science, 259(5096), 822-825.  
Shrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. 
A. (2010). Antiangiogenic agents can increase lymphocyte infiltration into tumor 
and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res, 
70(15), 6171-6180. doi:10.1158/0008-5472.CAN-10-0153 
Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009). T cell activation. Annu Rev 
Immunol, 27, 591-619. doi:10.1146/annurev.immunol.021908.132706 
Speiser, D. E., Baumgaertner, P., Voelter, V., Devevre, E., Barbey, C., Rufer, N., & 
Romero, P. (2008). Unmodified self antigen triggers human CD8 T cells with 
stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A, 105(10), 
3849-3854. doi:10.1073/pnas.0800080105 
Speiser, D. E., Utzschneider, D. T., Oberle, S. G., Munz, C., Romero, P., & Zehn, D. 
(2014). T cell differentiation in chronic infection and cancer: functional 
adaptation or exhaustion? Nat Rev Immunol, 14(11), 768-774. 
doi:10.1038/nri3740 
Spits, H., & Di Santo, J. P. (2011). The expanding family of innate lymphoid cells: 
regulators and effectors of immunity and tissue remodeling. Nat Immunol, 12(1), 
21-27. doi:10.1038/ni.1962 
Squadrito, M. L., Etzrodt, M., De Palma, M., & Pittet, M. J. (2013). MicroRNA-mediated 
control of macrophages and its implications for cancer. Trends Immunol, 34(7), 
350-359. doi:10.1016/j.it.2013.02.003 
Stahl, H. F., Fauti, T., Ullrich, N., Bopp, T., Kubach, J., Rust, W., . . . Mennerich, D. 
(2009). miR-155 inhibition sensitizes CD4+ Th cells for TREG mediated 
suppression. PLoS One, 4(9), e7158. doi:10.1371/journal.pone.0007158 
Stemberger, C., Huster, K. M., Koffler, M., Anderl, F., Schiemann, M., Wagner, H., & 
Busch, D. H. (2007). A single naive CD8+ T cell precursor can develop into 
diverse effector and memory subsets. Immunity, 27(6), 985-997. 
doi:10.1016/j.immuni.2007.10.012 
Straathof, K. C., Spencer, D. M., Sutton, R. E., & Rooney, C. M. (2003). Suicide genes 
as safety switches in T lymphocytes. Cytotherapy, 5(3), 227-230. 
doi:10.1080/14653240310001497 
Straus, D. B., & Weiss, A. (1992). Genetic evidence for the involvement of the lck 
tyrosine kinase in signal transduction through the T cell antigen receptor. Cell, 
70(4), 585-593.  
Sullivan, R. J., & Flaherty, K. T. (2013). Resistance to BRAF-targeted therapy in 
melanoma. Eur J Cancer, 49(6), 1297-1304. doi:10.1016/j.ejca.2012.11.019 
Surh, C. D., & Sprent, J. (2008). Homeostasis of naive and memory T cells. Immunity, 
29(6), 848-862. doi:10.1016/j.immuni.2008.11.002 
Swain, S. L., McKinstry, K. K., & Strutt, T. M. (2012). Expanding roles for CD4(+) T 
cells in immunity to viruses. Nat Rev Immunol, 12(2), 136-148. 
doi:10.1038/nri3152 
Swann, J. B., & Smyth, M. J. (2007). Immune surveillance of tumors. J Clin Invest, 
117(5), 1137-1146. doi:10.1172/JCI31405 
PhD Thesis   Amaia Martínez Usatorre 
 117 
Tabbekh, M., Franciszkiewicz, K., Haouas, H., Lecluse, Y., Benihoud, K., Raman, C., & 
Mami-Chouaib, F. (2011). Rescue of tumor-infiltrating lymphocytes from 
activation-induced cell death enhances the antitumor CTL response in CD5-
deficient mice. J Immunol, 187(1), 102-109. doi:10.4049/jimmunol.1004145 
Taganov, K. D., Boldin, M. P., Chang, K. J., & Baltimore, D. (2006). NF-kappaB-
dependent induction of microRNA miR-146, an inhibitor targeted to signaling 
proteins of innate immune responses. Proc Natl Acad Sci U S A, 103(33), 12481-
12486. doi:10.1073/pnas.0605298103 
Takemoto, N., Intlekofer, A. M., Northrup, J. T., Wherry, E. J., & Reiner, S. L. (2006). 
Cutting Edge: IL-12 inversely regulates T-bet and eomesodermin expression 
during pathogen-induced CD8+ T cell differentiation. J Immunol, 177(11), 7515-
7519.  
Tam, W., Ben-Yehuda, D., & Hayward, W. S. (1997). bic, a novel gene activated by 
proviral insertions in avian leukosis virus-induced lymphomas, is likely to 
function through its noncoding RNA. Mol Cell Biol, 17(3), 1490-1502.  
Tan, J. T., Whitmire, J. K., Ahmed, R., Pearson, T. C., & Larsen, C. P. (1999). 4-1BB 
ligand, a member of the TNF family, is important for the generation of antiviral 
CD8 T cell responses. J Immunol, 163(9), 4859-4868.  
Teijaro, J. R., Ng, C., Lee, A. M., Sullivan, B. M., Sheehan, K. C., Welch, M., . . . 
Oldstone, M. B. (2013). Persistent LCMV infection is controlled by blockade of 
type I interferon signaling. Science, 340(6129), 207-211. 
doi:10.1126/science.1235214 
Thai, T. H., Calado, D. P., Casola, S., Ansel, K. M., Xiao, C., Xue, Y., . . . Rajewsky, K. 
(2007). Regulation of the germinal center response by microRNA-155. Science, 
316(5824), 604-608. doi:10.1126/science.1141229 
Tili, E., Michaille, J. J., Cimino, A., Costinean, S., Dumitru, C. D., Adair, B., . . . Croce, 
C. M. (2007). Modulation of miR-155 and miR-125b levels following 
lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating 
the response to endotoxin shock. J Immunol, 179(8), 5082-5089.  
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, 
D. F., . . . Sznol, M. (2012). Safety, activity, and immune correlates of anti-PD-1 
antibody in cancer. N Engl J Med, 366(26), 2443-2454. 
doi:10.1056/NEJMoa1200690 
Tran, K. Q., Zhou, J., Durflinger, K. H., Langhan, M. M., Shelton, T. E., Wunderlich, J. 
R., . . . Dudley, M. E. (2008). Minimally cultured tumor-infiltrating lymphocytes 
display optimal characteristics for adoptive cell therapy. J Immunother, 31(8), 
742-751. doi:10.1097/CJI.0b013e31818403d5 
Trinchieri, G. (2003). Interleukin-12 and the regulation of innate resistance and adaptive 
immunity. Nat Rev Immunol, 3(2), 133-146. doi:10.1038/nri1001 
Trinh, V. A. (2008). Current management of metastatic melanoma. Am J Health Syst 
Pharm, 65(24 Suppl 9), S3-8. doi:10.2146/ajhp080460 
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J., Robert, L., . . 
. Ribas, A. (2014). PD-1 blockade induces responses by inhibiting adaptive 
immune resistance. Nature, 515(7528), 568-571. doi:10.1038/nature13954 
Utzschneider, D. T., Alfei, F., Roelli, P., Barras, D., Chennupati, V., Darbre, S., . . . Zehn, 
D. (2016). High antigen levels induce an exhausted phenotype in a chronic 
infection without impairing T cell expansion and survival. J Exp Med, 213(9), 
1819-1834. doi:10.1084/jem.20150598 
Utzschneider, D. T., Charmoy, M., Chennupati, V., Pousse, L., Ferreira, D. P., Calderon-
Copete, S., . . . Held, W. (2016). T Cell Factor 1-Expressing Memory-like CD8(+) 
PhD Thesis   Amaia Martínez Usatorre 
 118 
T Cells Sustain the Immune Response to Chronic Viral Infections. Immunity, 
45(2), 415-427. doi:10.1016/j.immuni.2016.07.021 
Valmori, D., Souleimanian, N. E., Tosello, V., Bhardwaj, N., Adams, S., O'Neill, D., . . . 
Ayyoub, M. (2007). Vaccination with NY-ESO-1 protein and CpG in Montanide 
induces integrated antibody/Th1 responses and CD8 T cells through cross-
priming. Proc Natl Acad Sci U S A, 104(21), 8947-8952. 
doi:10.1073/pnas.0703395104 
van Baren, N., Bonnet, M. C., Dreno, B., Khammari, A., Dorval, T., Piperno-Neumann, 
S., . . . Boon, T. (2005). Tumoral and immunologic response after vaccination of 
melanoma patients with an ALVAC virus encoding MAGE antigens recognized 
by T cells. J Clin Oncol, 23(35), 9008-9021. doi:10.1200/JCO.2005.08.375 
van den Eertwegh, A. J., Versluis, J., van den Berg, H. P., Santegoets, S. J., van 
Moorselaar, R. J., van der Sluis, T. M., . . . Gerritsen, W. R. (2012). Combined 
immunotherapy with granulocyte-macrophage colony-stimulating factor-
transduced allogeneic prostate cancer cells and ipilimumab in patients with 
metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. 
Lancet Oncol, 13(5), 509-517. doi:10.1016/S1470-2045(12)70007-4 
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den 
Eynde, B., . . . Boon, T. (1991). A gene encoding an antigen recognized by 
cytolytic T lymphocytes on a human melanoma. Science, 254(5038), 1643-1647.  
van der Most, R. G., Murali-Krishna, K., Whitton, J. L., Oseroff, C., Alexander, J., 
Southwood, S., . . . Ahmed, R. (1998). Identification of Db- and Kb-restricted 
subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-
infected mice. Virology, 240(1), 158-167. doi:10.1006/viro.1997.8934 
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999). Combination immunotherapy of 
B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-
4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing 
vaccines induces rejection of subcutaneous and metastatic tumors accompanied 
by autoimmune depigmentation. J Exp Med, 190(3), 355-366.  
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., . . 
. Schumacher, T. N. (2013). Tumor exome analysis reveals neoantigen-specific 
T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol, 31(32), 
e439-442. doi:10.1200/JCO.2012.47.7521 
Vasudevan, S., Tong, Y., & Steitz, J. A. (2007). Switching from repression to activation: 
microRNAs can up-regulate translation. Science, 318(5858), 1931-1934. 
doi:10.1126/science.1149460 
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011). Natural innate 
and adaptive immunity to cancer. Annu Rev Immunol, 29, 235-271. 
doi:10.1146/annurev-immunol-031210-101324 
Vigano, S., Utzschneider, D. T., Perreau, M., Pantaleo, G., Zehn, D., & Harari, A. (2012). 
Functional avidity: a measure to predict the efficacy of effector T cells? Clin Dev 
Immunol, 2012, 153863. doi:10.1155/2012/153863 
Vigorito, E., Perks, K. L., Abreu-Goodger, C., Bunting, S., Xiang, Z., Kohlhaas, S., . . . 
Turner, M. (2007). microRNA-155 regulates the generation of immunoglobulin 
class-switched plasma cells. Immunity, 27(6), 847-859. 
doi:10.1016/j.immuni.2007.10.009 
von Boehmer, H., Teh, H. S., & Kisielow, P. (1989). The thymus selects the useful, 
neglects the useless and destroys the harmful. Immunol Today, 10(2), 57-61. 
doi:10.1016/0167-5699(89)90307-1 
PhD Thesis   Amaia Martínez Usatorre 
 119 
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. 
M., . . . Bluestone, J. A. (1994). CTLA-4 can function as a negative regulator of 
T cell activation. Immunity, 1(5), 405-413.  
Wang, P., Hou, J., Lin, L., Wang, C., Liu, X., Li, D., . . . Cao, X. (2010). Inducible 
microRNA-155 feedback promotes type I IFN signaling in antiviral innate 
immunity by targeting suppressor of cytokine signaling 1. J Immunol, 185(10), 
6226-6233. doi:10.4049/jimmunol.1000491 
Weber, J., Boswell, W., Smith, J., Hersh, E., Snively, J., Diaz, M., . . . Bot, A. (2008). 
Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine 
in patients with stage IV melanoma. J Immunother, 31(2), 215-223. 
doi:10.1097/CJI.0b013e3181611420 
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., . . . Larkin, 
J. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma 
who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, 
controlled, open-label, phase 3 trial. Lancet Oncol, 16(4), 375-384. 
doi:10.1016/S1470-2045(15)70076-8 
Weber, J. S., O'Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., . . . Hersh, E. 
(2008). Phase I/II study of ipilimumab for patients with metastatic melanoma. J 
Clin Oncol, 26(36), 5950-5956. doi:10.1200/JCO.2008.16.1927 
Weide, B., Carralot, J. P., Reese, A., Scheel, B., Eigentler, T. K., Hoerr, I., . . . Pascolo, 
S. (2008). Results of the first phase I/II clinical vaccination trial with direct 
injection of mRNA. J Immunother, 31(2), 180-188. 
doi:10.1097/CJI.0b013e31815ce501 
Wensveen, F. M., van Gisbergen, K. P., Derks, I. A., Gerlach, C., Schumacher, T. N., van 
Lier, R. A., & Eldering, E. (2010). Apoptosis threshold set by Noxa and Mcl-1 
after T cell activation regulates competitive selection of high-affinity clones. 
Immunity, 32(6), 754-765. doi:10.1016/j.immuni.2010.06.005 
Wherry, E. J. (2011). T cell exhaustion. Nat Immunol, 12(6), 492-499.  
Wherry, E. J., Barber, D. L., Kaech, S. M., Blattman, J. N., & Ahmed, R. (2004). Antigen-
independent memory CD8 T cells do not develop during chronic viral infection. 
Proc Natl Acad Sci U S A, 101(45), 16004-16009. doi:10.1073/pnas.0407192101 
Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R., & Ahmed, R. (2003). 
Viral persistence alters CD8 T-cell immunodominance and tissue distribution and 
results in distinct stages of functional impairment. J Virol, 77(8), 4911-4927.  
Wherry, E. J., Ha, S. J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., . . . Ahmed, 
R. (2007). Molecular signature of CD8+ T cell exhaustion during chronic viral 
infection. Immunity, 27(4), 670-684. doi:10.1016/j.immuni.2007.09.006 
Wiedemann, A., Depoil, D., Faroudi, M., & Valitutti, S. (2006). Cytotoxic T lymphocytes 
kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and 
stimulatory synapses. Proc Natl Acad Sci U S A, 103(29), 10985-10990. 
doi:10.1073/pnas.0600651103 
Wiesel, M., Crouse, J., Bedenikovic, G., Sutherland, A., Joller, N., & Oxenius, A. (2012). 
Type-I IFN drives the differentiation of short-lived effector CD8+ T cells in vivo. 
Eur J Immunol, 42(2), 320-329. doi:10.1002/eji.201142091 
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J. J., Cowey, C. 
L., . . . Larkin, J. (2017). Overall Survival with Combined Nivolumab and 
Ipilimumab in Advanced Melanoma. N Engl J Med, 377(14), 1345-1356. 
doi:10.1056/NEJMoa1709684 
PhD Thesis   Amaia Martínez Usatorre 
 120 
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. 
M., . . . Sznol, M. (2013). Nivolumab plus ipilimumab in advanced melanoma. N 
Engl J Med, 369(2), 122-133. doi:10.1056/NEJMoa1302369 
Wong, R. M., Scotland, R. R., Lau, R. L., Wang, C., Korman, A. J., Kast, W. M., & 
Weber, J. S. (2007). Programmed death-1 blockade enhances expansion and 
functional capacity of human melanoma antigen-specific CTLs. Int Immunol, 
19(10), 1223-1234. doi:10.1093/intimm/dxm091 
Wu, H., Neilson, J. R., Kumar, P., Manocha, M., Shankar, P., Sharp, P. A., & Manjunath, 
N. (2007). miRNA profiling of naive, effector and memory CD8 T cells. PLoS 
One, 2(10), e1020. doi:10.1371/journal.pone.0001020 
Xiao, C., & Rajewsky, K. (2009). MicroRNA control in the immune system: basic 
principles. Cell, 136(1), 26-36. doi:10.1016/j.cell.2008.12.027 
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., . . . 
Delamarre, L. (2014). Predicting immunogenic tumour mutations by combining 
mass spectrometry and exome sequencing. Nature, 515(7528), 572-576. 
doi:10.1038/nature14001 
Yajima, T., Yoshihara, K., Nakazato, K., Kumabe, S., Koyasu, S., Sad, S., . . . Yoshikai, 
Y. (2006). IL-15 regulates CD8+ T cell contraction during primary infection. J 
Immunol, 176(1), 507-515.  
Yamada, A., Sasada, T., Noguchi, M., & Itoh, K. (2013). Next-generation peptide 
vaccines for advanced cancer. Cancer Sci, 104(1), 15-21. doi:10.1111/cas.12050 
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., . . . Harris, C. 
C. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and 
prognosis. Cancer Cell, 9(3), 189-198. doi:10.1016/j.ccr.2006.01.025 
Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., . . . 
Rosenberg, S. A. (2007). Ipilimumab (anti-CTLA4 antibody) causes regression 
of metastatic renal cell cancer associated with enteritis and hypophysitis. J 
Immunother, 30(8), 825-830. doi:10.1097/CJI.0b013e318156e47e 
Yarchoan, M., Johnson, B. A., 3rd, Lutz, E. R., Laheru, D. A., & Jaffee, E. M. (2017). 
Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer, 17(4), 
209-222. doi:10.1038/nrc.2016.154 
Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E., & Greenberg, P. 
D. (2002). Adoptive T cell therapy using antigen-specific CD8+ T cell clones for 
the treatment of patients with metastatic melanoma: in vivo persistence, 
migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A, 
99(25), 16168-16173. doi:10.1073/pnas.242600099 
Yi, R., Qin, Y., Macara, I. G., & Cullen, B. R. (2003). Exportin-5 mediates the nuclear 
export of pre-microRNAs and short hairpin RNAs. Genes Dev, 17(24), 3011-
3016. doi:10.1101/gad.1158803 
Yin, Q., McBride, J., Fewell, C., Lacey, M., Wang, X., Lin, Z., . . . Flemington, E. K. 
(2008). MicroRNA-155 is an Epstein-Barr virus-induced gene that modulates 
Epstein-Barr virus-regulated gene expression pathways. J Virol, 82(11), 5295-
5306. doi:10.1128/JVI.02380-07 
Youngblood, B., Oestreich, K. J., Ha, S. J., Duraiswamy, J., Akondy, R. S., West, E. E., 
. . . Ahmed, R. (2011). Chronic virus infection enforces demethylation of the locus 
that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity, 35(3), 400-412. 
doi:10.1016/j.immuni.2011.06.015 
Yuan, J., Ku, G. Y., Gallardo, H. F., Orlandi, F., Manukian, G., Rasalan, T. S., . . . 
Wolchok, J. D. (2009). Safety and immunogenicity of a human and mouse gp100 
DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun, 9, 5.  
PhD Thesis   Amaia Martínez Usatorre 
 121 
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-
Lieskovan, S., . . . Ribas, A. (2016). Mutations Associated with Acquired 
Resistance to PD-1 Blockade in Melanoma. N Engl J Med, 375(9), 819-829. 
doi:10.1056/NEJMoa1604958 
Zehn, D., Lee, S. Y., & Bevan, M. J. (2009). Complete but curtailed T-cell response to 
very low-affinity antigen. Nature, 458(7235), 211-214. doi:10.1038/nature07657 
Zhang, H., Cordoba, S. P., Dushek, O., & van der Merwe, P. A. (2011). Basic residues in 
the T-cell receptor zeta cytoplasmic domain mediate membrane association and 
modulate signaling. Proc Natl Acad Sci U S A, 108(48), 19323-19328. 
doi:10.1073/pnas.1108052108 
Zhang, N., & Bevan, M. J. (2011). CD8(+) T cells: foot soldiers of the immune system. 
Immunity, 35(2), 161-168. doi:10.1016/j.immuni.2011.07.010 
Zhou, X., Yu, S., Zhao, D. M., Harty, J. T., Badovinac, V. P., & Xue, H. H. (2010). 
Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 
1. Immunity, 33(2), 229-240. doi:10.1016/j.immuni.2010.08.002 
Zippelius, A., Batard, P., Rubio-Godoy, V., Bioley, G., Lienard, D., Lejeune, F., . . . Pittet, 
M. J. (2004). Effector function of human tumor-specific CD8 T cells in melanoma 
lesions: a state of local functional tolerance. Cancer Res, 64(8), 2865-2873.  
Zonari, E., Pucci, F., Saini, M., Mazzieri, R., Politi, L. S., Gentner, B., & Naldini, L. 
(2013). A role for miR-155 in enabling tumor-infiltrating innate immune cells to 
mount effective antitumor responses in mice. Blood, 122(2), 243-252. 
doi:10.1182/blood-2012-08-449306 
 
